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Idiopathic Intracranial Hypertension (IIH) is a rare condition characterised by 
increased intracranial pressure for unknown reasons. It predominantly affects obese 
women of child-bearing age, and it has been linked to altered sex hormone levels. While 
the mechanisms underlying IIH are unknown, IIH is thought to be related to an impairment 
of cerebrospinal fluid (CSF) dynamics, including CSF hypersecretion by the choroid plexus 
(CP). The present study was designed to explore the effects of diet on CSF secretion in the 
rat with the aim to unravel possible pathogenic mechanisms underlying IIH. Other 
parameters, such as sex and elevated cytokines in CSF, were also studied. A high-fat diet 
(HFD) was able to increase both body weight and CSF secretion in male and female rats. 
While the differences appeared earlier in males, they were larger in females. Furthermore, 
elevated levels of cytokines (TNFα, CCL2, IL-6, IL-17, hydrocortisone) in CSF of HFD-fed male 
rats were tested, from which hydrocortisone was the only one found to potentiate HFD-
induced CSF hypersecretion.  
In females, weight and plasma testosterone concentration positively correlated 
with CSF secretion. Females under HFD supplemented with peanut butter (HFD+PB) 
showed the highest CSF secretion rates, body weights and testosterone levels. HFD+PB rats 
also had the highest deregulation in CP gene expression. In HFD+PB rats, most of the genes 
related to CSF secretion remained unaltered; however, two transporters, Slc4a10 and 
Kcna6, and several tight junction molecules (TJs), including ZO-1, were downregulated. In 
vitro tests using a CP cell model showed that testosterone was able to alter gene expression 
including decreased expression of TJs including ZO-1, Slc4a10, and overexpression of AQP1 
and ATP1A1. Additionally, testosterone was also able to decrease barrier functionality in 
the in vitro CP model. It is hypothesised that, in IIH, obesity and elevated testosterone levels 
increase CP permeability, altering CSF dynamics.
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SLC23A1   Na+- dependent vitamin C transporter 
T    Testosterone 
T/E2    Testosterone to oestradiol 
TEER    Transepithelial Electrical Resistance 
TJs    Tight Junctions 




TNF-α    Tumor Necrosis Factor Alpha 
TTR   Transthyretin 
VLDL/LDL   very low-density lipoproteins / low-density            
lipoproteins 
WI    Water intake 
WIC    Water intake of the cage 
WIW     Water intake per body weight ratio 
ZO-1    Zona Occludens 1 
ZO-3    Zona Occludens 3 
 
  










Chapter 1. General Introduction 
1.1 Introduction into the Central Nervous System 
In vertebrates, the central nervous system (CNS) is a very delicate but essential 
organ necessary for survival. It processes and coordinates the information received from 
the sense organs and it controls most of the activities carried out by the body. The human 
brain consists of the cerebrum, divided into two cerebral hemispheres, and the cerebellum, 
and it is connected to the spinal cord, which is located inside the spine, forming the CNS 
(Figure 1.1). The brain is located inside the skull and is protected by several layers of tissue 
and suspended in a liquid, called the cerebrospinal fluid (CSF). The brain and spinal cord 
have communicating cavities filled with CSF. In the brain, four main cavities, called 
ventricles, can be found: two lateral ventricles, a third and a fourth ventricle. The hollow in 
the middle of the spinal cord is called the central canal. 
Figure 1.1. Lateral and anterior view of the human brain and the ventricular system. 
The human brain consists of the cerebrum, divided into two cerebral hemispheres, and the cerebellum. The 
brain is connected to the spinal cord, forming the CNS. In the brain, four main cavities, called ventricles, can 
be found: two lateral ventricles, a third and a fourth ventricle, whereas in the spinal cord a hollow in the 
middle, called the central canal, is found. These cavities are connected and filled with flowing CSF (modified 











A villous structure of vascularized layers can be found protruding from the walls of 
the four ventricles; this structure is called the choroid plexus (CP). The CP is formed by a 
monolayer of epithelial cells surrounding a stromal core of connective tissue and 
fenestrated capillaries and it forms an interface between the blood and the CSF 
(Dohrmann, 1970; Crispino and Crispino, 2015; Benarroch, 2016).  
1.2 Overview of Central Nervous System Fluids  
Three different types of extracellular fluid can be found in the CNS: interstitial fluid 
(ISF), CSF and blood. The ISF is produced by parenchyma cells and forms the 
microenvironment of the brain while the CSF is located in the brain ventricles, the central 
canal, the subarachnoid space and the channels connecting these structures. The ISF and 
the CSF can exchange by diffusion across the thin epithelial lining of the ventricular system 
called ependyma, and also across the glial layer at the surface of the brain facing the 
subarachnoid space (Abbott, 2004) (Figure 1.2). The blood is carried within blood vessels 
that perfuse the brain, deliver important substances such as nutrients and oxygen and 
remove waste products released as a result of normal cell function.  
 
 




Figure 1.2. Schematic representation of molecule diffusion between the blood, ISF and CSF in the brain.  
Four connected cavities, called ventricles, filled with CSF can be found in the brain (left). The choroid plexus 
(right) is a villous structure of vascularized layers protruding from the walls of the ventricles and it is thought 
to be the main site of CSF secretion. The epithelial cells of the choroid plexus form a tight barrier between 
CSF and blood and actively controls substance trafficking between these two fluids. In the brain parenchyma, 
the epithelial cells surrounding the blood vessels form the blood brain barrier (BBB) and they are in charge of 
actively controlling and restricting the interchange of molecules between blood and ISF (Diagram by Ester 
Pascual Baixauli). 
1.2.1 The Brain Fluids 
I. Blood 
The blood is an essential body fluid that delivers nutrients and oxygen to all the cells 
in the organism while removing metabolic waste and keeping the body at a stable 
temperature. In vertebrates, the blood is mainly composed of blood cells, proteins, glucose 
and ions in solution or suspended in plasma (Brody, 2017; Mathew and Bhimji, 2018). The 
most common blood cells are: erythrocytes, anucleated cells involved in transporting 
oxygen, facilitated by the iron-containing haemoglobin which increases oxygen binding; 
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leukocytes, immune cells in charge of protecting the body against infections and foreign 
bodies; and thrombocytes, anucleated cells whose main function is contributing to clotting 
(De Villota et al., 1981; Hart, 2001; Sharma and Sharma, 2018).  
Cerebral arteries and arterioles are formed by three distinctive concentric layers: 
an inner layer, the tunica intima, composed by a single layer of endothelial cells and the 
internal elastic membrane separating it from the next layer; the tunica media, mainly 
formed by smooth muscle cells, collagen and elastin fibres; and the tunica adventitia, which 
consists mostly of fibroblasts, associated cells such as pericytes and astrocytic end-feet, 
and collagen fibres. CNS arteries lack an outer elastic membrane and have thinner tunica 
media and adventitia containing a smaller percentage of elastic fibres than arteries in the 
rest of the body (Cipolla, 2009; Prince and Ahn, 2013). In humans, the blood is supplied to 
the brain through two pairs of large arteries, the left and right internal carotid and the left 
and right vertebral arteries (Figure 1.3). The internal carotids carry blood to the anterior 
cerebral circulation, middle and anterior cerebral arteries including the anterior choroidal 
artery; the vertebral arteries are connected to the posterior circulation, basilar artery and 
posterior cerebral arteries. The anterior and posterior cerebral circulations are connected 
through communicating arteries in the Circle of Willis (Alpers, 1959; Crispino and Crispino, 
2015; Tanaka, 2017; Haines, 2018).  
 




Figure 1.3. Anatomy of the cerebral arterial system.  
Blood is supplied to the brain through two groups of large arteries: the internal carotids, which carry blood 
to the anterior cerebral circulation, middle and anterior cerebral arteries; and the vertebral arteries, which 
supply blood to posterior circulation, basilar artery and posterior cerebral arteries. Anterior and posterior 
cerebral circulations are connected through the Circle of Willis (Illustration by Ester Pascual Baixauli). 
The cerebral venous circulation is comprised of cerebral veins and dural venous 
sinuses (Figure 1.4). While both types of blood vessels are valveless, cerebral veins have a 
thin wall lacking smooth muscle, and sinuses are larger channels lined with endothelial cells 
(Haines, 2018). Blood gets drained from the brain through two groups of valveless veins 
and sinuses: the superficial system and the deep system. The superficial system, comprising 
the sagittal sinuses and cortical veins, manage the venous outflow from the cerebral cortex 
and subcortical white matter (Cipolla, 2009; Purves et al., 2018). The deep system includes 
the lateral, sigmoid and straight sinuses along with the deep veins, such as the great and 





surrounding the lateral and third ventricles (Ono et al., 1984; Uddin, Haq and Rafique, 
2006). Venous blood is generally drained into the nearest venous sinus or, in the case of 
deeper structures, into a deep vein which will then drain into a venous sinus. Dural venous 
sinuses drain into the internal jugular veins (Moll and Waldron, 2014; Egemen and 
Solaroglu, 2017) .  
  
Figure 1.4. Anatomy of the cerebral venous system.  
The cerebral venous system comprises cerebral veins and dural venous sinuses. Blood gets drained through 
two systems: the superficial system, comprising the sagittal sinuses and cortical veins, manage the venous 
outflow from the cerebral cortex and subcortical white matter; the deep system includes the lateral, sigmoid 
and straight sinuses along with the deep veins and it drains the interior of the brain. Both systems drain into 
internal jugular veins (OpenStax, 2016). 
II. Interstitial Fluid 
The ISF is a clear fluid that bathes parenchymal brain cells in the extracellular spaces 
of the CNS. ISF is composed of water, ions, organic molecules such as proteins, extracellular 
vesicles and gaseous molecules such as O2 and CO2 (Cserr, 1983; Hladky and Barrand, 2016; 
Lei et al., 2017; Nakada and Kwee, 2019). Functions of the ISF include nutrient supply, 
intercellular communication, transport of molecules, waste removal and maintenance of 




brain volume (Szentistvanyi et al., 1984; Dóczi, 1993; Ueno et al., 2016; Bedussi et al., 
2017). The ISF mainly originates from a combination of water filtered by the blood brain 
barrier (BBB), water produced by cellular metabolism and fluid from the CSF. Molecular 
exchange happens mostly with CSF via the ependyma lining the brain ventricles (Abbott, 
2004; Damkier, Brown and Praetorius, 2010; Ueno et al., 2016).  
ISF flow along the perivascular space is driven by both diffusion and convection, 
which depend on pressure and homeostatic gradients. Different brain areas present 
different flow characteristics. In grey matter, ISF flow is mainly dependent on diffusional 
processes. On the other hand, in white matter, bulk flow through fluid-filled canals 
surrounding blood vessels delimited by the cerebrovascular basement membranes appear 
to be the main ISF flow motion (Healy and Vogelbaum, 2015; Boespflug and Iliff, 2018; 
Nakada and Kwee, 2019). Furthermore, ISF flow and volume increase during sleep, 
suggesting a mechanism boosting removal of waste products accumulated during 
wakefulness (Xie et al., 2013). It has also been shown that neuronal excitation is able to 
reduce local ISF flow (Shi et al., 2015). ISF drainage pathways include reabsorption into 
venous circulation, drainage into the lymphatic circulation and movement along astrocytes 
towards CSF compartments (Hladky and Barrand, 2016; Marchi, Banjara and Janigro, 2016; 
Bedussi et al., 2017).  
III. Cerebrospinal Fluid 
The CSF is a clear colourless fluid in which the brain and spinal cord are suspended. 
The CSF provides essential functions for CNS protection and maintenance. The CSF acts as 
a protective cushion for the CNS by protecting it against accidental mechanical damage 
while also reducing the brain net weight from approximately 1500g to 25-50g, allowing this 
organ to maintain its density without being impaired by its own weight (Saladin, 2014; 
Tumani, Huss and Bachhuber, 2017; Adigun and Al-Dhahir, 2019). The volume and 
biochemical components of the CSF play vital homeostatic roles, keeping the CNS 
temperature stable and disposing of neural waste substances while maintaining the 
osmotic pressure needed for normal brain perfusion. Additionally, the CSF contains 





micronutrients such as vitamin C and folate (Spector and Johanson, 2007; Spector, 2009). 
Furthermore, CSF contributes to the immunologic protection of the CNS because of its high 
turnover, which allows for constant cleansing of the brain tissues (Emerich et al., 2004; 
Falcão et al., 2012; Spector, Snodgrass and Johanson, 2015).  
1.2.2 The Brain Barriers 
Brain barriers are essential to ensure the maintenance of the concentration of ions 
and nutrients in the CSF and the ISF within the appropriate limits for proper brain 
functioning. Brain barriers are formed by tight junctions (TJs) between adjacent cells that 
reduce their permeability to solutes. There are three main barriers in the human brain: 
barriers at the brain surface, the blood-brain barrier and the blood-CSF barrier (Abbott et 
al., 2010; Engelhardt, Vajkoczy and Weller, 2017) (Figure 1.5).  
 
 




Figure 1.5. Schematic representation of the brain barriers. 
(a) In humans, the brain is covered by three membrane layers. The dura mater is the outer layer, adjacent to 
the arachnoid mater, which forms a barrier between CSF and blood. The subarachnoid space is filled with CSF 
and it is crossed by sheet-like trabeculae connecting the arachnoid matter to the pia mater and 
leptomeningeal arteries and veins. The pia mater separates the subarachnoid spacefrom the subpial space 
and surrounds arteries entering the brain. (b) The endothelial cells from the blood brain barrier are the main 
site of controlled transport into the CNS. Highly restricted diffusion is achieved by an increased expression of 
tight junction proteins. (c) The blood-CSF barrier is mainly formed by the epithelial cells located at the choroid 
plexus. The blood vessels in the choroid plexus do not have a BBB; instead, choroid plexus epithelial cells 
actively control diffusion of molecules and ions, which drive a passive movement of water from blood to CSF 
and is the main mechanism of CSF secretion. (d) the location of the three brain barriers within the structure 
of the brain (Diagram by Ester Pascual Baixauli). 
I. Barriers at the surface of the brain 
The CNS is surrounded by three membranous layers called meninges which, 
together with the CSF, protect the system from mechanical damage. In the head, the 







The outer layer is the dura mater, a thick and dense collagenous membrane that is 
tightly fixed to the inner surface of the skull. It contains numerous blood vessels, the dural 
venous sinuses, where the venous blood from the brain gets drained, and lymphatic vessels 
where the CSF gets drained (Brunori, Vagnozzi and Giuffrè, 1993; Dasgupta and Jeong, 
2019). The middle meninge is the arachnoid mater, a thin membrane containing a few 
layers of flattened epithelium cells. This layer is one of the three interfaces between blood 
and brain that can be found in mammal brains. However, its contribution to the molecular 
exchange between blood and CNS is insignificant due to its avascular nature and relatively 
small surface area (Abbott et al., 2010). The subarachnoid space (SAS), an area of 
connective tissue located underneath the arachnoid membrane, also provides openings 
through which blood vessels interconnect and CSF flows (Da Mesquita, Fu and Kipnis, 2018; 
Weller et al., 2018). Strands of connective tissue called arachnoid trabeculae can be found 
in the subarachnoid space connecting the arachnoid mater with the inner meninge, the pia 
mater. This membrane is formed by a single cell layer that closely adheres to the surface of 
the brain. It is separated from the brain parenchyma by a subpial space containing blood 
vessels and collagen and by the glial limitans, a thin barrier formed by astrocyte foot 
processes (Weller et al., 2018; Dasgupta and Jeong, 2019). Blood vessels branching out 
from subarachnoid space through pia mater and into the brain are also considered a 
continuation of this meninge (Lopes, 2009; Decimo et al., 2012).  
The meninges not only perform a protective function; recent evidence suggests that 
they also have complex functions including controlling and facilitating movement of solutes 
at the surface and within the parenchyma of the CNS (Weller et al., 2018). Furthermore, 
the outer barriers of the brain also play important roles in mechanisms such as the 
regulation of the immune cell entry into the CNS or the stem cell niche (Brøchner, Holst 
and Møllgård, 2015; Da Mesquita, Fu and Kipnis, 2018; Brioschi and Colonna, 2019). 
II. Blood-brain barrier 
The blood-brain barrier (BBB) separates peripheral blood from the CNS and is 
formed by a tight monolayer of brain endothelial cells (BEC) which constitute the walls of 
capillaries. BECs, together with surrounding pericytes, astrocytes, microglia and neurons 




form the neurovascular unit (Abbott et al., 2010; Obermeier, Verma and Ransohoff, 2016). 
Inter-endothelial junctions restrict paracellular diffusion of water-soluble substances which 
grants the BBB its characteristic restricted permeability. Furthermore, the BBB also shows 
restricted transport of most polar solutes and reduced vesicular transport across the 
barrier (Abbott et al., 2010; Hladky and Barrand, 2016; Ueno et al., 2016). Both 
characteristics are highly controlled by several different mechanisms including cytokines 
and vascular endothelial growth factor, and their disruption is linked to neuroinflammatory 
diseases such as Alzheimer´s and Multiple Sclerosis (Hawkins and Davis, 2005; Abbott, 
Rönnbäck and Hansson, 2006; Armulik et al., 2010; Ueno et al., 2016; Thomas and 
Eichmann, 2018) However, the BBB allows the diffusion of gasses such as O2 and CO2, and 
facilitates the passage of essential nutrients for brain metabolism such as glucose (Hladky 
and Barrand, 2016). Furthermore, recent research has shown that BBB also contributes to 
ISF secretion and CNS waste removal, although the movement rates are smaller than those 
at the CP level (Abbott, 2004; Zhao et al., 2015; Marchi, Banjara and Janigro, 2016).  
III. Blood-cerebrospinal fluid barrier 
The blood-cerebrospinal fluid barrier (BCSFB) is formed by choroid plexus epithelial 
cells (CPEC). The CP is a villous structure of vascularized layers protruding from the walls of 
the ventricles thought to be the main site of CSF secretion (Tumani, Huss and Bachhuber, 
2017; Ghersi-Egea et al., 2018). The microvessels found in the CP are fenestrated, however, 
the apical ends of CPEC express TJs, which prevents blood and CSF to diffuse freely (Kratzer 
et al., 2012; Liddelow et al., 2012). CPEC actively control molecular transport across the 
barrier. CSF secretion is mainly driven by active ion net transport from the blood side to 
the CSF side, which drives water movement in the same direction via alterations in osmotic 
pressures (Speake et al., 2001). 
The BCSFB interface is key for many processes, including CSF secretion and brain 
waste removal (Emerich et al., 2004; Wolburg and Paulus, 2010). The present study will 






1.2.3 Choroid Plexus  
I. Choroid Plexus Morphology 
The CP is formed by a tight epithelium enclosing a highly vascularized stroma. More 
specifically, this tissue is composed of a single layer of cuboidal CPECs surrounding a 
network of capillaries embedded in connective tissue. The capillaries in the CP are 
fenestrated, providing little resistance to the free movement of ions, small molecules and 
water from and to the blood (Keep and Jones, 1990; Tumani, Huss and Bachhuber, 2017). 
CPECs are polarized, with apical TJs and microvilli on the apical membrane facing the CSF 
(Figure 1.6). The apical microvilli on CPEC greatly increase its apical surface area (Keep, 
Jones and Cawkwell, 1986). In fact, Keep and Jones estimated that the apical surface area–
to-epithelium volume ratio in rat CPEC was ~ 30 fold bigger than expected from a 10 μm 
cuboidal cell with no microvilli (Keep and Jones, 1990). Furthermore, the CP structures also 
form elongated villi, further increasing the surface for molecular exchange (Ghersi-Egea et 
al., 2018; Fleischman and Berdahl, 2019).  
Intercellular junctions between CPEC comprise adherens junctions (AJs) and TJs 
(Figure 1.7). AJs are essential during development and their existence is required for TJs 
formation. AJs initiate cell-to-cell contacts and promote their maturation, plasticity and 
maintenance while also regulating tensile forces. AJs in the CP are usually formed by 
homophilic interactions of E-cadherin molecules between two cells. E-cadherin cytoplasmic 
tail binds to p120 and β catenin, which then binds to α catenin, connecting it to the actin 
cytoskeleton. AJs formed by the nectin-afadin complex are also thought to exist in the CP, 
although its presence is not well defined yet (Ikeda et al., 1999; Lagaraine et al., 2011).  
 




Figure 1.6. Schematic cross section of choroid plexus. 
The choroid plexus is formed by fenestrated capillaries, stroma and epithelium. The ventricle side of the 
epithelium is bathed in CSF (Diagram by Ester Pascual Baixauli). 
TJs are the most apical components of junctional complexes. TJs are essential for 
CSF secretion because they restrict the paracellular permeability and are the most apical 
components of junctional complexes (Szmydynger-Chodobska et al., 2007; Ghersi-Egea et 
al., 2018). TJs are comprised of a combination of transmembrane proteins, either claudins, 
occludin or JAM-3, interacting with the cytoskeleton through scaffold cytoplasmic proteins 
such as the zonula occludens (ZO) family (Kratzer et al., 2012; Ghersi-Egea et al., 2018). 
They are present at the most apical part of the lateral space between neighbouring cells 
and control paracellular movement of molecules between CSF and blood, and guarantee 
cell polarity by restricting diffusion of transmembrane proteins (Zihni et al., 2016; Ghersi-




















Figure 1.7. Intercellular junctions between choroid plexus epithelial cells. 
TJs in the CP are formed by a combination of transmembrane proteins interacting with scaffold proteins 
which, in turn, are bound to the cytoskeleton. TJs are essential for control of paracellular permeability and 
they form the BCSFB. CPEC also present AJs. AJs in the CP are normally formed by E-cadherin binding to p120 
or β catenin, which in turn binds to α catenin, which interacts with the cytoskeleton. AJs formed by the nectin-
afadin complex are also thought to happen in the CP. AF6 = afadin, TJs = tight junctions, AJs= adherens 
junctions. (Diagram by Ester Pascual Baixauli) 
CPECs have a large mitochondrial content, particularly in areas close to the apical 
“brush” border (Cornford et al., 1997; Bouzinova et al., 2005). This is an indicative that the 
BCSFB is an active interface rather than just a simple barrier. Controlling the molecular 
interchange between CSF and blood is very energy demanding as it is mediated by specific 
transmembrane transporters and reabsorptive transporters. (McComb, 1983; Ghersi-Egea 
et al., 2018). 
 




The local blood flow in CP is amongst the highest found in the brain as a result of 
the extensive network of wide capillaries throughout the choroidal stroma, around 4ml·g-1 
·min-1 in a healthy adult human. The blood arrives by the anterior and posterior choroidal 
arteries and is drained by the choroidal vein (Szmydynger-Chodobska, Chodobski and 
Johanson, 1994; Fleischman and Berdahl, 2019). 
II. Choroid Plexus Physiology 
The CP performs essential functions for CNS homeostasis. As indicated above, it 
provides a neuroprotective barrier controlling and restricting diffusion of substances 
between the blood and the CSF and secretes CSF, both of which are interrelated. Specific 
transporters expressed in apical and basolateral membranes control the molecular 
exchange between the blood and CSF (Figure 1.8). These transporters allow movement of 
ions against their concentration gradient, which drives water movement and CSF 
formation. For example, the activity of carbonic anhydrase and the sodium-potassium 
adenosine triphosphatase (Na+-K+ ATPase) enzymes drive a unidirectional active 
transcellular flux of Na+, Cl- and HCO3- from blood to CSF, which creates an osmotic gradient 
that results in water movement in the same direction. To complement this specific 
molecular transport, the CP also expresses metabolizing enzymes specialised in 
transforming endogenous molecules and toxicants into inactive metabolites. These 
enzymes, coupled with the basolateral specific transporters, form a highly efficient 
metabolic barrier which protects the CNS from unwanted substances, constituting the 






Figure 1.8. Schematic representation of transporters in choroid plexus epithelial cells. 
The CP consists of a monolayer of cuboidal epithelial cells surrounding a highly vascularised stroma. CPEC 
form the BCSFB because of the TJs joining adjacent cells, which restrict passage of solutes, ions and water. 
CPEC regulates production and composition of CSF and, because of that, it presents polarised expression of 
molecular transporters. The secretion of CSF by CPEC depends on the transport of sodium (Na+), potassium 
(K+), cloride (Cl-), bicarbonate (HCO3-) and water (H2O). The active movement of ions into the CSF creates an 
osmotic gradient which then drives the secretion of H2O mainly by aquaporin 1 (AQP1). CSF secretion requires 
the cell production of HCO3- by the carbonic anhydrase. HCO3- is involved in the transport of Cl- by the Cl--
HCO3- exchange (Slc4a2) in the basolateral membrane. Cl- is transported into the CSF by Cl- channels (Clir and 
VRAC) and also by the K+- Cl- cotransporter 4 (Slc12a7). CSF secretion is highly dependent on the active 
secretion of Na+ into the CSF by the sodium-potassium adenosine triphosphatase (Na+-K+-ATPase). Na+ is also 
transported by the Na+- HCO3- cotransporters (Slc4a5 in the apical membrane, Slc4a10 in the basolateral 
membrane) and by the Na+-H+ exchanger (Slc9a1). K+ is actively taken up from the CSF by the Na+-K+-ATPase, 
and also by the Na+-K+-2Cl- cotransporter-1 (Slc12a2). The majority of K+ is taken back to the CSF by the inward 
rectifying channels (KCNA 1, KCNA 3, KCNA 6 and KCNJ 13). CPEC also facilitate the transcellular passage into 
CSF of molecules essential for brain functioning, such as vitamin C, through the Na+- dependent vitamin C 
transporter (Slc23a1), and folate, through the folate receptor alpha (FOLR1), which transports the active 
metabolite of folic acid, 5-methyltetrahydrofolate. CPEC basolateral membrane expresses the multidrug 
resistance related proteins 1 and 4 (ABCC1 and ABCC4), and the apical membrane has the peptide transporter 




2 (Slc15a2) and the organic acid transporter 3 (Slc22a8). These transporters are thought to be involved in the 
reduced availability of therapeutic drugs in the CSF (Diagram by Ester Pascual Baixauli). 
In addition to the role in CSF formation, the CP is a key component of metabolic and 
neuroendocrine regulations. The CP synthesizes diverse signalling factors essential for CNS 
functioning, such as regulating factors of adult neural stem cell niches (Lun, Monuki and 
Lehtinen, 2015; Silva-Vargas et al., 2016). CPECs express a range of growth factor and 
hormone receptors, which respond to signals from the circulation, CNS and immune system 
by changing its secretome dynamically (Sawamoto et al., 2006; Grapp et al., 2013). 
Moreover, the CP is an important source of other CSF proteins, such as transthyterin (TTR), 
a thyroxine and retinol transport protein that is the most abundantly synthetized and 
secreted protein in the CP (Aldred, Brack and Schreiber, 1995). Evidence also suggests that 
the CP is one of the main regulators of CNS immunity by controlling immune cell entry into 
the ventricles of the brain (Nathanson and Chun, 1989; Reboldi et al., 2009; Netsky and 
Shuangshoti, 2013). 
1.2.4 Cerebrospinal Fluid Dynamics 
I. Composition. 
As indicated above, the CSF is derived from plasma and thus the composition of CSF 
is similar to that of plasma, but contains distinct concentrations of specific components. 
For example, CSF, contains less than 0.45mg ml-1 protein, the biggest fraction of which is 
albumin, which is around 300 times lower than protein concentrations in the blood (H 
Uhmer et al., 2006; Tumani, Huss and Bachhuber, 2017). Peptides and proteins found in 
the CSF can be either actively transported from the blood, such as leptin, or synthesized 
and secreted by CPEC, such as transthyretin (TTR) or insulin-like growth factor (Strazielle 
and Ghersi-Egea, 2013; Spector, Snodgrass and Johanson, 2015). In order to compensate 
for the lack of negative charges amongst CSF solutes due to reduced plasma proteins and 
lower concentrations of HCO3- and K+, the CSF has altered concentrations of some specific 
ions, such as increased concentrations of Mg++, ascorbic acid and folate and a Cl- 





concentration is 60% higher than in the serum, and fewer than 5000 mononuclear cells ml-
1 are to be found in healthy CSF (Sakka, Coll and Chazal, 2011; Spector, Snodgrass and 
Johanson, 2015; Adigun and Al-Dhahir, 2019). The active molecular transport through the 
CP allows for concentrations of some ions in the CSF to be carefully regulated 
independently of variations in the plasma concentrations of these ions (Husted and Reed, 
1976; Murphy, Smith and Rapoport, 1986; Praetorius and Damkier, 2017).  
The next sections will discuss current hypotheses regarding CSF secretion, 
circulation and drainage. However, it should be noted that knowledge of CSF dynamics is 
still a matter of debate and an area of active research which continues to generate 
additional experiments and interpretation.  
II. Secretion. 
The CSF is mainly produced by CPEC, although the brain interstitium and meninges 
are thought to contribute in a smaller scale (Sakka, Coll and Chazal, 2011; Damkier, Brown 
and Praetorius, 2013; Orešković and Klarica, 2014). In a healthy adult human, the volume 
of CSF is around 150 ml, with a rate of secretion from CP of approximately 0.4ml min-1g-1 
of tissue, suggesting that CSF is replaced between 3 and 4 times in a day (Speake et al., 
2001; Benarroch, 2016). . It is thought that CSF secretion rate varies during a 24 hour period 
in a cyclic manner and coupled with circadian rhythms (Nilsson et al., 1992; Myung et al., 
2018; Yamaguchi et al., 2020). 
The initial step that allows CSF secretion is passive filtration of plasma through the 
fenestrated capillary network into the connective tissue in the CP. The second step is 
dependent on the active unidirectional transport of ions by the CPEC, which creates the 
osmotic gradient that drives the movement of water into the ventricle. This task is carried 
out by transport proteins that are located on the apical and basolateral membranes of the 
cells (Speake et al., 2001; Alimajstorovic, Pascual-Baixauli, et al., 2020) (Figure 1.9). 
There are net fluxes of many ions, organic anions and organic cations across the CP, 
important for the normal function of the CNS. CPECs also mediate the net absorption of K+ 
into blood, necessary for maintaining K+ concentration in CSF, which is closely linked to CSF 




secretion (Ames, Higashi and Nesbett, 1965; Roepke et al., 2011). However, the ions that 
most contribute to the osmotic gradient that drives CSF secretion are Na+, Cl- and HCO3- 
(Saito and Wright, 1983; Brown et al., 2004). More specifically, it primarily depends on the 
active transport of Na+ by the Na+-K+ ATPase (ATP1) and the production of HCO3- by the 
carbonic anhydrase in CPEC, which catalyses the conversion of H2O and CO2 into HCO3- and 
H+ (Speake et al., 2001; Millar, Bruce and Brown, 2007). The Cl- transport from the blood 
side is driven by the anion exchange 2 (SLC4A2) which mediates HCO3- and Cl- interchange. 
The secretion of Cl- into CSF is mediated by the K+-Cl- cotransporter 4 (KCC4) and an inward 
rectifying channel, while the secretion of HCO3- happens through the electrogenic Na+-
HCO3- cotransporter (NBCe2). Water moves into the ventricles through either aquaporin 
channels in the cell membrane or the paracellular pathway once the osmotic gradient is 









 Figure 1.9. Model of cerebrospinal fluid secretion by the choroid plexus epithelial cell.  
Summary of ion transporter expression in CPEC and how they facilitate CSF secretion. CPEC form the BCSF 
because of the TJs joining adjacent cells, which restrict passage of solutes, ions and water. The secretion of 
CSF creates a net transport from blood into CSF of Na+, HCO3-, Cl- and H2O. This model of CSF secretion 
schematically represents locations of transporters. Briefly, the ion transporters the Na+-H+ exchanger 
(Slc9a1), the Na+- HCO3- cotransporter (Slc4a10) and the Cl--HCO3- exchanger (Slc4a2) are located basolaterally 
while the sodium-potassium adenosine triphosphatase (ATP1) and the Na+-K+-2Cl- cotransporter-1 (SLC12A2) 
are located in the apical membrane. Transport of HCO3- and Cl- into the CSF is mediated by HCO3-/ Cl- anion 
channels. Aquaporin 1 (AQP1) is expressed both basolateral and apically and it mediates passage of H2O. 
(Diagram by Ester Pascual Baixauli). 
A small percentage of CSF is also derived from extrachoroidal components. This 
extrachoroidal component usually results from exchanges between ISF in the CNS 
parenchyma, and CSF in the ventricles through the ependyma lining. However, this 
pathway appears to play a minimal role under physiological conditions (Sakka, Coll and 
Chazal, 2011; Benarroch, 2016). 





As previously mentioned, CSF fills the ventricular system and the cranial and spinal 
subarachnoid spaces. The constant production of new CSF by CPEC displaces fluid and 
drives its drainage, ensuring a stable environment for the brain and removing waste 
products (Orešković and Klarica, 2014; Bothwell, Janigro and Patabendige, 2019). Once 
thought to be unidirectional, CSF generally flows from secretion sites towards drainage 
points (Figure 1.10); however, growing evidence suggests that CSF circulation is an 
extremely complex process with changing rates, directions and paths depending not only 
on the circadian clock but also on behavioural states, such as stress response (Mokri, 2001; 
Sakka, Coll and Chazal, 2011; Tumani, Huss and Bachhuber, 2017). There seems to be a very 
strong cardiorespiratory pulsatile modulation of CSF movement, especially in adults 
(O’Connell, 1943; Greitz et al., 1992; Wagshul, Eide and Madsen, 2011; Dreha-Kulaczewski 
et al., 2018; Mestre et al., 2018). In large ventricles, CSF bulk flow is mostly driven by 
secretion and drainage rates, while in smaller spaces, such as the third ventricle, multi-
ciliated ependymal cells appear to have a big role on circulation dynamics (Orešković and 
Klarica, 2014; Linninger et al., 2016; Abdelhamed et al., 2018; Eichele et al., 2020).  
Generally, the CSF produced in the lateral ventricles flows through the 
intraventricular foramina into the third ventricle, then flows through the cerebral aqueduct 
to the fourth ventricle, where more fluid is secreted (Gideon et al., 1994; Falcão et al., 2012; 
Akay et al., 2015; Reiber, 2016). From there, the CSF can either reach the subarachnoid 
space near the pontine cistern via the lateral apertures and the median aperture or 
continue within the ventricular system flowing down the central canal of the spinal cord. 
The lateral apertures, also called foramina of Luschka, are located in each lateral recess of 
the fourth ventricle, while the median aperture, also called foramen of Magendie, is 










Figure 1.10. Cerebrospinal fluid dynamics in the human.  
Simplified representation of CSF dynamics in the human brain. 1. CSF is produced in the CP of each ventricle. 
2. CSF flows through the ventricles and into the subarachnoid space via the median and lateral apertures, or 
through the central canal of the spinal cord. 3. CSF flows through the subarachnoid space and 4. CSF can get 
drained in different sites, such as through arachnoid granulationsinto the sagittal sinus. (Illustration by Ester 
Pascual Baixauli). 
IV. Drainage 
CSF drainage is a complicated process that can occur at different sites, which fall 
into three functionally distinct categories: the arachnoid granulations, the perineural 
sheaths surrounding cranial and spinal nerves and the dural lymphatic vessels.  
The first described CSF drainage pathway was via the arachnoid villi granulations 
into the dural venous sinuses to reach the venous circulation. Each arachnoid villus acts as 
a one-way valve and allows the unidirectional flow of CSF from the subarachnoid space into 
















space (Ueno et al., 2016). Originally this was believed to be the only CSF drainage pathway. 
However, further evidence suggests that CSF drainage can also occur in other locations, 
such as via the spinal arachnoid villi, by diffusion into the ISF through the ependymal layer 
and then into the blood through the BBB, or via the nasal lymphatics (Pollay, 2012; Chen et 
al., 2015). Spinal arachnoid villi granulations are anatomically similar to the brain arachnoid 
villi granulations, and some research supports the idea that they also allow drainage of CSF 
into the venous blood system (Seyfert, Koch and Kunzmann, 2003).  
The importance of the lymphatic system on CSF drainage has been accepted 
relatively recently after several studies have provided strong support for the existence and 
relevance of this physiological pathway (Johnston and Papaiconomou, 2002; Iliff et al., 
2012; Raper, Louveau and Kipnis, 2016; Gillooly et al., 2017). The most commonly observed 
drainage routes by the lymphatic system involves CSF flowing along the perineural space 
of the olfactory nerve into nasal mucosa of the nasal cavity (Pollay, 2012; Chen et al., 2015) 
Here, it gets absorbed through the submucosal lymphatic system and gets ultimately 
drained to the nasopharynx regional lymph nodes (Raper, Louveau and Kipnis, 2016). 
The glymphatic pathway was firstly observed in the 1980s, although it was not until 
2012 when the pathway was properly identified and it has been gaining importance ever 
since (Figure 1.11) (Cserr et al., 1981; Fossan et al., 1985; Iliff et al., 2012). In this 
hypothesis, CSF flowing through the subarachnoid space enters the glymphatic flow by the 
perivascular space of major cerebral arteries on the brain surface. From there, the CSF 
flows towards the brain parenchyma along the arteries as it branches into penetrating 
arteries. The glymphatic system is characterized by an influx of CSF into ISF in extracellular 
spaces facilitated by a polarised expression of aquaporin 4 (AQP4) at the astrocytic end-
feet lining the perivascular space (Rasmussen, Mestre and Nedergaard, 2018; Nakada and 
Kwee, 2019). Bulk clearance of fluid from brain parenchyma moves towards the venous 
perivascular space; once this space is reached, the fluid is drained by convection into 
meningeal and cervical lymphatic drainage vessels (Xie et al., 2013; Marchi, Banjara and 
Janigro, 2016; Iliff, Thrane and Nedergaard, 2017; Da Mesquita, Fu and Kipnis, 2018; 






Figure 1.11. Glymphatic fluid drainage pathway in the brain.  
CSF enters the glymphatic flow by the perivascular space of major cerebral arteries on the brain surface. From 
there, the CSF flows towards the brain parenchyma along the arteries as it branches into penetrating arteries. 
The glymphatic system is characterized by an influx of CSF into ISF in extracellular spaces. Bulk clearance of 
fluid from brain parenchyma moves towards the venous perivascular space; once this space is reached, the 
fluid is drained by convection into meningeal and cervical lymphatic drainage vessels. (Diagram by Ester 
Pascual Baixauli). 
The proportion of CSF that efflux through each pathway is not yet known in humans. 
However, some animal studies suggest that CSF drainage through the lymphatic pathways 
might account for up to 50% of total CSF outflow (Pollay, 2012; Sokołowski et al., 2018). It 
is important to remark that these studies were performed in rodents; while they are 
accepted as a good model for disease research, there are important anatomical and 
physiological differences between species therefore the lymphatic pathway of CSF 
drainage in humans might be less important than in rodents. All main drainage pathways 
have shown to be pressure gradient dependent in healthy individuals (Boulton et al., 1998). 




1.2.5 Preclinical Research on Cerebrospinal Fluid Secretion 
Dynamics  
I. In vivo Assessment of Cerebrospinal Fluid Secretion 
In vivo CSF secretion measurements are challenging and many techniques have 
been developed in order to measure in vivo CSF secretion. The most common ones are 
summarized below.  
 Cerebrospinal fluid drainage  
CSF drainage is the simplest and oldest technique to measure CSF formation in vivo 
(Flexner and Winters, 1932; Greenberg et al., 1943; Orešković and Klarica, 2010). In brief, 
this method consists on introducing a needle into the CSF space and collecting the CSF 
outflow. At the beginning of the experiment, a large amount of CSF will escape, therefore 
it is necessary to wait until the CSF outflow rate stabilizes. Once the CSF flows out of the 
needle in a steadily manner, the CSF formation rate can be directly visualised and 
calculating by measuring the CSF volume in time (Flexner and Winters, 1932; Orešković and 
Klarica, 2010). Another variant of this technique involves measuring the in vivo CSF pressure 
before removing a known volume of CSF from the CSF space. The time elapsed between 
this removal until the initial pressure is reached again is measured and the secretion rate 
is calculated from this (Orešković and Klarica, 2010). However, this is not a very popular 
method for CSF secretion studies due to the possibility of this abrupt decrease on CSF 
volume affecting CSF secretion rates, which would make the measurement of 
physiologically normal secretion rates difficult to assess. 
 Magnetic resonance imaging  
MRI is a non-invasive imaging technique that can be performed in living animals. 
This method allows for evaluation of direction and velocity of liquid flow through an 
internal vessel, in this case the Sylvius aqueduct (Figure 1.12) (Mark and Feinberg, 1986; 
Mascalchi et al., 1988). General CSF flow happens from secretion sites towards drainage 





secreted CSF and therefore CSF secretion rate can be calculated from it using the equations 
specified in Figure 1.12 (Brinkmann et al., 2000). This method has been effectively used in 
humans (Brodsky and Vaphiades, 1998; Brinkmann et al., 2000; Akay et al., 2015). However, 
very specialised and expensive machinery is needed, making it a difficult technique for 
animal studies.  
 
Figure 1.12. Scheme of measurements of cerebrospinal flow rate in the human brain using MRI. 
 (a) Schematic of the human brain ventricles, with emphasis in the choroid plexi and the Aqueduct of Sylvius. 
(b) The equation that allows calculation of CSF secretion by calculation on CSF velocity using the MRI method, 
where QCSF= CSF flow (m3/s), AaqS= cross section area of Aqueduct of Sylvius (m2), vCSF=difference between 
integrated CSF velocity in cranial and caudal directions (m/s). r =radius. (Diagram by Ester Pascual Baixauli) 
 The ventriculo-cisternal perfusion technique. 
The main method used to measure CSF secretion in animals is the ventriculo-
cisternal perfusion technique, which has been used extensively for the study of CSF 
dynamics since it was first established (Heisey, Held and Pappenheimer, 1962; 
Pappenheimer et al., 1962) (Figure 1.13) . In this technique, artificial CSF (aCSF) is infused 
𝑄𝐶𝑆𝐹 =  𝐴𝑎𝑞𝑆  ·  𝑣𝐶𝑆𝐹  
𝐴𝑎𝑞𝑆 =  𝑟

















into the ventricles of a living anaesthetised animal and CSF samples are collected from 
cisterna magna. The aCSF contains a tracer molecule which allows calculation of dilution 
factors from the samples collected. Endogenous CSF secretion rates can be calculated 
based on dilution rates of the tracer. While this procedure has been widely used for CSF 
dynamic studies, it presumes that endogenous CSF secretion is the only factor that 
contributes to the dilution of aCSF. As such, other processes that could affect the dilution 
rate, such as diffusion of aCSF into ISF, are not considered (Martins, Newby and Doyle, 
1977). However, this technique presents advantages when compared to other CSF 
secretion measurement techniques. First of all, there is no need for highly specialised 
machinery and expertise on the procedure can be relatively easily acquired. Furthermore, 
the CSF at the cisterna magna flows freely, which balances the pressure increase due to 
aCSF insertion (Fenstermacher, 1972; Davson et al., 1982; Oreskovic et al., 2003).  
Figure 1.13. Schematic representation of the ventriculo-cisternal perfusion technique.  
Dextran blue is used as a marker and is infused in artificial CSF in both ventricles in the rat. The marker gets 


















II. In vitro Assessment of Cerebrospinal Fluid Secretion  
In vitro models are very important because they allow a controlled study of a 
specific process avoiding external factors that could affect an organism, such as water or 
food intake of the animal. They are also more financially viable as in vitro materials are 
usually cheaper than many in vivo studies. Furthermore, the ethical considerations of 
performing experiments in vivo are generally not applicable in an in vitro experiment.  
In vitro modelling of CSF secretion typically involves the use of CPECs, which can be 
obtained from ex vivo CP or from an immortalised cell line, or the use of whole CP, and are 
used to assess CSF secretion directly or by the use of surrogates of CSF secretion (Vates, 
Bonting and Oppelt, 1964; Pollay et al., 1972; Klarr et al., 1997; Petersen et al., 2020). 
Porcine primary cultures have been used to assess CSF secretion and study the 
effect of certain molecules on this process (Hakvoort, Haselbach and Galla, 1998). 
However, lack of availability of primary pig cells and differences between the pig and 
human CNS limit the usefulness of this model. Human immortalized CPECs have also been 
used in an attempt to more closely model human physiology. However, because human 
CPECs are obtained from a CP carcinoma, whether they accurately replicate healthy CP 
tissue is questionable (Redzic, 2013; Bernd et al., 2015; Dinner et al., 2016). Rodent CPEC 
lines are the most commonly used in this kind of research because of their easy care and 
research versatility (Kitazawa et al., 2001; Zheng and Zhao, 2002; Kläs et al., 2010; Strazielle 
and Ghersi-Egea, 2011).  
Direct measurement of CSF secretion can be done by assessing the production of 
fluid or dilution of marker in the apical side or transport through the cell layer of specific 
molecules such as thyroxine, thymidine or leptin (Kitazawa et al., 2001; Strazielle and 
Preston, 2003; Shi et al., 2008) 
Indirectly, CSF secretion can be estimated by measuring the activity of enzymes or 
transporters that are involved in CSF production (e.g. Na+K+ATPase activity) (Vates, Bonting 
and Oppelt, 1964). Assessing ionic movements and ATPase activity can therefore allow for 
estimation of CSF secretion in vitro (Klarr et al., 1997; O’Reilly et al., 2019).  




 Extracorporeal perfusion of the choroid plexus 
This technique is performed by the rapid dissection of CP from freshly sacrificed 
animals followed by a perfusion of the ex vivo CP with a saline infusion (Pollay et al., 1972; 
Deane and Segal, 1985). It is important to preserve the vessels at the base of the CP when 
extracting it from the brain, as they will be used for the perfusion. The carotid artery above 
the anterior choroidal artery is ligated and the internal cerebral vein is cannulated and 
perfused (Pollay, 1975). The CSF secretion is then calculated from the change in 
haematocrit between the inflow and outflow fluids (Orešković and Klarica, 2010). Although 
this method is no longer in use by the scientific community due to the intrinsic difficulty of 
the technique and the development of easier reliable methods, it is important to note that 
it played an essential role in the acceptance of the hypothesis of CSF secretion by the CP.  
 Functional studies on human choroid plexus samples. 
Human CP samples may be obtained as spare material from neurosurgery, usually 
following the procedure of removal of a large CP papilloma. If this is the case, it is important 
to separate pathologically-unaltered tissue and use it for uptake studies, 
immunocytochemistry or molecular biology (Nyland and Matre, 1978; Redzic, 2013).  
Uptake studies usually involve use of test and reference molecule, which also serves 
as a marker of the extracellular space (Fagan and Cowan, 1971; Kaplan et al., 1973). Both 
molecules are incubated in aCSF after which the sample is analysed to determine the 
quantity of each molecule in the CP cells. The total amount of test molecule found in the 
sample after incubation is composed of two groups: molecules diffused from aCSF into the 
extracellular fluid of the CP; and molecules that entered the CPECs during the experiment 
via membrane transporters. In order to estimate the molecules that were taken up by the 
cells, the reference molecule is used. An ideal reference molecule extracellularly behaves 
as the test molecule but is unable to enter CPEC due to the lack of specific transporters. 
Therefore, the amount of test molecule in the extracellular fluid can be calculated by 
determining the quantity of reference molecule, which is then extracted to the total 





difficulty in using this technique is the lack of human samples and the ethical concerns 
associated with working with human tissues. 
 In vitro cell cultures of choroid plexus epithelial cells 
CPEC cell lines, either primary or immortalised, can be used to study vectorial 
transport of solutes as a model for CSF secretion. However, it is important to take into 
account the possible phenotypic differences between immortalised cell lines and in vivo 
CPECs, due to their origin, which is usually a carcinoma for human cells, but also due to the 
process used to confer cell immortality. It is also important to consider the innate 
differences due to the species from which they are derived. Nevertheless, they are a good 
in vitro model of blood-CSF barrier and they can be used for uptake and secretion studies 
(Kitazawa et al., 2001; Wollack et al., 2008; Alimajstorovic, Westgate, et al., 2020). CPEC 
used for BCSFB studies are usually grown on a permeable membrane which separates two 
compartments; the upper chamber representing the CSF side and the bottom one as the 
stromal blood side (Figure 1.14). 
Figure 1.14. Blood-cerebrospinal fluid barrier in vivo and in vitro. 
Comparison of blood-cerebrospinal fluid-barrier (BCSFB) in vivo (left) and an in vitro model composed of 
choroidal epithelium cells grown on a permeable membrane. In the model, the basolateral area which is 
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composed by cell medium on top of the cells represent the cerebrospinal fluid. (Diagram by Ester Pascual 
Baixauli) 
 In order to stimulate CSF secretion in vitro, ion gradients across the cell monolayer 
are needed (Strazielle and Ghersi-Egea, 2005). Inhibition of the Na+K+ATPase has shown to 
decrease the fluid secretion in in vitro cultures of CPEC (Haselbach et al., 2001), showing 
that the mechanism by which the cultured CPEC secrete CSF can be related to the in vivo 
pathway. 
1.1 Idiopathic Intracranial Hypertension 
Idiopathic Intracranial Hypertension (IIH), previously called Pseudotumor Cerebri or 
Benign Intracranial Hypertension, is a rare disorder in which the patient shows elevated 
intracranial pressure (ICP) for no obvious reasons (Farb et al., 2003; Binder et al., 2004; 
Julayanont et al., 2016). The first cases of IIH were reported in the 1890s by the German 
physician Heinrich Quincke under the name “meningitis serosa” (Quincke, 1893). The term 
Pseudotumor Cerebri was coined by Max Nonne in 1904 due to symptomatic similarities 
with a brain tumour but without the existence of such. Many cases appeared in the 
literature afterwards. However, several of them were actually due to underlying conditions, 
making them secondary intracranial hypertensions. In order to be able to distinguish 
between these and IIH, the neurosurgeon Walter Dandy developed in 1937 several 
diagnosis criteria (Dandy, 1937). In 1955, this disease was renamed “Benign Intracranial 
Hypertension” to distinguish it from increased ICP due to life-threatening conditions, such 
as cancer (Foley, 1955). Nevertheless, because of the association with severe symptoms 
which are not considered to be benign, the name was further changed in 1989 to Idiopathic 
(of unknown causes) Intracranial Hypertension (Baker, Baumann and Buncic, 1989). 






1.2.6 What is Idiopathic Intracranial Hypertension? 
A patient suffering from IIH shows normal neurodiagnostic tests, including an 
absence of disruption or damage to the ventricular system including brain tumours. 
However, individuals with IIH will have an increased ICP that is greater than 200 mm of 
water measured in a lumbar puncture (Wall, 1991; Friedman and Jacobson, 2002; Binder 
et al., 2004; Bidot and Bruce, 2015). 
The symptoms of IIH usually include debilitating headaches, hearing problems such 
as pulsatile tinnitus or hearing loss, back, shoulder and/or neck pain, and visual problems 
such as visual loss, diplopia, reduced acuity or transient visual obscuration (Radhakrishnan 
et al., 1993; Binder et al., 2004; Fraser et al., 2010). 
Nowadays, treatments for IIH do not ensure an improvement in the symptoms 
experienced by the patient or the condition itself. As the underlying reasons for the 
increase in ICP during IIH are unknown, current therapies are focused on tackling the 
patient’s symptoms (Bagga et al., 2005; Dykhuizen and Hall, 2011; Karmaniolou, 
Petropoulos and Theodoraki, 2011). The only available cure is weight loss, which can take 
weeks or months until the patient shows any improvement (Kupersmith et al., 1998; Rowe 
and Sarkies, 1999; Manfield et al., 2017). Furthermore, if visual problems are experienced 
by the patient, these might become chronic if not solved on time (Moreau, Lao and Farris, 
2014; Wagner et al., 2016; Agarwal et al., 2017). 
1.2.7 Epidemiology 
IIH is considered a rare disease and not much information about its incidence and 
prevalence is available. In Iowa and Louisiana, USA, an epidemiological study on IIH was 
performed to try to get a wider view about this condition. In this study, IIH incidence was 
estimated to be around 0.9 in 100,000 in the general population. However, in women that 
are 20% or more above their ideal weight, the incidence rose up to 19 cases in every 
100,000. Furthermore, 90% of IIH patients were female (Durcan, Corbett and Wall, 1988). 
The incidence of this disease is slowly increasing in the world population, probably due to 
both a higher awareness of the condition and the current global epidemic of obesity. 




Recently, a new study was performed in Scotland, a nation with a 29% prevalence of obesity 
on its adult population. In this study, the incidence of IIH was found to be 38 in 100,000 in 
obese females of childbearing age. Nevertheless, the true incidence is probably higher as 
numerous patients suffering from IIH do not present with papilledema, which can make 
their condition potentially misdiagnosed as this is still considered to be one of the main IIH 
characteristics. 
1.2.8 Diagnosis 
In order to diagnose IIH, three characteristics should be met: no signs of 
abnormalities on brain imaging, raised ICP with normal CSF constituents, and exclusion of 
any other possible causes for raised ICP. Modified Dandy criteria are usually used to assure 
an accurate diagnosis (Table 1.1). These criteria were established in 1955 and further 
updated in 2002 (Friedman and Jacobson, 2002) to distinguish individuals with IIH from 
patients with increased ICP due to another underlying condition.  
 
Fundus exam is an initial investigation that the practitioner might use to quickly 
assess the possibility of increased ICP (Figure 1.15). In this exam, the optic disc, situated at 
the back of the eye, is observed. A normal disc is small in size and has very defined borders. 
However, if the disc is swollen and present blurry borders, an excess of ICP will be 
suspected (Karmaniolou, Petropoulos and Theodoraki, 2011). This optic disc increased in 
1. Symptoms (if present) may only reflect those of generalized intracranial 
hypertension or papilledema. 
2. Signs (if present) may only reflect those of generalized intracranial hypertension 
or papilledema. 
3. Elevated ICP measured in the lateral decubitus position. 
4. Normal CSF composition regarding CSF levels of protein and main ions. 
5. No evidence of brain lesion or venous sinus thrombosis on imaging. 
6. No other identifiable cause of raised ICP.  





size is named papilledema; while papilledema is always related to increased pressure in the 
optic nerve, an increased ICP does not always result in an occurrence of papilledema 
(Binder et al., 2004; Chen and Wall, 2014; Markey et al., 2016).  
Brain imaging, preferably magnetic resonance imaging (MRI), is used to exclude 
brain anomalies. However, it is important to take into account that patients who suffer 
from high CSF pressure for a long time might present small changes in ventricular 
compression, partial empty sella and perioptic CSF distension (Brodsky and Vaphiades, 
1998; Agarwal et al., 2017).  
Figure 1.15. Comparation between an eye with a normal optic disc and an eye with papilledema.  
In papilledema, cerebrospinal fluid (CSF) increases pressure around the optic nerve, which creates a bilging 
optic disc classified as papilledema, which can be seen in an eye fundus exam. (Normal retina photography 
obtained from Häggström, 2014. Retina with papilledema photography obtained from Trobe, 2011. Eye 
diagrams by Ester Pascual Baixauli). 
A lumbar puncture is used to measure CSF pressure. In adult humans, CSF has a 
normal opening pressure between 100 and 200 mm of water in a lumbar puncture (Adigun 



















and Al-Dhahir, 2019). A pressure of > 250 mm of water is indicative of IIH (Figure 1.16). 
Using this technique, CSF samples can also be obtained for further analysis to determine 
cell count, glucose, ions and protein concentrations, and cell count, all of which should be 
within the normal range. Further investigations to exclude underlying pathologies might 
include thrombophilia screens, serum vitamin A and iron levels and renal and thyroid 
function tests. (Brodsky and Vaphiades, 1998; Wolburg and Paulus, 2010)  
 
Figure 1.16. Measurement of intracranial pressure by lumbar puncture.  
A pressure higher than 250 mm of water will be considered high. Furthermore, a CSF sample can be released 
to relieve pressure and/or to analyse CSF components and dismiss other possible reasons for elevated ICP. 
(Modified from Blaus, 2014). 
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1.2.9 Risk Factors 
Although the pathogenesis of IIH remains unknown, there are several 
characteristics that many IIH patients share, therefore they can be classified as risk factors 
for developing this condition. 
I. Obesity 
IIH is indisputably linked to obesity. This association has been confirmed by many 
studies (Radhakrishnan et al., 1993; Rowe and Sarkies, 1999; Glueck et al., 2005; Sinclair et 
al., 2008, 2010; Schwartz et al., 2013; Chen and Wall, 2014; Goudie et al., 2019). The 
incidence of IIH is higher in countries where rates of obesity are high (McCluskey et al., 
2018). For instance, a study performed in Spain determined an incidence of 5.1 IIH cases 
every 100 000 in the general population (Asensio-Sanchez et al, 2007), but another study 
in the UK measured a prevalence of 10.9 per 100 000 (Raoof et al, 2011). In Spain the 
incidence of obesity in the adult population is 13.3%, which is significantly lower than the 
22.7% obesity incidence in the UK. Furthermore, it has been frequently observed that losing 
weight reduces ICP and lowers headache symptoms in female IIH patients (Kupersmith et 
al., 1998; Manfield et al., 2017). Recent weight gain is also a common characteristic in 
newly diagnosed patients (Giuseffi et al., 1991; Friedman and Jacobson, 2002) 
The importance of obesity in IIH pathogenesis is also highlighted by the 
effectiveness of weight loss in improving the disease. Weight loss has been shown to be 
the most reliable treatment for reducing ICP and improving symptoms and even a small 
weight loss can yield better results than the most common drug treatment, the carbonic 
anhydrase inhibitor acetazolamide, alone (Johnson et al., 1998; Kupersmith et al., 1998; 
Binder et al., 2004; Subramaniam and Fletcher, 2017) In addition, reduction in body weight 
is the most effective mechanism to eliminate IIH symptoms (Wong et al., 2007; Manfield et 
al., 2017) 
Although there is a strong association between obesity and IIH, it is likely that IIH is 
caused by a mix of factors, in which obesity would play an important but not exclusive role. 
Indeed, even if obesity nowadays is a common condition in Europe and North America, IIH 




remains a rare disease. Recently, chronic inflammation associated with obesity has been 
proposed as one of the possible factors for IIH development. However, no definitive 
association between inflammation and IIH has yet been established (Sinclair et al., 2008; 
Dhungana, Sharrack and Woodroofe, 2009a).  
II. Sex Hormones 
Several studies have suggested that sex hormones may also play an important role 
in IIH development. This is supported by the higher incidence of IIH in adult females, 
whereas a sex difference is almost non-existent in paediatric patients (Glueck et al., 2005; 
Fraser et al., 2010; Besch et al., 2012; Sheldon et al., 2016). Many patients have a history 
of menstrual irregularities and a link has been established between IIH and polycystic ovary 
syndrome (PCOS), which is a condition characterized by a dysregulation of sex hormones 
(Glueck et al., 2003, 2005; Hornby et al., 2016; O’Reilly et al., 2019). Numerous cases have 
been reported of IIH linked to the use of oral hormonal contraception, emergency oral 
contraception and pregnancy (Giuseffi et al., 1991; Radhakrishnan et al., 1993; Bagga et al., 
2005; Zotz, 2015). In addition, at least three cases of secondary intracranial hypertension 
have been reported in association with testosterone treatment in transgender patients 
(Park et al., 2014; Bedolla, Buchanan and Hansen, 2017; Hornby et al., 2017).  
The study of hormone levels in IIH patients has been a long quest in IIH research. 
The main impediment for this kind of study is the usual protocol followed for collecting 
samples from female patients. As IIH is a rare disease, these kind of studies tend to be 
performed retrospectively using data that was collected when the patient was admitted 
for treatment, a time at which some practitioners collect blood and CSF samples for 
analysis. However, with this method, the menstrual cycle of the patient will not be taken 
into account and samples will be obtained at random days. Reproductive hormone levels 
of any woman of child-bearing age will greatly vary over the month (Sherman and 
Korenman, 1975). Therefore, the comparison of hormonal levels in blood and CSF samples 
of women at different stages of their menstrual cycle will not yield reliable results, as 
usually concluded by the authors themselves. Nevertheless, the most important 





Several studies have demonstrated increased levels of oestrogens in IIH patients 
compared to a control group (Donaldson and Horakt, 1982; Toscano et al., 1991). However, 
the stage of the cycle was not taken into account when comparing samples and these 
studies had a very low number of samples. Recent studies reported that IIH patients had 
increased concentrations of testosterone in the serum and increased CSF testosterone and 
androstenedione compared to age-matched controls with either simple obesity or PCOS, a 
condition which is usually related to obesity and androgen excess (Hornby et al., 2016; 
O’Reilly et al., 2019).  
Following these results, it would be easy to deduce that men should suffer IIH more 
often due to their higher levels of testosterone, which is not the case. However, it is 
important to note that androgens exert sexually dimorphic effects in human metabolism, 
and men with hypogonadism develop similar metabolic phenotypes to women with an 
excess of androgens (Kautzky-Willer, Harreiter and Pacini, 2016; Schiffer et al., 2017). A 
possible explanation for the involvement of androgens in IIH is that the IIH symptoms 
would be triggered by a certain concentration of testosterone rather than simply a very 
high level; this hypothetic IIH triggering androgen concentration would be higher than the 
normal levels in females and lower than the normal male concentrations, but closer to the 
former. Therefore it would be “easier” for females experiencing an increase of androgen 
concentration to reach that level (O’Reilly et al., 2019). It is important to note that men 
suffering with IIH tend to be morbidly obese and have larger waist circumference and waist-
to-hip ratio than female patients (Schwartz et al., 2013); those characteristics have been 
linked to decreased androgen levels in men, which supports this hypothesis (Giagulli, 
Kaufman and Vermeulen, 1994; Allan and McLachlan, 2010). Furthermore, androgen 
deprivation therapy can increase the chance of developing IIH in men (Valcamonico et al., 
2014). 
III. Growth Hormone alteration 
Growth Hormone (GH) and its primary mediator insulin-like growth factor 1 (IGF-1) 
are thought to play a role in IIH development because some cases have been reported in 
individuals following treatment with either of them, especially in children and adolescents 




(Darendeliler, Karagiannis and Wilton, 2007; Obinata et al., 2010; Besch et al., 2012). 
Moreover, Octreotide, a drug that mimics the GH inhibiting hormone, has been effectively 
used to treat IIH in several patients (House and Stodieck, 2016), including improvement in 
both symptoms and CSF pressure (Panagopoulos et al., 2007).  
IV. Other associated conditions 
In addition to obesity and variations in sex hormone concentrations, other 
conditions and medications have also been associated with increased risk of developing 
IIH. Some of the diseases most frequently reported are hypothyroidism and lupus 
erythematosus (Markey et al., 2016; Mollan et al., 2016). Tetracyclines, vitamin A 
medications and steroid withdrawal have also been associated with increased ICP leading 
to symptoms similar to those experienced in IIH (Markey et al., 2016). However, cases such 
as the ones where the ICP can be linked to a specific underlying disease or medication are 
better described as secondary intracranial hypertension, especially if the symptoms remit 
after the disease is treated or the medication is withdrawn. These cases can provide an 
insight into possible mechanisms driving the increase of ICP and can thus be incredibly 
helpful for IIH research.  
1.2.10 Treatment 
Current treatments for IIH are palliative and focused on ameliorating symptoms. 
The main goal after IIH is diagnosed is to preserve the patient’s visual function (Wall, 1991; 
Karmaniolou, Petropoulos and Theodoraki, 2011; Wagner et al., 2016). Overweight 
patients will be encouraged to lose weight, as it has been shown to be able to improve mild 
symptoms. However, patients who show intractable headaches and/or optic nerve 
involvement should be further treated. Treatment options include weight loss, drug 
therapies, lumbar punctures and surgery. 
I. Weight loss 
Weight loss improving symptoms on IIH patients was firstly described in 1974 





remission and a decrease in ICP (Rowe and Sarkies, 1999; Daniels et al., 2007). Moreover, 
some studies have shown that patients that lose weight have a more rapid recovery of 
visual problems than those who do not (Johnson et al., 1998; Kupersmith et al., 1998; 
Glueck et al., 2006). 
However, not all cases show improvement after weight loss (Panagopoulos et al., 
2007; House and Stodieck, 2016). Those cases typically need more aggressive therapies to 
achieve recovery. 
II. Drug therapies 
Pharmaceutical treatment of IIH usually involves administration of drugs that 
reduce CSF production. Among these, acetazolamide, a carbonic anhydrase inhibitor that 
acts by decreasing Na+ transport across the CPEC and therefore decreases CSF production, 
is the most frequently prescribed (Johnson et al., 1998; Wall et al., 2014; Bidot and Bruce, 
2015; Supuran, 2015). For individuals who cannot tolerate acetazolamide, other diuretic 
drugs may be used, such as topiramate, an anti-epileptic drug which possibly reduces CSF 
production by carbonic anhydrase inhibition and also helps with weight loss (Çelebisoy et 
al., 2007; Noda et al., 2017; Meibodi et al., 2018). 
Patients who develop rapid visual deterioration and do not respond to other types 
of medication may be administered corticosteroids (Binder et al., 2004; Thambisetty et al., 
2007). However, these drugs will not be the first therapy choice due to their side effects, 
which include weight gain, and also because steroid withdrawal is thought to be related to 
the development of IIH in some cases (Zadik et al., 1985; Liu et al., 1994).  
III. Lumbar puncture 
Lumbar puncture is an emergency procedure to relieve ICP acutely (Thambisetty et 
al., 2007; Obinata et al., 2010; Biousse, Bruce and Newman, 2011). This technique is not 
desirable to use as a long-term therapy because of their painful nature and difficulties to 
perform on obese patients (House and Stodieck, 2016). Furthermore, there is little 
evidence of its efficacy long-term (Yri et al., 2014; Hoffmann, 2019).  





Surgical treatment is usually contemplated if the patient does not respond to 
medication or if visual loss is progressing irremediably and the probability of chronic visual 
problems is increasing. Nowadays the surgery of choice is usually either optic nerve 
decompression or CSF diversion (Bidot and Bruce, 2015; Wagner et al., 2016). 
Optic nerve decompression is usually achieved by performing an optic nerve sheath 
fenestration (Figure 1.17, left). In this procedure, the surgeon will make an incision in the 
meninges surrounding the optic nerve, which will relieve the ICP exerted against the nerve. 
This technique is very effective in reducing papilledema and the patient will usually 
experience an improvement in their sight. However, the probabilities of experiencing post-
operative complications, such as ocular motility disturbance or retinal vascular problems, 
can be as high as 40% (Moreau, Lao and Farris, 2014; Julayanont et al., 2016).  
The most widely performed CSF diversion surgery is lumboperitoneal shunt due to 
its relative simplicity when compared to other shunt surgeries (Figure 1.17, right) (Tarnaris 
et al., 2011; Julayanont et al., 2016). In this procedure, a valved tube is implanted to 
connect lumbar CSF to the abdomen to allow unidirectional flow of CSF into the abdomen 
(Abubaker et al., 2011; El-Saadany, Farhoud and Zidan, 2012). The patient will show a rapid 
resolution of ICP soon after shunt surgery. However, there is a high chance of experiencing 
complications such as problems with the catheter, valve obstruction, shunt infection or 
overdrainage (Jusué-Torres, Hoffberger and Rigamonti, 2015). Furthermore, this type of 
shunt is less durable than ventriculoperitoneal ones (a catheter connecting brain lateral 
ventricles with abdomen) although the insertion surgery is easier to perform (Tarnaris et 
al., 2011). 
In summary, surgery options for IIH patients can be useful in extreme cases but they 







Figure 1.17. Some of the surgery options available for IIH patients.  
(a) In the optic nerve fenestration surgery, an incision is made in order to release some CSF and decrease ICP. 
(b) In shunt surgery, a catheter is inserted into the lateral ventricles which then empties the excess of CSF 
into the chest cavity or, more commonly, in the abdomen cavity (a by Ester Pascual Baixauli, b) by Cancer 
Research UK, 2014). 
 
1.2 Cerebrospinal Fluid in Idiopathic Intracranial 
Hypertension. 
1.2.11 Cerebrospinal Fluid Composition in Idiopathic 
Intracranial Hypertension. 
One of the characteristics of IIH is the normal composition of CSF in terms of protein 
and ion content (Friedman and Jacobson, 2002; Friedman, Liu and Digre, 2013). Ion 
concentrations in the CSF of 150 mM Na+, 2.86 mM K+, 113 mM Cl- and 23.3 mM HCO3- are 
considered to be within the normal range. Some IIH patients present protein 
concentrations lower than normal CSF, although this is not considered to be the usual case 










cases of IIH where the concentration of other components, such as cytokines or hormones, 
was different from those measured in healthy individuals (Edwards et al., 2013; Samancı et 
al., 2017; O’Reilly et al., 2019). However, there is no consensus on the concentration of 
these molecules in the CSF of IIH patients. For example, one study assessing the different 
levels in serum and CSF of a range of cytokines such as TNF-α, found no significant 
differences between IIH patients and a group of unmatched controls (Ball et al., 2009). By 
contrast, another study found that TNF-α concentrations in IIH patients were elevated 
compared to healthy unmatched controls (Altokika-Uzun et al., 2015). Regarding hormonal 
concentration, studies are scarce and contradicting. However, two studies have found 
increased levels of androgens in IIH patients (Hornby et al., 2016; O’Reilly et al., 2019). 
While the mechanisms by which sex hormones could alter CSF dynamics are unknown, in 
vitro studies have demonstrated that oestrogen and progesterone are able to reduce CSF 
secretion by the CP while testosterone can increase it (Lindvall-Axelsson and Owman, 1989; 
O’Reilly et al., 2019).  
In summary, there is not a profile yet on CSF composition regarding smaller 
components, thus further work is needed in this topic. 
1.2.12 Cerebrospinal Fluid Dynamics in Idiopathic 
Intracranial Hypertension 
The mechanisms underlying the pathogenesis of IIH remain unknown, however it is 
probable that the condition is a disorder of CSF dynamics regulation, including CSF 
secretion and drainage impairments.  
I. Cerebrospinal fluid hypersecretion 
A significant and sustained increase in CSF secretion has been hypothesised to 
contribute to the formation of IIH. Some initial perfusion studies suggested CSF 
hypersecretion as one of the mechanisms in IIH (Donaldson, 1979). However, long-term 
infusion investigation into CSF hydrodynamics of IIH patients did not find an increase in CSF 
secretion (Malm et al., 1992). Modern MRI studies have not provided conclusive results 





flow dynamics which can be directly linked to increased secretion (Akay et al., 2015; 
Agarwal et al., 2018), others pointed to abnormalities within the CSF fluid cavities rather 
than increased flow rate as the main differences between patients and controls (Yılmaz et 
al., 2019). A study by Gideon et al, reported the analysis of CSF secretion, flow and of blood 
flow using velocity mapping MRI in a small number of IIH patients and healthy controls. The 
authors found a correlation between CSF volume flow amplitude and resistance to CSF 
outflow (Gideon et al., 1994). While there was no statistically significant difference 
between mean CSF secretion rates in patients and controls, three of the patients were 
found to have hypersecretion, and increased CSF transependymal flow in another two 
(Gideon et al., 1994). While it is not fully understood yet whether CSF hypersecretion 
occurs, the fact that the most effective drug treatments for IIH, such as acetazolamide and 
topiramate, act by reducing CSF production, points out to the strong possibility of this 
mechanism being deregulated and contributing to IIH. 
II. Cerebrospinal flow obstructions and malabsorption 
MRI imaging studies have found that a considerable number of IIH patients share 
several characteristics: empty sella, slit-like ventricles, subarachnoid space volume 
alterations or venous sinus stenosis. While some authors defend that these anatomical 
alterations are caused by the increase in ICP or that their effects on CSF flow are negligible, 
others hypothesise that they could be contributing directly to IIH (Higgins et al., 2004; 
Dykhuizen and Hall, 2011; Zotz, 2015; Morris et al., 2017). Empty sella is a flattening of the 
pituitary gland caused by an increased in ICP. Empty sella can lead to altered endocrine 
functions, although in most cases the pituitary gland will continue to work normally despite 
its appearance (Ranganathan et al., 2013; Saindane et al., 2013). Lateral ventricles are 
considered slit-like when their walls are collapsed, which decreases their volume. This 
phenomenon is probably caused by increased ICP or brain edema, although it could 
contribute to the former (Binder et al., 2004; Degnan and Levy, 2011). In IIH, the 
subarachnoid cisterns appear tighter while the subarachnoid space surrounding the optic 
nerve appears distended. The former could be caused by brain edema and contribute to 
raised ICP, while the latter could be explained by increased ICP (Killer et al., 2007; Bäuerle 




and Nedelmann, 2011). Venous sinus stenosis is the narrowing of venous sinus, which could 
be caused and consequence of higher ICP values, and is hypothesised to strongly contribute 
to IIH (Bussiere et al., 2010; Dykhuizen and Hall, 2011). According to this hypothesis, the 
narrowing of dural venous sinuses would increase the pressure inside these vessels. As CSF 
drainage is thought to be driven by a pressure gradient from the CSF ventricles outwards, 
this increase in venous pressure would lead to a decrease in CSF drainage, causing a further 
increase in ICP (Nedelmann, Kaps and Mueller-Forell, 2009; De Simone, Ranieri and 
Bonavita, 2010). The reason why sinus stenosis would happen is not clear yet; however, 
some authors claim that this narrowing would be caused by an increase of ICP, therefore 
hypothesising that venous sinus stenosis is not the original cause of IIH although it can 
contribute to it (Friedman, 2010; Giridharan et al., 2018). One long-term study of 16 
patients with IIH for up to 15 years after onset reported persistent disturbances in CSF 
hydrodynamics. These disturbances were classified into two categories depending on the 
identified mechanism: rise of sagittal sinus pressure, whose cause was speculated to be 
due to extracellular edema causing partial compression of the major venous sinus; or a low 
conductance of CSF flow coupled with a compensatory increase in CSF pressure in order to 
sustain the bulk flow (Malm et al., 1992). Venous sinus stenting, which involves surgically 
widening narrowed venous sinus by introducing a stent, has been suggested as a surgical 
option for IIH patients whose symptoms are not alleviated by medical therapy, weight-loss 
regimens or classical surgery options. However, while this procedure has been shown to 
relieve increased ICP, the patients experienced many post-surgical complications (Bussiere 
et al., 2010), emphasizing the need for further studies into possible pathogenic 
mechanisms of IIH.  
Other authors point to increased arachnoid resistance to CSF efflux and reduced 
drainage by arachnoid villi as characteristic phenomenon in IIH patients, which would 
reduce CSF secretion and contribute to an increased ICP (Malm et al., 1992; Orefice et al., 
1992). An impairment in the glymphatic drainage has also been postulated as an influence 
for increased ICP in IIH (Lenck et al., 2018; Mondejar and Patsalides, 2020). According to 
this hypothesis, the decrease in drainage through other mechanisms would overflow and 





interstitium and/or paravascular spaces and contributing to the ICP increase characteristic 
of IIH. Nevertheless, the glymphatic dysfunction as cause of IIH hypothesis is relatively 
recent and further investigations are needed in order to further characterise its 
mechanisms and its influence in the development of IIH. 
III. Other factors 
It has been hypothesised that IIH is influenced by an increase in intra-abdominal 
pressure caused by obesity which would then increase venous pressure and alter drainage, 
as mentioned above (Bloomfield et al., 1997; Sugerman et al., 1997; Sugerman, 2001). 
Other studies postulate adipokines and other inflammatory mediators typically associated 
with overweightness as factors for IIH development (Sinclair et al., 2008; Samancı et al., 
2017). However, despite the rise in obesity worldwide, IIH remains a rare disease (Mollan 
et al., 2016; Goudie et al., 2019). Furthermore, its preference for women indicates that IIH 
pathophysiology might be related not just to the overweightness state but also to the 
female sex. As a matter of fact, previous studies from our group examining the role of diet 
and cytokines on CSF secretion rate and resistance to drainage in male and female Wistar 
rats found increased baseline CSF secretion and reduced CSF drainage rates in female 
animals fed a high fat diet (Alimajstorovic, Pascual-Baixauli, et al., 2020). These results 
support a role for obesity and female sex as important contributors to regulation of CSF 
dynamics. Furthermore, a recent study that found increased levels of androgens in serum 
and CSF of IIH patients also reported an increase of CSF secretion in vitro when CPECs were 
exposed to testosterone (O’Reilly et al., 2019). 
In summary, the exact pathophysiologies underlying IIH are unknown. IIH is likely to 
be a disorder of CSF dynamic regulation in which CSF secretion and drainage are impaired, 
and which might be related to obesity and female sex. 
1.3 Hypothesis and Objectives 
We hypothesise that CSF secretion can be altered by diet-induced obesity and 
increased inflammatory mediators in the CSF or sex hormones.  




The present research was aimed at studying the molecular mechanisms that 
mediate CSF secretion in the obese rat. In order to do so, four objectives were set: 
1. To determine if there is an additive effect of pro-inflammatory and diet-induced obesity 
on CSF secretion in male rats. 
Previous work from our group has shown that CSF secretion is significantly 
increased in male and female rats fed a diet high in fat (Alimajstorovic, Pascual-Baixauli, et 
al., 2020). Obesity is associated with chronic low-grade pro-inflammation and increased 
levels of cytokines have been identified in IIH patients (Dhungana, Sharrack and 
Woodroofe, 2009a; Edwards et al., 2013; Samancı et al., 2017). Therefore, the first 
objective of this thesis was to study the effect of hydrocortisone (HC, synthetic cortisol), 
Tumour Necrosis Factor Alpha (TNFα), Chemokine Ligand 2 (CCL2), Interleukin 6 (IL-6) and 
Interleukin 17 (IL-17) on CSF secretion in lean and overweight male rats in order to study 
their effect without interferences from female hormones. 
2. To characterise CSF secretion in overweight and obese female rats  
It has been shown that administration of a high fat diet to female rats significantly 
increases CSF secretion in after 7 weeks of feeding (Alimajstorovic, Pascual-Baixauli, et al., 
2020). However, more longitudinal studies and analysis of hormone levels have not been 
conducted. This aim was to assess CSF secretion in female rats fed calorically dense foods 
to induce obesity.  
 
 
3. To identify changes in the gene expression profile of the choroid plexus in diet-induced 
female rats, especially expression of genes associated with CSF secretion 
Dietary fat is a known gene expression regulator (Jump and Clarke, 1999; Jump, 





gene expression levels of the CP (Janssen et al., 2013; Kant et al., 2018). CP samples of 
female rats fed a control and calorically dense foods were assessed by RNAseq to 
determine the molecular changes associated with obesity-induced increase in CSF 
secretion and validation of protein expression. 
4. To investigate the effects of testosterone in an in vitro model of CP 
Testosterone has been shown to be increased in IIH patients. Furthermore, this hormone 
increases CSF secretion in vitro (O’Reilly et al., 2019). This aim investigated the effects of 
testosterone on permeability and gene expression in an in vitro model of the CP.




Chapter 2. Effect of Diet and Cytokines on 
Cerebrospinal Fluid Secretion in Male Rats 
2.1 Introduction 
As mentioned previously, the development of IIH is strongly correlated with being 
overweight or obese. Obesity is a chronic condition in which there is an excess of 
accumulated white adipose tissue that may affect health negatively (Kopelman, 2000). This 
condition is often associated with other problems such as hypertension or glucose 
intolerance. Obesity has also been linked to predisposition of developing chronic 
inflammation mainly due to the endocrine properties of adipose tissue. Several studies 
have demonstrated a connection between obesity and increased levels of pro-
inflammatory cytokines such as TNFα, CCL2 and IL6 (Lyon, Law and Hsueh, 2003; Stępień et 
al., 2014; Ellulu et al., 2017). Therefore, given the association between IIH and obesity, it 
has been suggested that IIH might be related to a specific inflammatory profile (Sinclair et 
al., 2008).  
Since this association was proposed, many experts in the field have been trying to 
unravel the possible connection between cytokines and IIH. The current set of experiments 
focus on the impact of HC (synthetic cortisol), TNFα, CCL2, IL-6 and IL-17 on CSF secretion. 
It has been reported there is an increase in cortisol levels within CPEC in IIH obese patients 
(Sinclair et al., 2010). Table 2.1 shows a summary of the results of concentrations of IL6, IL-
17, CCL2 and TNFα in plasma of IIH patients obtained from different studies. Some studies 
have shown cytokine profiles or inflammation levels in serum and/or CSF specific to IIH, 
such as increased levels of CCL2 and IL17 in CSF or altered levels of TNF-α in plasma 
(Edwards et al., 2013; Altıokka-Uzun et al., 2015; Samancı et al., 2017). Others have found 
no difference in cytokine CSF or plasma levels between IIH patients and control individuals 
including individuals with headaches, multiple sclerosis and cerebrovascular diseases 
(Dhungana, Sharrack and Woodroofe, 2009b).  




Table 2.1. Cytokine concentration in plasma and CSF of IIH patients.  
*Concentrations in IIH patients compared to controls.  
--- the cytokine was not measured. 
 
It has been speculated that cytokines might contribute to the aetiology of IIH by 
ultimately altering CSF dynamics (Sinclair et al., 2008). However, the physiological impact 
of cytokines on CSF secretion in vivo is not clear. Furthermore, the impact that increased 















































































































































































IIH is highly related to obesity (Friesner et al., 2011; Markey et al., 2016). Previous 
work by our group investigated the effect of obesity on CSF dynamics in male and female 
rats, followed by an investigation into the effect of cytokines on CSF dynamics in the 
context of obesity in female rats (Alimajstorovic, Pascual-Baixauli, et al., 2020). This work 
led to the finding that female rats fed a HFD had the biggest changes in CSF dynamics when 
compared to their control group (Figure 2.1). It is possible that the effect of cytokines on 
CSF secretion was masked by female hormones, therefore a study focusing on the effect of 
diet and cytokines on CSF secretion in the male was necessary in order to determine if 
those results were specific to females. The present study was a contribution to a larger 
study that was performed by Dr Alimajstorović (Alimajstorovic, Pascual-Baixauli, et al., 
2020) the present research was carried out on male rats.  
Figure 2.1. Effect of diet and cytokine administration on CSF secretion of female rats.  
Female rats were kept under either ND or HFD for seven weeks. CSF secretion was measured by ventriculo-
cisternal perfusion of blue dextran. A) CSF secretion rates of rats depending on diet. B) results after treatment 
with cytokinecalculated as a percentage change from each respective control. Data is shown as average ±SD, 
n=3. A t-test (a) or two-way ANOVA (b) were used to analyse the statistical significance. *=P value  ≤ 0.05, 
***=P value≤ 0.001, ****=P value ≤ 0.0001. (Alimajstorovic et al., 2020) 
The experiments carried out in this chapter were aimed at exploring the effects that 
HFD and cytokines added to CSF can have on CSF secretion. In order to do that, CSF 
secretion rates were measured in rats under dietary manipulation. Furthermore, the CSF 
secretion rates of males with added cytokines into their CSF was also measured. 
N HControl HFD 
a) b) 




2.2 Materials and Methods 
2.2.1 Materials 
All materials used were obtained from Sigma-Aldrich (Poole, Dorset, UK) unless 
otherwise specified. 
2.2.2 Animals 
Male Wistar rats were ordered at 4 weeks of age from Envigo (UK) and maintained 
in the Biological Research Unit at the Open University for 7 weeks on either ND or HFD.  
The animals were housed in standard polypropylene cages (three animals per cage) 
and maintained under controlled humidity (55 ± 5%) and temperature (22 ± 2 0C) on a 
12:12h light and dark cycle. Rats were fed ad-libitum and weighed every week. Fresh water 
was always available for them to drink. Rats were killed by Schedule 1 procedures. All 
animal work was performed in accordance with Home Office project licence 
("Cerebrovascular changes in the aged and diseased brain", PPL number: 70/8507) and with 
approval from the Open University Animal Welfare and Ethical Review Body. 
2.2.3 Dietary manipulation 
The ND was the commercially available “Rat and Mouse No. 1 Maintenance Diet”, 
containing 2.7% fat, 45% carbohydrates and 14.3% protein, purchased from Special Diet 
Services (SDS, Essex, UK). The HFD diet was the “Rodent Maintenance Atwater Fuel Energy 
High Fat Diet”, containing 22.6% fat, 39.8% carbohydrates and 23% protein, purchased 
from SDS, (Essex, UK).  
Further information about diet composition can be found in Appendix A( Table 0.1, 
Table 0.2). 




2.2.4 Preparation of artificial cerebrospinal fluid 
Artificial CSF (aCSF) containing 0.5% (w/v) blue dextran was used for the in vivo 
ventriculo-cisternal perfusion (Table 2.2). The final ion concentrations were based on those 
previously described in the rat CSF (Davson, 1967). 
Table 2.2. Composition of aCSF, including the molecular weight (MW) for every compound and their 





















































To study the effect of cytokines on CSF secretion, aCSF was supplemented with one 
specific cytokine for each experiment at the concentration indicated in Table 2.3 as based 
on literature reports. 
 
 




Table 2.3 Concentration of treatment of interest in aCSF for ventriculo-cisternal perfusion. 
Treatment Dose Reference 
Hydrocortisone 
 (HC) 
500 ng/ml Sinclair et al., 2010 
Tumour Necrosis Factor 
Alpha (TNFα) 
0.1 ng/ml Hayakata et al., 2004 
Chemokine Ligand 2 
(CCL2) 
50 ng/ml  Dhungana, Sharrack, & Woodroofe, 2010 
Interleukin 6  
(IL-6) 
0.1 ng/ml ReihaniKermani, Faramarzi, Ansari, & Ghafarinejad, 2008 
 Interleukin 17  
(IL-17) 
0.1 ng/ml Li, Yu, Li, Zhang, & Jiang, 2012 
2.2.5 Ventriculo-cisternal perfusion 
CSF secretion rate was measured by performing the ventriculo-cisternal perfusion 
technique in the brain of anaesthetised living rats (Davson et al., 1982; Oreskovic et al., 
2003). Before starting the procedure, the rat was introduced to an inhalation chamber 
where 4% isofluorane inhalation vapour (Merial Animals Health, Essex, UK) mixed with 
oxygen at 3.5l min-1 was administered for 5 minutes. A dose of 20μl/100g weight of Domitor 
(medetonidine hydrochloride) and 50μl/100 g weight of Vetalar (ketamine) (both supplied 
by the Home Office Named Veterinary Surgeon, Red Kite Veterinary Consultants Centaur 
Services, Castle Cary, UK) were administered by intraperitoneal injections on both sides of 
the animal. The rat was again put in the inhalation chamber with 2% isofluorane inhalation 
vapour mixed with oxygen at 2.5 l min-1 for 5 further minutes to potentiate the action of 
the injectable anaesthetic. After that, the animal was removed from the chamber and laid 
on a warm pad to maintain constant body temperature throughout the procedure. Once 
an anaesthetized rat did not respond to reflex-inducing external stimuli (i.e. toe pinch) for 
more than 2 minutes, it was mounted into a stereotaxic frame (Kopf Instruments, Los 
Angeles, USA). Using a scalpel, a midline incision was made in order to expose the top of 
the skull. A 0.65 mm hand-chuck drill (Farnell Element, Leeds, UK) was used to drill bilateral 
holes above the lateral ventricles, followed by insertion of two metal cannulae with a 




diameter of 0.6 mm (0.8 mm posterior, 1.5mm laterally either side, 4mm depth, relative to 
Bregma). Both cannulae were attached to a water manometer. A drop in pressure when 
the cannulae were in place confirmed correct positioning within the ventricle. 
Simultaneous perfusion of both lateral ventricles with aCSF containing Blue Dextran using 
a Harvard slow-drive syringe pump (Harvard Apparatus UK, Cambridge, UK) was started 
immediately and taken as time zero of the experiment.  
The experiments were carried out using aCSF with or without cytokine of interest 
(Figure 2.2). The perfusion was performed for a period of 90 minutes per animal. Two 10 
ml syringes, one for each ventricle, with a diameter of 14.5 mm, were used. Perfusion 
inflow rate of aCSF was 20 μl min-1 for each ventricle for the first 20 minutes and 10 μl min-
1 for the remaining 70 minutes. The experiment started with a period of 20 minutes when 
the aCSF was perfused at a higher rate in order to remove possible blood clots resulting 
from cannulae insertion and to rapidly flush out endogenous CSF.  
Figure 2.2 In vivo experiment of ventriculo-cisternal perfusion in male adult Wistar rats. 
 aCSF (containing blue dextran) was perfused into each lateral ventricle of the rat brain. Samples were 
collected every 10 min for a period of 90 min from the cisterna magna. Each sample was analysed by reading 
the absorbance at a 625 nm wavelength on a spectrophotometer (Cin for initial aCSF, Cout for Sample). The 
dilution of the blue dextran within the aCSF in each sample indicates CSF secretion over the course of the 
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A 1 mm diameter blunt needle was inserted into the cisterna magna for collection 
of CSF. The needle was attached to a 5 cm piece of tubing with a 1 mm bore (Altec Products 
Ltd, St Austell, UK). The insertion point was determined by locating the base of the occipital 
bone, at the back of the exposed rat skull. The subarachnoid membrane was pierced below 
the bone and the needle was inserted into the subarachnoid space in the cisterna magna. 
Correct positioning was confirmed by immediate visualisation of flowing CSF through the 
needle into the tubing. CSF samples from the cisterna magna were collected over 10-
minute periods during the whole experiment and then stored in ice for further analysis. 
The amount of dextran in each sample was measured using a spectrophotometer (Fluostar 
Optima, BMG labtech, Aylesbury, UK) at 625nm wavelength. 
The CSF secretion rate was calculated from the samples collected once the initial 
endogenous CSF had been removed. This was determined by establishing the steady state. 
In order to do so, the absorbance value of each sample was divided by the absorbance 
value of the initial aCSF (Equation 2.1), and the results were plotted. The steady state was 
determined when a plateau was reached.  
Equation 2.1. Steady state calculation. 





• Cout= Absorbance value of sample (composed of aCSF and CSF) 
• Cin = Absorbance value of aCSF. 
The CSF secretion rate was calculated using Equation 2.2. The final calculation of 
secretion rate of the individual was an average of secretion rates measured from samples 
in the steady state. 
Equation 2.2. CSF Secretion rate calculation. 
𝑺𝑹 =
𝑪𝒊𝒏 −  𝑪𝒐𝒖𝒕 
𝑪𝒐𝒖𝒕
 ∙  𝑷𝑹  





• SR = CSF secretion rate (μl min-1) 
• Cin = Absorbance value of aCSF. 
• Cout = Absorbance value of sample (composed of aCSF and CSF) 
• PR = Perfusion rate (μl min-1); Sum of the inflow rate of both syringes used. 
 
The initial volume of endogenous CSF was calculated by multiplying the CSF 
secretion rate from each sample by the period the animal was perfused in order to obtain 
that sample, adding up the results from all the samples, and then subtracting the CSF 
secreted during the time the experiment was running (Equation 2.3). 
 Equation 2.3.Calculations of initial CSF volume. 
 𝑰𝒏𝒊𝒕𝒊𝒂𝒍 𝑪𝑺𝑭 𝑽𝒐𝒍𝒖𝒎𝒆 (𝝁𝒍) ==  𝑽𝑻 − −𝑽𝑺 −  




𝑽𝑺 = 𝑺𝑹𝑨𝒗  ∙  𝑻 
 Where: 
• VT = Total volume (μl) of endogenous CSF measured during the whole 
experiment. 
• Vs= Volume (μl) of CSF secreted while the experiment was running. 
• SRn= CSF secretion rate (μl min-1) calculated from a specific sample 
• Tn= Duration of a specific sample collection (min) 
• SRAv= Average CSF secretion rate (μl min-1) at the steady state. 
• T= Duration of the experiment (min). 
2.2.6 Statistical analysis 
Each group had three individuals (n=3) and all results are presented as average ± 
SEM unless otherwise specified. Normal distribution of data was confirmed by Q-Q plot. 




Differences in weight gain and CSF between ND and HFD at individual time points were 
analysed using a one way repeated measures ANOVA with Tukey post hoc to control for 
repeated sampling of the same animal across multiple time points. The final weight and 
differences in CSF secretion were analysed by two-tailed t test while the changes due to 
cytokine administration were analysed by a one way ANOVA with Tukey post hoc. The 
relationship between two parameters was measured using the Pearson correlation 
coefficient (r), where a coefficient higher than 0.6 and a significant P value was considered 
a strong correlation. A P value < 0.05 was considered significant. Statistical analysis was 
performed using IBM SPSS Statistics (IBM Corporation, 2017), JASP (JASP Team, 2019) and 










2.3.1 Animal model: diet and weight 
To study the effects of obesity on CSF secretion, rats were fed either ND or HFD ad 
libitum for 7 weeks starting at 4 weeks of age. The mean weights for ND and HFD rats over 
time are shown in Figure 2.3. Weight increased with time in both groups ( F(1.682, 35.322) 
= 623.662, P < 0.001) although the increase was significantly greater in the HFD group 
compared to ND-fed rats ( F(1.682, 35.322) = 14.925, P value < 0.01).  
Figure 2.3 Weight of male rats on ND or HFD over a seven-week period. 
Rats were obtained at 4 weeks of age and kept under either ND or HFD for 7 weeks. Weights were recorded 
weekly. Data is presented as average±SEM ND n=5, HFD n=18. A one-way repeated measures ANOVA was 
used to test the statistical significance of the change over time. Statistical differences between groups at each 
time point were tested using Tukey Post Hoc test. n=3,  **= P value <0.01, *** = P value<0.001  
Although both groups had similar weights when they started the respective diets, 
the final weight of rats under ND was 290.36 ± 1.74% of their initial weight, while rats under 
HFD weighed 361.94 ± 8.06% of their initial weight after 7 weeks under the diet (Figure 
2.4). 

























Figure 2.4 Final weight comparison between ND and HFD rats. 
Rats were obtained at 4 weeks of age and kept under either ND or HFD for 7 weeks. Data is calculated as 
percentage of final weight compared to initial weight and it is presented as average±SEM ND n=5, HFD n=18. 
A t-test was used to test statistical difference between groups. n=3,  *** = P value<0.001 
2.3.2  Effect of Diet on Cerebrospinal Fluid Secretion Rates 
I. Steady state determination 
To determine whether diet-induced obesity affects the dynamics of CSF secretion 
and volume, ND and HFD rats underwent ventriculo-cisternal perfusion as adapted from 
Oreskovic et al. 2003. Endogenous CSF was flushed and a steady state of CSF secretion was 
determined. The steady state was typically reached within 20 minutes of the start of the 
experiment (Figure 2.5) and, while Cout/Cin values obtained for the whole experiment 
changed over time, ( F(9, 36)=508.638, P value < 0.001), values obtained during the steady 
state were not altered across the perfusion time ( F(6, 24)=0.711, P value > 0.05). Diet did 
























































Figure 2.5 Steady state determination using Cout/Cin values.  
Cout/Cin values were calculated using Equation 2.1. Steady state determined from Cout/Cin values was used to 
select which samples could be used for CSF secretion rate calculations. Data represented as average ±SEM, 
n=3. A one-way repeated measures ANOVA was used to test the statistical significance of the change over. 
Statistical differences between groups at each time point were tested using Tukey Post Hoc test. n=3 
II. Cerebrospinal fluid secretion rate 
The absorbance values of the perfusate samples collected from the cisterna magna 
at steady state were then used to calculate CSF secretion rates for each diet. As shown in 
Figure 2.6, the secretion rate in rats fed with ND was significantly lower than those fed the 
HFD.  




Figure 2.6 CSF Secretion rates in male Wistar rats. 
CSF secretion rates were calculated by averaging secretion rates once the steady state was reached. Data 
shown as average ±SEM, n=3. A t-test was used to test statistical difference between groups. * = P value<0.05 
CSF secretion rates were plotted against final weight in order to evaluate a possible 
relationship between the two values (Figure 2.7). Although there was a trend towards a 
positive correlation between rat weight and rate of CSF secretion, it did not reach statistical 




































































Figure 2.7. Correlation between CSF secretion rate and weight in male rats.  
CSF secretion rate was measured using the ventriculo-cisternal perfusion technique. Weight measurement 
was taken on the day of the surgery. Data was analysed with Pearson correlation. n=3 
III. Initial Cerebrospinal Fluid Volume 
Because higher CSF volume is one of the main characteristics of IIH (Friedman and 
Jacobson, 2002), the initial volume of endogenous CSF was also calculated. The initial 
volume of CSF was calculated using Equation 2.3 and is represented in Figure 2.8. Initial 
CSF volume in ND rats was significantly lower than in HFD rats.  
r=0.78 
p value>0.05 



























Figure 2.8 Initial CSF volume in male Wistar rats.  
Initial endogenous CSF volume was measured using the ventriculo-cisternal perfusion technique. Data shown 
as average ±SEM, n=3. A t-test was used to test statistical difference between groups. * = P value<0.05.  
Endogenous CSF volume was plotted against weight to evaluate a possible 
relationship (Figure 2.9). There was a significant correlation between these two values 
(r=0.85, P value <0.05). 






























Figure 2.9. Initial endogenous CSF volume versus weight. 
Initial endogenous CSF volume was measured using the ventriculo-cisternal perfusion technique. Weight 
measurement was taken on the day of the surgery. Data was analysed with Pearson correlation. n=3 
2.3.3 Effect of diet and cytokine administration on CSF 
secretion. 
To investigate the effects of cytokines on CSF secretion in the presence of obesity, 
the ventriculo-cisternal technique was repeated but in this case the perfused aCSF was 
supplemented with various cytokines as stated in Table 2.3.  
I. Steady state determination  
The steady state determination calculations were performed for all rats in order to 
be able to select the appropriate samples for CSF secretion calculations. As in the previous 
experiment, the steady state was typically reached after 20 minutes (Figure 2.10). 
r=0.85 
p value<0.05 


























Figure 2.10. Mean steady state values for each cytokine treatment. 
Cout/Cin values were calculated using Equation 2.1. Steady state determined from Cout/Cin values was used to 
select which samples could be used for CSF secretion rate calculations. Data represented as average ±SEM, 
n=3. A one-way repeated measures ANOVA was used to test the statistical significance of the change over 
time. Statistical differences between groups at each time point were tested using Tukey Post Hoc test. 
There was a variation related to time on Cout/Cin values for all treatments (F(2.559, 
30.712)=1764.026, P value < 0.001). However, treatment did not specifically alter these 
values (F(12.797, 30.712)=1.205, P value > 0.05). Cytokine treatment did not alter CSF 
secretion rates at any time point during the steady state period (F(3.822, 45.867)=1.146, P 
value > 0.05). 
II. Cerebrospinal fluid secretion rate 
The CSF secretion rates of rats fed HFD in the presence of different cytokines were 
measured and are shown in Figure 2.11.  











































Figure 2.11. CSF Secretion rates in male Wistar rats under HFD and different treatments using ventriculo-
cisternal perfusion.  
Data shown as average ±SEM, n=3. A one-way ANOVA was used to test statistical difference HFD and each 
treatment. n=3, * = P value<0.05 
 
Rats perfused with HC showed higher rates of CSF secretion compared to untreated 
HFD-fed rats. Although administration of other cytokines caused a small fluctuation in CSF 
secretion rates, none were statistically significant compared to untreated HFD-fed rats. 
III. Initial Cerebrospinal Fluid Volume 
As explained previously, cytokines were administered with the aCSF during the 
ventriculo-cisternal perfusion, therefore it could not affect initial endogenous CSF volume. 
However, it is important to calculate the initial volume of the CSF in the rats in order to 
assess inter-individual variability and confirm the absence of underlying disturbances in CSF 
dynamics that could affect the results; a significantly higher initial CSF volume could 
indicate an underlying impairment between CSF secretion and drainage which would affect 
the results of the experiment.  




The initial CSF volume was calculated and compared between the rats prior to 
treatments to determine if CSF was building up inside the skull. The initial volume for each 

































Figure 2.12 Initial CSF volume in male Wistar rats using ventriculo-cisternal perfusion before treatment.  
Rats were obtained at 4 weeks of age and kept under either ND or HFD for 7 weeks. Initial endogenous CSF 
volume was calculated using the ventriculo-cisternal perfusion technique. Data shown as average ±SEM, n=3. 
A one-way ANOVA was used to test statistical difference HFD and each group.  
There was no significant difference in initial volume of CSF among any of the groups 
when compared to the control. 
2.4 Discussion 
IIH is a neurological condition which typically affects overweight or obese adults 
and its main characteristic is an excess of intracranial pressure (ICP) for unknown reasons. 
ICP can be raised by different mechanisms, such as impaired CSF dynamics and increased 
CSF secretion. Some studies have found that IIH patients have altered cytokine levels in CSF 
(Dhungana, Sharrack and Woodroofe, 2009a; Edwards et al., 2013; Samancı et al., 2017). 
The present study hypothesised that overweightness is associated with increased CSF 
secretion rates, and increased levels of some specific cytokines in CSF could potentiate this 




difference. The results of the present study suggest that overweightness can increase CSF 
secretion rates; only the addition of HC into CSF in HFD-fed rats increased these rates 
further.  
In order to study IIH, it was essential to use an overweightness animal model and 
compare it to a lean control group. IIH patients have also typically gained a high percentage 
of body weight over the year prior to diagnosis, which is why it is important to compare 
weight gain with respect to the individual initial weight between overweight and lean 
groups when studying this condition (Daniels et al., 2007).The statistically significant 
difference between the final weight as a percentage of starting weight for animals fed ND 
and HFD allows the consideration of HFD rats as overweight for the purposes of this 
experiment.  
In order to perform an accurate calculation of CSF secretion using the ventriculo-
cisternal perfusion technique, it is essential to properly determine when the steady state is 
reached and only use the values obtained during that state (Davson et al., 1982; Oreskovic 
et al., 2003). The steady state is characterised by a stability on Cout/Cin values. While these 
values increase directionally at the beginning of the experiment due to the presence of 
endogenous CSF, they must remain invariable during the rest of the experiment to allow 
for accurate calculations. During these experiments, Cout/Cin values increased greatly at the 
beginning, as expected. They also presented a steady state, thus allowing for proper 
measurements. There was no statistical difference on Cout/Cin values related to diet.  
An increased CSF secretion rate and initial CSF volume related to HFD was observed. 
Since HFD also increased weight gain and final body weight as expected, it was necessary 
to explore a possible relationship between these parameters and CSF secretion and initial 
volume. There was no significant correlation between CSF secretion and body weight. 
There was however a strong positive correlation between initial CSF volume and weight. In 
humans, CSF pressure has been shown to have a positive correlation with overweightness 
(Berdahl et al., 2012; Ren et al., 2012). While CSF volume was not measured in these clinical 
studies, increased CSF volume can cause increased CSF pressure; therefore, these patients 
might also have had increased CSF volume. 




It is known that obesity increases the concentration of some cytokines but, 
according to some studies, IIH patients show a specific cytokine concentration pattern both 
in blood and CSF (Dhungana, Sharrack and Woodroofe, 2009b; Edwards et al., 2013; Shaw 
et al., 2014; Samancı et al., 2017). However, authors have yet to agree on a specific pattern. 
Some authors have reported different cytokine patterns on CSF or blood of IIH patients 
(Edwards et al., 2013; Altıokka-Uzun et al., 2015; Samancı et al., 2017), while others found 
no differences between patients and controls (Dhungana, Sharrack and Woodroofe, 
2009b). Such discrepant and sometimes conflicting results point to the probable 
heterogeneity of the condition. It is possible that what is nowadays considered to be IIH 
will, in the future, be categorised into several different conditions depending on their 
pathophysiology or other differentiated characteristics of which we are not yet aware. 
Furthermore, the use of various different techniques with distinct detection limits may 
account for discrepancies in results. Furthermore, different patterns of deregulated 
cytokines could have similar causes and/or end up causing the same consequences. While 
this might also indicate that a similar treatment could have positive effects for patients with 
different etiologies of IIH, this is just a speculation and no evidence has been obtained yet 
pointing to this direction. On the other hand, if IIH patients can eventually be classified into 
several distinct conditions in need of different treatments, the rarity of these diseases 
would increase exponentially, increasing also the difficulties to overcome when studying 
them, including lack of funding and shortage of patients to study. At the moment however 
there is no research in this specific direction.  
While obesity also increases cytokine concentration (Shaw et al., 2014), the specific 
patterns mentioned in the previous paragraph could be related to IIH pathophysiology 
either causally or consequentially. The present study was designed to investigate the effect 
of increased cytokine levels in CSF in combination with overweightness on CSF secretion, 
which is thought to be one of the mechanisms by which ICP is increased in IIH (Sinclair et 
al., 2008). Several cytokine treatments, as well as a HC treatment, were selected on the 
basis of published studies of cytokine and cortisol levels in IIH patients, and were added 
individually at clinically relevant concentrations to the artificial CSF that was perfused 
during the ventriculo-cisternal technique.  




HC was the only cytokine that caused a significant change in CSF secretion when 
compared to control rats. HC has been previously reported to increase CSF secretion in 
females (Alimajstorovic, Pascual-Baixauli, et al., 2020). In the literature, there have been 
several cases of IIH related to acute steroid withdrawal (Zada et al., 2010; Wagner et al., 
2016), while other studies report increased cortisol in IIH patients and decreased cortisol 
levels in patients under weight management treatments (Tomlinson et al., 2004; Pollak et 
al., 2015). While HC has not been reported as an altered cytokine in CSF of IIH patients, the 
fact that it was able to increase CSF secretion matches a case report recently published 
(Mohammad et al., 2019). A 19-year-old man presented headaches and pulsating tinnitus 
for 2 months. He also presented normal brain venography and optic disc swelling; CSF 
pressure was not measured but a case of IIH was suspected. However, there was an 
underlying treated condition that might have been causing the symptoms: the patient had 
been previously diagnosed with psoriasis for which he had been applying topical HC three 
to four times a day. IIH symptoms started showing after the patient had started this 
treatment, and they improved after treatment with acetazolamide for increased ICP and 
cessation of topical hydrocortisone. This case, although rare, is very interesting because it 
is the first reported case that links overuse of topical steroids with IIH symptoms, and also 
matches the results of the present research: in both cases, HC lead to altered CSF dynamics.  
The approach of studying the effect of one cytokine at a time was selected in order 
to simplify experiments and be able to distinguish the effect a certain cytokine will have on 
CSF secretion; thus the interaction between the effects of different cytokines was not 
explored. The fact that IIH could show a specific pattern of cytokine levels might indicate 
that the final effect is produced by a combination of these mediators, thus an additional 
study investigating this possibility further would be beneficial. 
In conclusion, HFD was related to higher weight, higher initial volume of 
endogenous CSF and also higher rates of CSF secretion, which match with the typical IIH 
patient and one of the possible causes for such increased ICP. In HFD rats, only HC increased 
CSF secretion rates, which could be relevant for understanding how topical HC could alter 
CSF dynamics in a case study (Mohammad et al., 2019) . In the future, performing a study 




including more biological replicates or different diets would be appropriate in order to 
further investigate the relationships between weight, CSF volume and CSF secretion. 
Nonetheless, and also taking into account the results obtained by Dr Alimajstorović 
(Alimajstorovic, Pascual-Baixauli, et al., 2020), the focus of our project was switched to a 
more promising animal model. The subsequent research activities were designed to 
explore the molecular and physiological mechanisms by which female sex coupled with a 
HFD was able to alter CSF secretion so extremely in vivo.  
 




Chapter 3. Characterisation of the Effect of 
High-Fat Diet on Physiological Functions and 
Cerebrospinal Fluid Secretion in Female Rats  
3.1 Introduction 
In preclinical biomedical research, the preference of using male animals over 
females is, unfortunately, a reality. Moreover, many papers fail to report the sex of the 
subjects or cells used, making it impossible to assess whether their results were influenced 
by sex (Mogil and Chanda, 2005; Zucker and Beery, 2010; Beery and Zucker, 2011; Itoh and 
Arnold, 2015). These issues raise the concern that previous scientific findings might actually 
just apply to male individuals. The bias over the use of male animal models is usually a 
product of the common assumption that female individuals are more variable due to the 
oestrous cycle. However, recent research has shown that hormone levels in female rodents 
are not more variable than males and, under some conditions, males are more variable 
than females (Prendergast, Onishi and Zucker, 2014; Becker, Prendergast and Liang, 2016; 
Smarr, Rowland and Zucker, 2019). It is thought that male variability is mainly caused by 
the dominance hierarchy established in group-housed male rodents, while female 
variability is due to the oestrous cycle (Selmanoff, Goldman and Ginsburg, 1977; Machida, 
Yonezawa and Noumura, 1981; Henry, Meehan and Stephens, 1982). Our research was 
carried out in female rodents because of the female sex being an important risk factor for 
IIH development, as mentioned in Chapter 1, but also to explore further the effect of a high 
fat diet on different body parameters in the female. 
The oestrous cycle in the rat has been shown to affect many aspects of the 
individual ranging from effects of opioids to the stress response in critical situations, 
therefore, cycle monitoring is essential in order to reduce bias of research results (Pfaff, 
1970; Eliasson and Meyerson, 1975; Roberts, Bennett and Vickers, 1989; Marcondes et al., 
2001; Terner, Lomas and Picker, 2005; Friesner et al., 2011). The typical young adult female 
Wistar rat has a weight ranging between 250 and 300g and an oestrous cycle lasting 
between 4 and 5 days (Rivest, 1991; McCutcheon and Marinelli, 2009; Sengupta, 2013). 
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The rat oestrous cycle can be divided into four clearly identified stages. The cycle starts 
with proestrus, lasting around 12 hours, which corresponds to the onset of mating 
behaviour. This behaviour includes increased running activity, hopping, and the oestrus 
dance, which features freezing and ear quivering when handled (Stramek, Johnson and 
Taylor, 2019). In proestrus there is an increase in levels of prolactin, luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH) coupled with the beginning of ovulation. 
Elevated levels of these hormones persist until the end of the next stage, oestrus, which 
lasts 26 hours. Metoestrus, the next stage, takes around 8 hours and it is followed by 
dioestrus which can last up to 50 hours and is the stage at which the sex hormones are at 
their lowest levels (Feder, 1981; Westwood, 2008; Stramek, Johnson and Taylor, 2019). The 
gold standard for cycle monitoring is by cytologic analysis of vaginal lavage samples. Each 
stage of the cycle is characterised by different proportions of nucleated cells, cornified cells 
and leucocytes evident in the lavage (Westwood, 2008). Furthermore, the oestrus dance 
has been shown to be very effective for cycle monitoring due to its specificity: this 
behaviour only appears at the beginning of the proestrus, which usually starts with the dark 
period of the day. The simultaneous use of both vaginal cytology and detection of the 
oestrus dance increases the reliability of the cycle monitoring (Westwood, 2008; Stramek, 
Johnson and Taylor, 2019).  
Diet has been proven one of the most important environmental factors in health 
and disease, and it can also impact health state of offspring (Ng et al., 2010; Jakobsdottir 
et al., 2013; Nizari, Carare and Hawkes, 2016; Contu and Hawkes, 2017). A diet high in fat 
can affect many metabolic and physiological processes such as reproduction, energy 
storing, feeding behaviours and cholesterol level (Corbit and Stellar, 1964; Akiyama et al., 
1996; Buettner et al., 2006; Aubin et al., 2008; Aslani et al., 2015; Bazzano et al., 2015). 
Diet can directly impact adiposity and obesity, which is a risk factor for IIH. Increased 
adiposity is linked to cholesterol problems, specifically an excess of low-density 
lipoproteins (LDL) and a reduction of high-density lipoproteins (HDL) (Tchernof and 
Després, 2013). While cholesterol is a necessary molecule for many biological processes, 
an imbalance of LDL/VLDL and HDL can have a negative impact on cardiovascular health 




(Kannel, 1983; Jakobsdottir et al., 2013; Martins et al., 2015). However, the impact of 
cholesterol on CSF dynamics is unknown. Adiposity can also alter sex hormone levels, which 
in their turn might be linked to other altered parameters, such as CSF secretion.  
The aims of this chapter were to determine the effect of a diet high in fat on female 
rats, specifically on: feeding and drinking behaviour; physiological effects including weight, 
plasma cholesterol concentrations and sex hormones; and rates of CSF secretion. In order 
to study this, rats were divided into two groups depending on the length of dietary 
manipulation, and further divided into smaller subgroups depending on the type of diet 
used.  
3.2 Materials and Methods 
3.2.1 Materials 
All materials used were obtained from Sigma-Aldrich (Poole, Dorset, UK) unless 
otherwise specified. 
3.2.2 Animals 
Female Wistar rats were obtained from Envigo (Bicester, UK) at 4 weeks of age and 
maintained in the biological research unit of the Open University for either 7 or 11 weeks.  
The animals were housed in standard wiretop ventilated polypropylene cages in 
groups of three to four within larger cabinets (Scantainer, Scanbur, Denmark). Four males 
housed in groups of two were also present in the Scantainer to keep female rats cycling 
normally. Rats were maintained under controlled humidity (55 ± 5%) and temperature (22 
± 2°C) on a 12:12h light and dark cycle. Fresh water was always available for them to drink. 
All animal work was performed in accordance with Home Office project licence 
("Cerebrovascular changes in the aged and disease brain", PPL number: 70/8507) and with 
approval from the Open University Animal Welfare and Ethical Review Body. 
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3.2.3 Dietary manipulation 
The study was separated into two different groups depending on age: a first group 
was kept until they were 11 weeks of age (11w) and they were fed either ND or HFD for 7 
weeks; and a second group that was kept until they were 15 weeks of age (15w) that was 
fed either ND or HFD for 11 weeks, with an additional HFD group supplemented with 
peanut butter (HFD+PB) from weeks 7-11.  
ND was the commercially available “Rat and Mouse No. 1 Maintenance” in pellets, 
containing 2.7% fat, 45% carbohydrates and 14.3% protein, purchased from SDS (Essex, 
UK). The HFD used was the commercially available “Western Rodent Diet”, containing 
21.4% fat, 50% carbohydrates and 17.5% protein, purchased from SDS (Essex, UK). The 
HFD+PB diet was the “Western Rodent Diet” supplemented with approximately 8g of 
peanut butter (PB) per cage each day. The PB was the commercially available “Grandessa 
Peanut Butter Crunchy”, containing 50% fat, 13% carbohydrates and 26% protein, 
purchased from Aldi, UK. 
Further details about dietary components and ingredients can be found on 
Appendix A (Table 0.1, Table 0.3, Table 0.4) 
Rats were fed ad-libitum and weighed every week. Water intake was recorded daily 
and food consumption was recorded weekly except for the peanut butter supplement, 
which was refreshed and recorded daily. All consumption was recorded per cage and 
further calculations are described in section 3.2.4. 
 
3.2.4 Food, water and caloric intake calculations 
Absolute food intake (FI) and absolute caloric intake (CI) were calculated using 
Equation 3.1. Values were corrected to represent daily intake. Caloric intake of rats on a 
HFD+PB diet was calculated by adding the caloric value of the amount of PB added.  









𝑪𝑰(𝒌𝒄𝒂𝒍) = 𝑭𝑰 ∙  𝑪𝑽 
Where: 
FI= absolute food intake per animal (g) 
FIC= Food Intake of the cage (g) 
n= number of rats in the cage 
CI = absolute caloric intake per animal (kcal) 
CV= Caloric value of diet (kcal·g-1) 
 
Adjusted daily food intake (AdFI), calculated as food intake per g of body weight, 
and the adjusted daily caloric intake (AdCI) calculated as the caloric intake per g of body 
weight were calculated using Equation 3.2. 












AvW= Average weight of the animals in the cage (g) 
Absolute water intake (WI) and adjusted water intake (AdWI) were calculated using 
Equation 3.3. 
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WIC = Water intake of the animals in the cage (ml) 
Food, water and caloric intakes of 11w rats were taken from one cohort while the 
ones of 15w rats were recorded from two different cohorts: the rats which CSF secretion 
was measured in this chapter and those used for gene and protein expression analysis in 
Chapter 4. 
3.2.5 Measurement of body parameters 
I. Weight calculations 
Final weight was measured just prior to the ventriculo-cisternal perfusion 
experiments, while the other body parameters were measured and calculated afterwards. 
The body mass index (BMI) was calculated using Equation 3.4 (Gargiulo et al., 2014), and 
body fat content was estimated using Equation 3.5 (Rogers and Webb, 1980). Nasoanal 
length was measured on supine position. The gonadal fat pad was located surrounding the 
ovaries. 
Equation 3.4. BMI calculation. 





∙  (𝑵𝒂𝒔𝒐𝒂𝒏𝒂𝒍 𝒍𝒆𝒏𝒈𝒕𝒉 (𝒄𝒎) 𝟎.𝟕𝟐𝟓) ∙  𝟎. 𝟎𝟎𝟕𝟏𝟖𝟒  








Equation 3.5. Body fat content calculation. 
𝑩𝒐𝒅𝒚 𝑭𝒂𝒕 𝑪𝒐𝒏𝒕𝒆𝒏𝒕 =
𝑾𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝒈𝒐𝒏𝒂𝒅𝒂𝒍 𝒇𝒂𝒕 𝒑𝒂𝒅 (𝒈)
𝑩𝒐𝒅𝒚 𝒘𝒆𝒊𝒈𝒉𝒕 (𝒈)
 ·  𝟏𝟎𝟎  
II. Oestrous cycle recordings 
On the two weeks prior to the ventriculo-cisternal experiment, oestrous cycle of 
each female rat was recorded daily by vaginal cytology. Vaginal lavages were obtained 
every day, approximately one hour after the dark period started. The cellular composition 
of these lavages was used to determine the stage of the cycle (Figure 3.1). Most times, 
vaginal lavages were easily classified in one of the four stages of the oestrous cycle. 
However, in the odd occasions when the observed cell types of a lavage appeared to belong 
to two different but consecutive stages, the rat was classified as being between those 
stages. For example, a lavage showing a big proportion of leucocytes and also some 
nucleated cells would be classified as between dioestrus and proestrus. The presence of 
the oestrus dance was also used to confirm the cycle stage (Stramek, Johnson and Taylor, 
2019).Length of oestrous cycle was calculated as the average time in days between a rat 
being in proestrus and getting into proestrus again in the time period of two weeks. 
(normally 3-4 cycles). 
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Figure 3.1. Typical cell composition of vaginal lavage samples in each stage of the oestrous cycle of the 
female rat. 
X100 magnification  
III. Hormone and cholesterol analysis 
Blood samples were collected by cardiac puncture under terminal anaesthesia 
when the rats were in dioestrus. Plasma samples were separated using tubes with heparin 
(Sarstedt, Nümbrecht, Germany) and stored at -80 oC until further processing. Plasma was 
then used to measure hormone and cholesterol levels. 
Hormone levels were measured using commercially available ELISA kits following 
the manufacturer’s instructions: Oestradiol and Testosterone kits were purchased from 
Calbiotech, El Cajon, CA, USA, while Cortisol kit was obtained from BT-Lab, Birmingham, UK 
and Progesterone kit was acquired from Crystal Chem, Netherlands. Testosterone to 
Oestradiol ratio (T/E2) and oestradiol to progesterone (E2/P) ratio were also calculated. 
LDL/VLDL, HDL and Total Cholesterol levels were measured using a commercially available 
ELISA kit purchased from Abcam, Cambridge, UK, following the manufacturer’s protocols. 




3.2.6 Ventriculo-cisternal perfusion  
The preparation of aCSF is described in Section 2.2.2. The ventriculo-cisternal 
perfusion technique was performed following the protocol described in section 2.2.3, with 
some small changes. In brief, the rat was introduced to an inhalation chamber where 4% 
isofluorane inhalation vapour (Merial Animals Health, Essex, UK) mixed with oxygen at 3.5 
l·min-1 was administered for 10 min in order to induce anaesthesia. After that, the animal 
was transferred to the stereotaxic frame fitted with an anaesthesia facemask. During the 
experiment, anaesthesia was maintained with 2.5% v/v isofluorane inhalation vapour 
mixed with oxygen at 2 l·min-1. The animal was placed on a warm pad with an output 
maintained at approximately 37°C and was covered with insulation material to prevent the 
body temperature dropping. Body temperature was always monitored using a rectal 
thermometer and kept between 37oC and 38oC (Rufiange et al., 2020). Once anaesthetized 
rats did not respond to reflex-inducing external stimuli (i.e. pinching) for longer than 2 min, 
the skull was exposed, and two holes were drilled using a 0.65 mm hand-chuck drill on 0.8 
mm posterior to bregma and 1.5 mm laterally either side. Two 21-gauge metal cannulae 
(Bilaney Consultants Ltd, Sevenoaks, UK) were inserted into the skull to a depth of 4mm, 
where lateral ventricles are located. The perfusion was started immediately and taken as 
time zero of the experiment, which kept running for 120 min per animal. Perfusion inflow 
rate was 10 μl·min-1 for each ventricle for the first 20 min and 5 μl·min-1 for the remaining 
time. A 1 mm blunt needle was inserted into the cisterna magna for collection of CSF. 
Samples were collected over 20 minutes. Further analysis and calculations were performed 
following the procedure explained on section 2.2.3. All CSF secretion rate measurements 
were performed when the rats were in dioestrus. 
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I. ICP monitoring 
In 15w rats, ICP was monitored for the length of the ventriculo-cisternal perfusion. 
Pressure readings were obtained using the LifeSens single channel signal conditioner 
system and the Opp-M250 fibre optic pressure sensor (OpSens Solutions, Québec, Canada) 
following a protocol described previously (Murtha, Mcleod and Spratt, 2012). In summary, 
once the holes for ventriculo-cisternal perfusion were drilled, a third hole was drilled using 
a 2 mm hand-chuck drill on 3 mm posterior to bregma and 2 mm laterally on the right side, 
ensuring the dura was not damaged. A polyetheretherketone screw (Misumi, Frankfurt am 
Main, Germany) was screwed into the hole and secured using PermaCem Smartmix (DMG 
Dental, Porthcawl, UK). The screw had been previously perforated with a 0.7 mm drill. The 
hole in the screw was filled with 0.9% w/v NaCl solution in water. An ICP probe was inserted 
into the screw and was lowered to the end of the screw, avoiding piercing the dura. The 
depth of insertion was then carefully adjusted until ventilation and blood pressure pulse 
waves were detected by the pressure transducer. The probe was sealed in place using 
Silagum-Light Fast (DMG Dental, Porthcawl, UK) and pressures were recorded for the 
length of the ventriculo-cisternal perfusion. A schematic representation of the setup can 
be found in Figure 3.2. 
Figure 3.2. Schematic representation of setup for intracranial pressure monitoring. 
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 PRESSURE TRANSDUCER 




3.2.7 Statistical analysis 
Each 11w diet group had n=3 rats and each 15w diet group had n=5 unless 
otherwise specified. All results are presented as average ± SEM. Normal distribution of data 
was confirmed by Q-Q plot. Differences in weight gain, food intake and water intake over 
time were analysed using a two-way repeated measures ANOVA and differences between 
groups at each time point were tested using Tukey Post Hoc test. The differences on final 
measured parameters, such as final weight and CSF secretion rates between the HFD and 
ND at 11w were carried out using a two-tailed t-test, while differences between 15w ND, 
HFD and HFD+PB were analysed using a one-way ANOVA with Tukey Post Hoc test. The 
coefficient of variation was calculated in order to evaluate irregularities of oestrous cycle 
length. A data set was considered highly variable when their coefficient of variation >20%. 
The relationship between two parameters was measured using the Pearson correlation 
coefficient (r), where a coefficient higher than 0.6 was considered a strong correlation. A P 
value smaller than 0.05 was considered to indicate a significant difference. 
Statistical analysis was performed using IBM SPSS Statistics (IBM Corporation, 2017) 
for statistical analysis of weight increase over time, JASP (JASP Team, 2019), and for the 
remaining experiments, one-way repeated measures ANOVA and their post-hoc tests. 
GraphPad (Graphpad Software, 2019) was used for graph plotting and all other statistical 
analyses. 
3.3 Results 
3.3.1 Animal model: diet and weight  
Due to the strong relationship between IIH and obesity and female sex, this study 
was focused on exploring the effect of HFD-induced obesity on CSF secretion in females. 
An experiment was designed in which five groups of rats would be exposed to either ND, 
HFD or HFD+PB with their CSF secretion being measured at 11 weeks of age (ND 11w and 
HFD 11w) or 15 weeks of age (ND 15w, HFD 15w and HFD+PB 15w). The weight was 
recorded during the experiment and is represented on Figure 3.3 and Figure 3.4.  
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Figure 3.3. Weight of female rats on ND or HFD over a seven-week period. 
Weights were recorded weekly and averaged per diet group. Data is presented as average ± SEM, n=3. A one-
way repeated measures ANOVA was used to test the statistical significance of the change over time. Statistical 
differences between groups at each time point were tested using Tukey Post Hoc test. 
In the first cohort of rats, weight increased over time in both the ND and HFD groups 
(F(7,28)=918, P value <0.001), but there was no difference in weight gain between diets 
(F(7,28)=0.262, P value>0.05). As HFD did not induce overweightness in these rats, we 
decided to add a third group to the second cohort of rats, to be studied at 15w, which 
would be fed HFD until week 11 and then their HFD would be supplemented with a small 
amount of PB daily in order to increase weight gain. 














































Figure 3.4. Weight of female rats on ND or HFD over an eleven-week period. 
Weights were recorded weekly and averaged per diet group. Data is presented as average ± SEM, n=11. A 
two-way repeated measures ANOVA was used to test the statistical significance of the change over time. 
Statistical differences between groups at each time point were tested using Tukey Post Hoc test. ***= P value 
< 0.001, **** = P value < 0.0001.  
In the second cohort of rats, weight also increased with time in all groups (F(2.284, 
352)=1464.332, P value<0.001). The addition of PB to HFD in HFD+PB group from week 11 
led to a weight gain higher than that in the other two groups (Figure 3.4). This difference 
was observed as early as week 12, within a week of introduction of the PB supplement, and 
the increase in body weight of HFD+PB group was maintained until the end of the 
experiment. Rats fed the HFD also weighed significantly more than those fed the ND at 
weeks 14 and 15.  
Assessment of the effect of dietary manipulation at 11w and 15w of age is shown 
in Figure 3.5. The percent weight gain of HFD 11w rats was not different to that of ND 11w 
rats (ND 11w 227.77 ± 11.12%, HFD 11w 245.34 ± 33.12%, P value>0.05). However, in 15w 
rats, there was a significant increase on final weight as percentage of initial weight in both 
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HFD groups when compared to ND, especially in the HFD+PB (ND 15w 244.26 ± 13.55%, 
HFD 15w 284.43 ± 24.28%, HFD+PB 15w 388.14 ± 26.98%, P value<0.01)  
 
Figure 3.5. Evaluation of overweightness level of rat model depending on diet and age. 
 (a) Data is calculated as percentage of final weight measured on the day of the surgery relative to weight at 
4 weeks of age. (b) Data is calculated using Equation 3.4. (c) Data is calculated using Equation 3.5. All data is 
presented as average ± SEM, 11w n=3, 15w n=5. Groups were compared amongst each other on the same 
age group using a t-test for 11w and one-way ANOVA for 15w. * = P value <0.05, **= P value <0.01, *** = P 





























































































































































BMI was calculated using Equation 3.4 as a way of assessing overweightness. There 
was no significant difference between ND 11w and HFD 11w, but at 15w the HFD groups 
had a significantly higher BMI when compared to ND, specially the HFD+PB. 
Body fat content of rats was calculated using Equation 3.5 as a way of assessing 
adiposity level. All HFD groups had a higher body fat content than their respective controls 
at both 11 and 15w. The largest difference observed was that between ND and HFD+PB, 
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3.3.2 Food and water intake  
Data on food and caloric intake from 11w rats is shown in Figure 3.6. 
Figure 3.6. Daily food (a, c) and caloric (b, d) intake in 11w rats.  
Data is calculated as average of cage. (a) FI and (b) CI data is calculated per rat per day. (c) AdFI and (d) AdCI 
data is calculated per weight of rat per day. A two-way repeated measures ANOVA was used to test the 
statistical significance of the change over time. Statistical differences between groups at each time point were 
tested using Tukey Post Hoc test. n=3 
There was an increase in absolute food intake (FI) with time (F(5, 20)=4.226, P 
value<0.05), however adjusted food intake (AdFI) decreased with time for both diets (F(5, 
20)=17.9, P value<0.001 ). Absolute caloric intake (CI) increased with time for both diets 
























































































































(F(5, 20)=3.717 P value<0.05), but adjusted caloric intake (AdCI) decreased with time (F(5, 
20)= 16.418, P value<0.001). There was no difference in food or caloric intakes between 
diets ( FI: F(1, 4)=6.32, P value>0.05; AdFI: F(1,4)=13.399, P value>0.05; CI: F(1, 4)=5.355, P 
value>0.05; AdCI: F(1, 4)= 3.141, P value>0.05 ). There was no significant difference in 
either food or caloric intake between both diet groups at any given week. 
Data on water intake values are represented in Figure 3.7. 
 Figure 3.7. Daily water intake for 11w rats. 
Data is calculated as average of cage. (a) WI data is calculated per rat per day. (b) AdWI data is calculated per 
weight of rat per day. A one-way repeated measures ANOVA was used to test the statistical significance of 
the change over time. Statistical differences between groups at each time point were tested using Tukey Post 
Hoc test. n=3 
Absolute water intake (WI) increased with time (F(5, 20)=11.586, P value<0.05) 
while adjusted water intake (AdWI) decreased with time (F(5, 20)=7.618, P value<0.05), but 
they showed no difference between diet groups (WI: F(1,4)=0.509, P value>0.05; AdWI: F(1, 
4)=1.23, P value>0.05). There was no significant difference in water intake between both 
diet groups at any given week. 

























































 Characterisation of the Effect of High-Fat Diet on Physiological Functions and Cerebrospinal Fluid 




A separate group of rats (15w) was studied for 4 further weeks, including an 
additional group of HFD animals that received a supplementation with PB starting at week 
11 to increase the calorific value of the diet and enhance weight gain. The diet intake data 
for these older rats is represented in Figure 3.8. Note that the FI values represented on 
Figure 3.8 were calculated based on the intake of the HFD and does not include PB weight; 
however, caloric calculations do take PB into account. 
Figure 3.8. Daily food (a, c) and caloric intake (b, d) on 15w rats.  
Data is calculated as average of cage. (a) FI and (b) CI Data is calculated per rat per day. (c) AdFI and (d) AdCI 
data is calculated per weight of rat per day. All data is presented as average ± SEM, n=11. A one-way repeated 
measures ANOVA was used to test the statistical significance of the change over time. Statistical differences 









































































































































between groups at each time point were tested using Tukey Post Hoc test. **= P value <0.01, *** = P 
value<0.001.  
FI did not change significantly with time (F(1.133, 10.196)=2.459, P value>0.05) or 
diet (F(1.133, 10.196)=2.459, P value<0.05) (Figure 3.8.a), however, AdFI decreased with 
time (F(1.544, 13.895)=18.610, P value<0.001) although there was no difference related to 
diet (F(3.088, 13.895)=2.642, P value>0.05) (Figure 3.8.c). CI and AdCI had a sudden 
increase in week 11 and 12 and they varied with time (Figure 3.8.b, d) (CI F(3.265, 29.386) 
= 10.889, P value<0.001; AdCI F(8,72)=24.989, P value<0.001) and also differed between 
diet groups (CI F(6.53, 29.386) = 4.094, P value<0.01; AdCI F(16,72)=3.697, P value<0.001). 
Water intake was recorded daily and is represented on Figure 3.9. 
Figure 3.9. Daily water intake during the experiment.  
Water intake was recorded daily and data is calculated as average of cage. (a) WI data is calculated per rat 
per day. (b) AdWI data is calculated per weight of rat per day. All data is presented as average ± SEM, n=11. 
A one-way repeated measures ANOVA was used to test the statistical significance of the change over time . 
Statistical differences between groups at each time point were tested using Tukey Post Hoc test.  
WI increased with time (Figure 3.9.a) (F(3.478, 31.298)=12.836, P value<0.001) 
whereas AdWI decreased with time (Figure 3.9.b) (F(3.051, 27.46)=8.907, P value<0.01). 
Moreover, WI was affected by diet (F(6.955, 31.298)=2.367, P value<0.05) (Figure 3.9.a), 
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being higher in average in the HFD+PB group and lower in the HFD; while AdWI was not 
altered by diet (Figure 3.9.b) (F(6.102, 27.46)=1.941, P value>0.05). 
3.3.3 Cholesterol levels 
Increased adiposity has been shown to be linked to an excess of LDL/VLDL and a 
reduction of HDL (Tchernof and Després, 2013). Plasma concentrations of LDL, HDL and 
total cholesterol are shown in Figure 3.10.  
 Figure 3.10. Cholesterol concentration in plasma of rats under different diets and at different ages.  
 (a) LDL/VLDL, (b) HDL and (c) total cholesterol were measured from plasma samples. (d) LDL/HDL ratio was 










































































































































































































n=3, ND 15w n=4, HFD 15w n=4, HFD+PB 15w n=5. Groups were compared within the same age group using 
a t-test for 11w and one-way ANOVA for 15w. * = P value <0.05 
 
There was no difference in LDL/VLDL concentrations between ND and HFD rats at 
11w. In the 15w groups, there was a significant increase in HFD+PB when compared to ND 
(Figure 3.10.a). 
There was an increase in HDL concentrations in the HFD 11w compared to its 
control. At 15w, ND and HFD had similar levels of HDL while it was significantly increased 
in the HFD+PB group (Figure 3.10.b). 
There was no significant difference in total cholesterol between any of the groups 
(Figure 3.10.c). A similar finding was also observed for the LDL/HDL ratio (Figure 3.10.d). 
In order to investigate the relationship between adiposity and cholesterol, both 
parameters were compared to each other. There was a strong positive correlation between 
body fat and both LDL/VLDL concentration and total cholesterol concentration, but there 
was no correlation between body fat and HDL concentration nor with LDL/HDL ratio (Figure 
3.11). 
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Figure 3.11. Correlation between body fat composition and plasma cholesterol levels depending on diet 
and age.  
Rats were obtained at 4 weeks of age and kept for either 7 or 11 weeks. Rats were fed either ND or HFD. 
HFD+PB rats were fed HFD until week 7, after which their food was supplemented with a small quantity of PB 
daily. (a) LDL/VLDL, (b) HDL and (c) total cholesterol were measured from plasma samples. (d) LDL/HDL ratio 
was calculated with the individual values of each rat. Data was analysed with Pearson correlation. 11w n=3, 
ND 15w n=4, HFD 15w n=5, HFD+PB 15w n=5 
3.3.4 Oestrous cycle 
To evaluate the impact of diet on the oestrous cycle, vaginal lavage was taken daily 
during the last 12 days of diet feeding. Four examples of each group are represented in 
Figure 3.12 and Figure 3.14. 















































































































































Figure 3.12. Oestrous cycle of 11w rats.  
Rats were obtained at 4 weeks of age and were fed either ND or HFD for 7 weeks. The stage of the cycle was 
assessed daily for the last 2 weeks. Four examples for (a) ND and (b) HFD were plotted in order to visually 
estimate regularity. Day 1 is adjusted to be the first day of proestrus for each individual.  
Cycle lengths were compared between groups (Figure 3.14). There was no 
significant difference in cycle length between 11w rats nor was there was any significant 
difference between the 15w groups. However, the coefficient of variation was higher in 
HFD groups than their respective ND, and the HFD 15w and HFD+PB 15w were highly 
variable.  
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c) Figure 3.13. Oestrous cycle of ND (a), HFD (b) and 
HFD+PB (c) 15w rats. 
Rats were obtained at 4 weeks of age and kept for 
either 7 or 11 weeks. Rats were fed either ND or 
HFD. HFD+PB rats were fed HFD until week 7, after 
which their food was supplemented with a small 
quantity of PB daily. The stage of the cycle was 
assessed daily for the last 2 weeks. Four examples 
for (a) ND, (b) HFD and (c) HFD+PB were plotted in 
order to visually estimate regularity. Day 1 is the 
first day of proestrus for each individual. 
 





Figure 3.14. Length of oestrous cycle of rats under different diets and ages.  
The stage of the cycle was assessed daily for the last 2 weeks. All data is presented as average ± SEM, 11w 
n=4, 15w n=11. Groups were compared amongst each other on the same age group using a t-test for 11w 
and one-way ANOVA for 15w. Cv = coefficient of variation 
3.3.5 Hormone levels 
All experiments were run on rats that were in dioestrus, therefore all sex hormone 
levels should be similarly low (Smith, Freeman and Neill, 1975; Marcondes et al., 2001). The 
plasma concentrations of progesterone, oestradiol, testosterone and cortisol in all groups 




















































 Characterisation of the Effect of High-Fat Diet on Physiological Functions and Cerebrospinal Fluid 




Figure 3.15. Hormone concentrations on plasma of rats under different diets and ages.  
(a) Cortisol, (b) progesterone, (c) oestradiol and (d) testosterone were measured from plasma samples. All 
data is presented as average ± SEM, ND 11w and HFD 11w n=3, ND 15w n=4, HFD 15w n=4, HFD+PB 15w n=5, 
except for progesterone at 15w where n=3. * = P value <0.05, **= P value <0.01, *** = P value<0.001 
No differences were observed between ND 11w and HFD 11w groups for any of the 
measured hormones. In 15w rats, there was a significant increase of testosterone 
concentration in the animals fed HFD+PB when compared to ND, coupled with a significant 
decrease in plasma oestradiol when compared to those in the ND and HFD groups. As a 













































































































































































15w diet groups (Figure 3.16). Animals in the ND 15w group showed a significant increase 
in oestradiol compared to ND 11w. No other differences were observed between the diet 
groups for any of the other hormones. 
Figure 3.16. Hormone ratios of rats under different diets and ages. 
 (a) Testosterone to oestradiol ratio and (b) oestradiol to progesterone ratio were calculated for each 
individual. All data is presented as average ± SEM, ND 11w and HFD 11w n=3, ND 15w n=4, HFD 15w n=4, 
HFD+PB 15w n=5, except for E2/P ratio where 15w n=3. Groups were compared amongst each other on the 
same age group using a t-test for 11w and one-way ANOVA for 15w. * = P value <0.05, **= P value <0.01 
3.3.6 Effect of Diet on Cerebrospinal Fluid Secretion Rates 
I. Steady state determination 
To determine whether age and diet-induced obesity affected the dynamics of CSF 
secretion, 11w and 15w rats underwent ventriculo-cisternal perfusion (Pappenheimer et 
al., 1962; Oreskovic et al., 2003; Alimajstorovic, Pascual-Baixauli, et al., 2020). Endogenous 
CSF was flushed, and a steady state of CSF secretion was confirmed. The steady state was 
typically reached within 40 min of the start of the experiment (Figure 3.17). Cout/Cin values 
obtained changed over the perfusion period for both 11w and 15w rats, (11w: F(6, 
24)=1407.021, P value < 0.001; 15w: F(2.505, 30.058)=8746.083, P value < 0.001). However, 
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F(3, 12)= 0.468, P value > 0.05; 15w F(3, 6)=0.681, P value>0.05). Diet did not affect Cout/Cin 
values (11w: F(6,24)=0.156, P value > 0.05; 15w F(5.01, 30.058)=4.08, P value > 0.05). 





















Figure 3.17. Steady state determination using Cout/Cin values. 
Cout/Cin values were calculated using the Equation 2.1 . Data represented as average ±SEM, 11w n=3, 15w 
n=5. A two-way repeated measures ANOVA was used to test the statistical significance of the change over 
time amongst the same-age group (Greenhouse-Geisser correction). Statistical differences between same-
age groups at each time point were tested using Tukey Post Hoc test. 
  




II. Cerebrospinal fluid secretion rates 




















































Figure 3.18. Cerebrospinal fluid secretion rates of rats under different diets and ages. 
CSF secretion rate was measured using the ventriculo-cisternal perfusion technique. CSF secretion rates were 
calculated by averaging secretion rates once the steady state was reached using Equation 2.2 (see Chapter 
2). 11w n=3, 15w n=5, ** = P value<0.01, ****= P value<0.0001  
There was no significant difference between groups at 11w. However, at 15w the 
CSF secretion rates of both HFD groups were significantly higher than their ND controls. 
While secretion rates of animals fed HFD+PB were the highest, they were not significantly 
different to HFD rats.  
Intracranial pressure was also measured at the beginning, middle and the end of 
the ventricular perfusion procedure in order to compare this measure between diets but 
also to monitor the CSF perfusion surgery, as a drastic change in pressure during the 
procedure would mean that the ventricular system might be disrupted (Figure 3.19). 
Baseline intracranial pressures are represented relative to those recorded for animals on 
ND, while pressures during the perfusion procedure are represented as a percentage of 
each individual’s starting pressure.  
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Figure 3.19. Intracranial pressures depending on diet. 
In figure a) data is represented as pressure relative to ND. In figure b) data is represented as percentage of 
baseline pressure for each individual. n=5 * = P value<0.05 
Both high fat diet groups had significantly higher initial pressures than ND 15w, and 
HFD+PB pressures were significantly higher than those recorded for HFD animals. There 
was a decrease in pressure after 60 min of perfusion in all three diet groups, but the 
pressure had returned to initial values by the end of the perfusion.  
III. Cerebrospinal fluid secretion and obesity 
The correlation between CSF secretion rate and obesity was analysed (Figure 3.20). 
There was a strong positive correlation between CSF secretion rate and BMI, body fat and 
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IV. Cerebrospinal fluid secretion and cholesterol 
A similar analysis was carried out to determine the relationship between plasma 
cholesterol levels and CSF secretion rates (Figure 3.21). 
There was no correlation between CSF secretion and HDL concentrations or 
LDL/HDL ratio. A moderate positive correlation between LDL/VLDL levels and CSF secretion 
rates was observed. Total cholesterol also had a moderate positive correlation with CSF 
secretion rates.   









































































CSF Secretion and Body Fat

































Figure 3.20. Correlation between CSF secretion 
and overweightness from rats under different 
diets and ages. 
CSF secretion rate was measured using the 
ventriculo-cisternal perfusion technique. 
Overweightness was estimated using body 
weight (a), BMI (b) or body fat composition (c), 
all of which were calculated based on 
measurements taken on the day of the surgery.  
Data was analysed with Pearson correlation. 
11w n=3, 15w n=5 
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Figure 3.21. Correlation between CSF secretion and cholesterol on plasma of rats under different diets and 
ages. 
LDL/VLDL (a), HDL (b) and total cholesterol (c) were measured from plasma samples. LDL/HDL ratio (d) was 
calculated with the individual values of each rat. Data was analysed with Pearson correlation. ND 11w and 
HFD 11w n=3, ND 15w n=4, HFD 15w n=4, HFD+ PB 15w n=5 
V. Cerebrospinal fluid secretion and hormones 
The correlation coefficients between cortisol, progesterone, oestradiol and testosterone 
and rate of CSF secretion were calculated and are represented on Figure 3.22. 
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Figure 3.22. Correlation between hormone concentrations and CSF secretion.  
Cortisol (a), progesterone (b), oestradiol (c) and testosterone (d) were measured from plasma samples. 
Testosterone to oestradiol ratio (e) and oestradiol to progesterone ratio (f) were calculated for each 
individual. CSF secretion rate was measured using the ventriculo-cisternal perfusion technique. Data was 
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analysed with Pearson correlation. ND 11w and HFD 11w n=3, ND 15w n=4, HFD 15w n=4, HFD+PB 15w n=5, 
except for progesterone 15w n=3. 
 
Neither cortisol, progesterone, oestradiol nor E2/P ratio showed any correlation 
with CSF secretion. However, testosterone and CSF secretion did show a strong correlation. 
Furthermore, T/E2 ratio and CSF secretion also showed positive correlation. 
3.4 Discussion 
The increased prevalence of IIH in overweight women of childbearing age points to 
the likelihood of age, weight and sex being directly related to the disease. In this chapter, 
the relationship between diet and CSF secretion was studied. No difference in final weight, 
BMI, total cholesterol, sex hormone levels or CSF secretion rates was found between ND 
and HFD-fed rats at 11w, while body fat content and HDL concentration were increased in 
rats fed a HFD when compared to ND. The 4 weeks of further feeding and the addition of 
PB also resulted in an increased fat content and elevated cholesterol, while also 
significantly increasing body weight, LDL, testosterone and oestradiol concentrations, CSF 
secretion and CSF baseline pressure, compared to ND-fed rats. CSF secretion was found to 
show a strong and positive correlation with overweightness and testosterone 
concentrations.  
The rapid, significant increase in weight after the introduction of PB was caused by 
a sudden increase in caloric intake. This increase in caloric intake was related to both higher 
calories per gram of diet but also to a change in flavour or texture of the diet, increasing its 
palatability. It is known that rats fed a HFD tend to eat smaller quantities of food to 
compensate for the higher caloric values (Oscai, Brown and Miller, 1984; Buettner, 
Schölmerich and Bollheimer, 2007; Aslani et al., 2015). On the other hand, rats enjoy highly 
palatable foods such as chocolate and PB, and will indulge in them if given the chance 
(Cabanac and Johnson, 1983; Anderson, 1990; Zeeni et al., 2013). All 15w rats fed HFD, 
regardless of PB addition, had significantly higher BMI, greater body weight and body fat 




content compared to ND of the same age, which supports the appropriateness of this 
model to induce obesity in rats. 
Rats studied at 11w did not show any diet-induced differences in CSF secretion rates 
in this study. At 15w, however, the CSF secretion rate was significantly increased in the two 
HFD groups, especially in the HFD+PB, which matches the results described in Chapter 2. 
Similarly, baseline intracranial pressure was increased in both HFD groups at 15w, 
especially in the HFD+PB group. These results indicate that our model of diet-induced 
obesity resulted in increased CSF secretion, making it a suitable model for the study of the 
effects of diet on CSF dynamics and, ultimately, IIH.  
In our study, CSF secretion showed a significant positive relationship with body 
weight, BMI and body fat content. Severe obesity can affect CSF pressure directly by 
increasing abdominal pressure, which can concurrently alter CSF drainage or cause CSF 
leaks (Hogan et al., 1996; Bloomfield et al., 1997; Sugerman, 2001; Stucken, Selesnick and 
Brown, 2012; Rabbani et al., 2018). However, the effect of obesity on CSF secretion is not 
well known yet (Bono et al., 2002; Whiteley et al., 2006). Our results supported the 
hypothesis that CSF dynamics, specifically CSF secretion, can be altered by obesity.  
While hypercholesterolemia is present in approximately half of IIH patients, the 
relationship between cholesterol levels and CSF dynamics are still unknown and, it has been 
suggested that the increase in cholesterol is directly related to obesity status rather than 
IIH itself (Pollak et al., 2015). In the present study, HDL levels were elevated in HFD rats, 
which is in keeping with previous reports that dietary fat increases HDL in rodents (Hayek 
et al., 1993; Stephens et al., 2010). HDL did not appear to alter CSF secretion, while LDL and 
total cholesterol did show a small positive correlation with CSF secretion. While cholesterol 
itself is not able to cross the BBB or the BCSFB, the side-chain oxidized metabolites 24S-
hydrocholesterol and 27-hydroxycholesterol can cross the barrier (Meaney et al., 2002; 
Björkhem, Leoni and Svenningsson, 2019). The possibility and extent at which an excess of 
these molecules caused by elevated cholesterol levels in plasma could affect CSF secretion 
are unknown. However, it is important to keep in mind that excess weight and obesity are 
known drivers for increased levels of cholesterol (Akiyama et al., 1996; Dobrian et al., 2000; 
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Tchernof and Després, 2013), thus we hypothesised that the weak correlation between 
higher CSF secretion rates and higher cholesterol levels are actually related to the obesity 
of the individuals, as discussed above, rather than the cholesterol increase itself.  
Sex hormones have significant effects on the brain and they also vary greatly during 
the oestrous cycle (Marcondes et al., 2001; Terner, Lomas and Picker, 2005). In women, 
obesity caused by diets high in fat has been linked to altered sex hormones and 
reproductive function (Bennett and Ingram, 1990; Varlamov, 2017). In rats, a HFD increases 
the chance of irregular cycles even in rats genetically resistant to diet-induced obesity 
(Whitaker, Shaw and Hervey, 1983; Balasubramanian et al., 2012; Lie, Overgaard and 
Mikkelsen, 2013; Bazzano et al., 2015; Markey et al., 2016; Broughton and Moley, 2017). 
In the present study, a difference in cycle regularities between HFD and ND rats was 
detected, especially in 15w rats. No difference was found in plasma oestradiol levels 
between 11w diet groups, but there was an increase between 11w and 15w in animals fed 
a ND. This difference could be related to ongoing growth of the rats, as oestradiol 
concentration has shown a positive correlation with body weight in lean female rats (Banu 
et al., 2001). Oestradiol levels were further increased in HFD 15w compared to animals of 
the same age in the ND group, but in the HFD+PB group at this age, plasma levels of this 
hormone were significantly lower than that observed in both the ND and the HFD groups. 
This may relate to the higher body fat content, as diet-induced obesity is associated with 
lower levels of oestradiol in the rat (Balasubramanian et al., 2012). The effects of low 
oestrogen levels in females include increase of overeating behaviours and adipose tissue 
formation, which can increase obesity in the individual further (Leeners et al., 2017).  
Plasma testosterone levels in 11w and ND 15w were similar to those reported in 
the literature for rats (Zeng et al., 2003). However, testosterone concentration was 
increased in HFD+PB 15w when compared to ND 15w. This result is consistent with reports 
in the literature of increased plasma testosterone levels in dioestrus as a result of diet-
induced obesity in rats (Volk et al., 2017). This phenomenon has also been described in 
obese women and it is linked to lower fertility rates in both species (Kopelman et al., 1980; 
Wajchenberg et al., 1989; Nestler, 2000; Tchernof and Després, 2013). Testosterone was 




the parameter measured in the present study which showed the strongest positive 
correlation with CSF secretion rates. Raised levels of androgens have been found in IIH 
when compared to healthy overweight women (Hornby et al., 2016; O’Reilly et al., 2019). 
These results suggest that ours was a reliable model to study the mechanisms behind the 
possible increase in CSF secretion that result in IIH.  
The testosterone to oestradiol ratio is an important steroid hormone ratio to 
evaluate the steroidogenesis pathway. This pathway occurs mainly in the ovary, and it 
starts with androgen synthesis occurring in theca cells, followed by testosterone 
transformation into oestrogens in the granulosa cells (Fauser and Van Heusden, 1997). A 
decrease of oestradiol and an imbalance between testosterone and oestradiol 
concentrations could be due to two different reasons. Firstly, it could be caused by a 
decrease in the conversion rate of testosterone to oestradiol, but it could also be due to an 
increase in testosterone production which is not coupled with an increase in the conversion 
enzyme. In the present research, the decrease in oestradiol and increase in testosterone 
levels which resulted in an altered T/E2 ratio in the animals in the HFD+PB group when 
compared to ND at 15w suggests that both mechanisms could be contributing to this 
observation. While it has been shown that testosterone concentration was increased, the 
concentrations and effectivity of the conversion enzyme were not evaluated. In the future, 
studying these parameters could help in discovering whether T/E2 ratio discrepancy is 
caused by an alteration in conversion rate or if its origins are more complicated.  
Although no correlation was found between CSF secretion rate and cortisol, 
progesterone or oestradiol levels, there was strong positive correlation with testosterone 
levels and also with the T/E2 ratio. These results fit with the previous findings that 
testosterone can alter CSF dynamics and, especially, increase CSF secretion in IIH female 
patients (Klein et al., 2013; Hornby et al., 2017; O’Reilly et al., 2019). Additionally, 
testosterone has been shown to increase hyperphagia and fat storage in females, whereas, 
on the other hand, obesity in females has been linked to altered androgen secretions 
(Evans et al., 1983; Bray, 1997; Tchernof and Després, 2000; Watson, Mayes and Watson, 
2004; Pasquali, 2006). Whether increased testosterone levels drive obesity or if obesity 
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increases testosterone concentration in females is not yet known; nevertheless, we 
hypothesised that an increase in testosterone concentration in the plasma of our rats 
affected CSF secretion rates by altering protein expression patterns of the CP in the lateral 
ventricles. In order to test this, the gene and protein expression of CP from 15w rats was 
studied and data from these investigations are presented in the following chapter. 




Chapter 4. Diet-related Changes to the mRNA 
and Protein Expression Profile in the Choroid 
Plexus of Female Rats  
4.1 Introduction 
The CP is essential to CSF dynamics as it is considered to be the main site for CSF 
secretion (Speake et al., 2001; Emerich et al., 2004; Tumani, Huss and Bachhuber, 2017). 
As previously described in Chapter 1, the CP is a secretory epithelium which actively 
controls the passage of molecules and water in and out of the CSF in order to keep its 
composition stable and adequate for CNS homeostasis. Although the specific mechanisms 
by which this equilibrium is maintained are not well known, three main types of proteins 
are involved in the functioning of the CP: transport proteins, water channels and tight 
junctional proteins. (Emerich et al., 2004; Quintela et al., 2013; Orešković and Klarica, 2014; 
Praetorius and Damkier, 2017).  
Transport proteins and channels, such as the solute carrier family (Slc) and KCNA6, 
mediate transcellular movement of molecules between blood and CSF, facilitating the 
movement of specific ions between the apical and basolateral areas of the CP and thus 
inducing an osmosis gradient which drives water movement from the blood into the CSF. 
Active transport of molecules requires cellular energy in the form of ATP, produced by 
Na+/K+ ATPase 1 (ATP1) and an available transporter protein (Kyte, 1981; Praetorius & 
Damkier, 2017; Speake, Whitwell, Kajita, Majid, & Brown, 2001). ATP1 found in the CP is an 
heterodimer formed by two units, ATP1A1 and either ATP1B1 or ATP1B2, the first of them 
being the dominant catalytic subunit (Zlokovic et al., 1993; Kant et al., 2018).  
Water channels expressed in the membrane of CPEC facilitate water transport 
between apical and basolateral areas of the CP following the ion gradient. Aquaporin-1 
(AQP1) is thought to be the main water channel expressed in CP, although expression of 
AQP7 and 9 has also been observed (Speake, Freeman and Brown, 2003; Yaba et al., 2017). 
While Aqp4 has been reported to appear diffusely expressed in the cytosol of CP epithelial 




cells (CPEC), it is mainly expressed by ependymal cells lining the ventricles and therefore its 
contribution to CSF dynamics would be independent of CP activity (Frigeri et al., 1995; 
Venero et al., 1999; Speake, Freeman and Brown, 2003). Deregulation of aquaporin 
expression in the CP has been shown to affect brain fluid dynamics (Oshio et al., 2004; 
Trillo-Contreras et al., 2019). 
The barrier properties of the BCSFB are dependent on the presence of organised 
tight junctional complexes between CPECs, which are mediated by intracellular proteins 
like ZO1, and transcellular proteins such as JAM3 or CLDN1. These junctions act as a barrier 
to paracellular molecular movement, restricting it to the more controlled transcellular 
transport mentioned above (Damkier, Brown and Praetorius, 2010; Kratzer et al., 2012; 
Ghersi-Egea et al., 2018). Nevertheless, an underexpression of tight junction proteins could 
lead to an increase of barrier leakiness, which might alter CSF dynamics (Redzic, 2011; 
Naessens et al., 2018).  
It is known that diet can affect many different biological aspects of an individual, 
ranging from changes in physiological processes to epigenetic alterations. As a matter of 
fact, it has been shown that dietary fat can alter gene expression by mechanisms such as 
regulation of transcription factors at the cellular level or alteration of hormonal levels at 
the organismal level (Beato, 1993; Jump and Clarke, 1999). In the CP, HFD and diet-induced 
obesity can alter not only the expression of functional genes such as prolactin and lactin 
receptors but also those involved in the formation of TJs such as claudin 5 (Lin, Storlien and 
Huang, 2000; Kanoski et al., 2010; Kalyani et al., 2016). In addition, there appear to be sex-
based differences in the gene expression profile of the CP. Indeed, the CP expresses both 
oestrogen and androgen receptors (ER and AR), and sex hormones have been shown to 
regulate the expression of choroid plexus genes, such as transthyretin and circadian clock 
genes (Alves et al., 2009; Quintela et al., 2009, 2015; Santos et al., 2017). 
The current study was designed to investigate whether the change in CSF secretion 
observed between diet groups in female rats in Chapter 3 was related to alterations in gene 
expression in the CP. The gene expression profile of CP isolated from female rats fed HFD, 
HFD+PB or ND for 11w and 15w was first characterised using RNAseq techniques. Then, 




differences in the expression of selected water channels, ion transporters and TJ proteins 
between diet groups at 15w were further investigated at the protein level using 
immunohistochemistry. 
4.2 Materials and Methods 
All materials used were obtained from Sigma-Aldrich (Poole, Dorset, UK) unless 
otherwise specified. 
4.2.1 Animals 
Animals were housed and cared for as specified in Chapter 3.  
Choroid plexus of rats used for the preliminary gene expression study were 
obtained from rats used for CSF secretion measurement (Chapter 3) after the surgery was 
performed. 
Animals used for the further gene expression experiments, including Massive 
Analysis of cDNA Ends (RNAseq-MACE) and qPCR, belonged to a separate cohort that did 
not undergo surgery.  
4.2.2 Choroid plexus extraction 
Rats were terminally anaesthetised with 140 mg/kg pentobarbital. Once 
anaesthetized rats did not respond to reflex-inducing external stimuli (i.e. pinching) for 
more than 2 min, blood samples were obtained by cardiac puncture and, immediately after, 
perfusion with PBS was started and run for 10 min or until waste liquid ran clear. Rats were 
then perfused with 0.5% toluine blue for 3 min to help visualise the CP. Brains were 
dissected and cut sagittally to reveal the lateral ventricles. The lateral ventricle CP was 
dissected on ice using forceps and its RNA was extracted using RNeasy Micro Kit (Qiagen, 
Manchester, UK) and stored at -80C.  




4.2.3 Gene expression analysis 
Three samples of each group (ND 15w, HFD 15w, HFD+PB 15w) were sent to 
GenXPro (Frankfurt am Main, Germany) for analysis using RNAseq-MACE. RNA samples 
were processed and analysed using a modified protocol previously described in the 
literature using the MACE kit (Nold-Petry et al., 2015). In brief, 100ng of DNase-treated RNA 
were used for library preparation. cDNA was produced by oligo dT priming, sheared to an 
average size of 200bps and ligated to “TrueQuant” unique molecular identifiers included in 
the MACE kit. Tags were amplified with 13 PCR cycles. Libraries were sequenced using an 
Illumina NextSeq 500 sequencer. 
For qPCR analysis, reverse transcription was performed using the High Capacity 
cDNA Reverse Transcription Kit (Thermofisher Scientific, UK) and qPCR was carried out 
using the QuantiTect SYBR® Green PCR Kit (Qiagen, Manchester, UK) and KiCqStart® SyBR® 
Green predesigned primers for rat (Table 4.1). Relative expression was calculated using the 
2-ΔΔCt method as previously described in the literature (Livak and Schmittgen, 2001; 
Schmittgen and Livak, 2008). ND was taken as a control for the respective ages, and actin-
β was used as reference gene to measure relative expression. For the preliminary study, 
genes were selected from literature to scan for changes in expression of water channels, 
ATP1, molecular transporters and sex hormone receptors. 
 
 
Table 4.1. Sequences of primers used in qPCR analysis. 
Gene Symbol Sequence 
Actin Beta Actin β 
Forward 5’-AAGACCTCTATGCCAACAC 
Reverse 5’-TGATCTTCATGGTGCTAGG 
Aquaporin 1  AQP1 
Forward 5’-CAAACCACTGGATTTTCTGG 
Reverse 5’-ATATCATCAGCATCCAGGTC 
Aquaporin 4 AQP4 
Forward 5’-GAAAACCACTGGATATATTGGG 
Reverse 5’-CAGAAGACATACTCGTAAAGTG 
Aquaporin 7 AQP7 
Forward 5’-CTTCGTGGATGAGGTATTTG 
Reverse 5’-TGATTGCATATCCTGTGTTC 




Gene Symbol Sequence 
Aquaporin 9 AQP9 
Forward 5’-CATGTTTGACTCCAGAAACC 
Reverse 5’-CAACTGTGAAGACCTCAAAC 










Basolateral Na-K-Cl Symporter SLC12A2 
Forward 5’-AGTGTCTGTAGGTTCTTGTG 
Reverse 5’-GCAGAAGTACAGTTAGTTAGC 
Androgen Receptor AR 
Forward 5’-CCTTGTTCCCTTTTCAGATG 
Reverse 5’-GTAAAAGAGGCAGAGAAGAAG 
ATPase Na+/K+ Transporting Subunit Alpha 1 ATP1A1 
Forward 5’-GAGTAGAAGAAGGTCGTCTG 
Reverse 5’-CCGGAATGTTACTTGTTAGG 
ATPase Na+/K+ Transporting Subunit Beta 1 ATP1B1 
Forward 5’-CAAGAATGAATCCTTGGAGAC 
Reverse 5’-GTAGGGATAGTACTGCAGAG 
ATPase Na+/K+ Transporting Subunit Beta 2 ATP1B2 
Forward 5’-GTGTTGGGAAGAAAGATGAAG 
Reverse 5’-AATACATCAGGTCGATGTTG 
Oestrogen Receptor Alpha ERa 
Forward 5’-GGCTGCGCAAGTGTTACGAA 
Reverse 5’-CATTTCGGCCTTCCAAGTCAT 
Oestrogen Receptor Beta ERb 
Forward 5’-GAGGCAGAAAGTAGCCGGAA 
Reverse 5’-CGTGAGAAAGAAGCATCAGGA 
Claudin 1 CLDN1 
Forward 5’-AGAATTCTATGACCCCATGAC 
Reverse 5’-GTAGTCTTTCCCAGTAGAAGG 
Claudin 2 CLDN2 
Forward 5’-GAAATCCCTTATCATCACAG 
Reverse 5’-CAAGAAGGCATCTAGAAAACG 





Zona Occludens 1 ZO-1 
Forward 5’-CACTCTTCCAGAACCAAAAC 
Reverse 5’-ACCCACACTATCTCCTTTTC 
Zona Occludens 3 ZO-3 
Forward 5’-AAGAAACAGCGAAGAGTTTG 
Reverse 5’-TCACTCAGGGATAGATTAGC 




4.2.4 Bioinformatic analysis of RNAseq-MACE results 
An initial bioinformatic analysis of the RNAseq-MACE data was performed by 
GenXpro. Raw data sets were quality trimmed, including deletion of PCR duplicated reads. 
Filtered reads were aligned to the Rattus norvegicus reference genome (Rnor_6.0) using 
the Bowtie 2 mapping tool (Langmead and Salzberg, 2012). The Rnor_6.0 Ensembl 
annotation file was imported into the Htseq-count annotation tool to annotate bam files. 
Normalization of gene count data and differential gene expression analysis between the 
samples were performed using the DEGseq R/Bioconductor package (Wang et al., 2010).  




A P value smaller than 0.05 determined that the difference in gene expression levels 
between two groups was significantly altered. Relevantly up- and downregulated genes 
were selected following two criteria: log2fold change greater than 1 or less than -1, and a 
P value smaller than 0.05.  
The first step to further analyse deregulated genes was to determine the functional 
classification of their related protein using Panther Classification System (Mi et al., 2019). 
Upregulated and downregulated genes from each comparison were studied as two 
different groups, and in each, their molecular and biological function, cell compartment 
and protein classification were determined. PANTHER did not hold enough information on 
some of the selected genes, which were then excluded from the analysis, thus the number 
of genes in each analysis differ from the total number of deregulated genes found in each 
comparison. For each group, the total number of genes included in the analysis is shown 
next to the title, while each parameter also shows the number of hits that were found. 
These two numbers can differ for two reasons: either the parameter is not known for all 
the genes selected, or they fulfil two or more different categories, such as performing 
several functions.  
 Each comparison was then analysed to find expression trends or deregulated 
pathways that could affect CSF secretion or increase leakage of the BCSFB using DAVID 
Bioinformatics Resources 6.8 (Huang, Brad T Sherman and Lempicki, 2009; Huang, Brad T. 
Sherman and Lempicki, 2009). 
4.2.5 Immunohistochemistry 
Three rats per dietary condition were anaesthetised and perfused intracardially 
with 0.01M PBS. Brains were extracted, snap frozen and stored at -80oC. Brains were sliced 
on a cryostat to a thickness of 20µm and collected on glass slides, which were then 
desiccated under vacuum in a desiccator for 24h and kept at -80C until the experiments 
started. 
Sections were fixed with either acetone (ZO1 and CLDN1 staining) or ethanol (AQP4 
staining) for 10 min, washed with 0.01M PBS (5 min, 3 times) and blocked with 15% goat 




serum in PBS for 15 min. Sections were incubated overnight at 4oC with either anti-ZO1, 
anti-CLDN1 or anti-AQP4 (1:100; Thermofisher Scientific, UK), washed with 0.01M PBS at 
RT (5 min, 3 times) and incubated with Alexa Fluor 488 anti-rabbit (1:500; Thermofisher 
Scientific, UK) protected from light for 2h at RT. The mounting media used was ProLong™ 
Gold Antifade Mountant with DAPI (Thermofisher Scientific, UK). After mounting, slides 
were left to dry for at least 48h at 4oC and then were imaged using confocal microscopy 
(Leica confocal, Leica Microsystems Ltd, UK). Five sections per animal were analysed for 
each protein of interest. 
Images were processed using ImageJ software (Rasband and U. S. National 
Institutes of Health, 2018). Area of interest was the area where the protein was expected 
to be expressed, e.g. the CP was selected for CLDN1 analysis while the ependyma was the 
area of interest for AQP4 expression. The area of interest was manually traced and selected 
for further analysis. Cellular fluorescence intensity and area of staining were used to 
compare protein expression levels between samples for each protein studied. Corrected 
total cellular fluorescence (CTCF) was calculated using Equation 4.1. Relative area of 
staining was calculated using Equation 4.2. 
Equation 4.1. Calculation of corrected total cellular fluorescence. 
𝑪𝑻𝑪𝑭 = 𝑰𝒏𝒕𝒆𝒈𝒓𝒂𝒕𝒆𝒅 𝑫𝒆𝒏𝒔𝒊𝒕𝒚 − (𝑨𝒓𝒆𝒂 𝒐𝒇 𝑰𝒏𝒕𝒆𝒓𝒆𝒔𝒕 ·  𝑴𝒆𝒂𝒏 𝑭𝒍𝒖𝒐𝒓𝒆𝒔𝒄𝒆𝒏𝒄𝒆 𝒐𝒇 𝑩𝒂𝒄𝒌𝒈𝒓𝒐𝒖𝒏𝒅) 
 
Equation 4.2. Calculation of relative area of staining 
𝑹𝒆𝒍𝒂𝒕𝒊𝒗𝒆 𝑨𝒓𝒆𝒂 𝒐𝒇 𝑺𝒕𝒂𝒊𝒏𝒊𝒏𝒈 =
𝑨𝒓𝒆𝒂 𝒐𝒇 𝑺𝒕𝒂𝒊𝒏𝒊𝒏𝒈 𝒐𝒇 𝑷𝒓𝒐𝒕𝒆𝒊𝒏 𝒐𝒇 𝑰𝒏𝒕𝒆𝒓𝒆𝒔𝒕 (%)
𝑨𝒓𝒆𝒂 𝒐𝒇 𝑺𝒕𝒂𝒊𝒏𝒊𝒏𝒈 𝒐𝒇 𝑫𝑨𝑷𝑰 (%)
 
4.2.6 Statistical analysis 
Each diet group had 3 animals (n=3). All data is presented as average ± SEM unless 
otherwise specified. Differences in gene expression measured by RNAseq were analysed 
statistically using the DESeq2 analysis (Love, Huber and Anders, 2014). Shapiro-Wilk 
normality test and Q-Q plots were used to assess normal distribution of qPCR and 




immunostaining data. Statistical analysis was performed using one-way ANOVA with Tukey 
post hoc test. Pathway analysis was assessed using Fisher’s Exact Test. A P value smaller 
than 0.05 was considered significantly different. Statistical analysis was performed using 
Graphpad 8 (Graphpad Software, 2019).  
4.3 Results 
4.3.1 Preliminary study of gene expression profile of choroid 
plexus related to age and diet 
A preliminary study was performed in which the CP gene expression profile of some 
key genes for CSF secretion or CP function, were studied as a function of duration of dietary 
manipulation. Comparative expression of genes associated with water channels, ATP1, 
tight junction proteins and sex hormones was carried out in HFD and ND rats of the same 
age, and the results are shown in Figure 4.1. 
In 11-week rats fed diets for 7 weeks, mRNA levels of Slc4a5 were significantly 
higher and levels of AQP7 and AQP9 were significantly lower in HFD-groups compared to 
ND-fed rats (Figure 4.1.a). In 15-week rats, HFD-fed rats showed significantly higher mRNA 
levels of ATP1B1, Slc4a5 and ERb compared to ND 15w (Figure 4.1.b). HFD 15w rats also 
expressed significantly lower levels of AQP7 and AQP9. The expression of other genes were 
not significantly changed.  




 Figure 4.1. RT-qPCR showing relative gene expression on CP of female rats depending on diet. 
Gene expression in HFD groups were compared to ND group for a) 11w and b) 15w rats. *=P value < 0.05, 
***=P value < 0.001, **** P value < 0.0001. ER=Oestrogen Receptor, AR=Androgen receptor. n=3 
Based on these results, the focus of further gene expression studies focused on 15w 
rats due to the bigger changes in gene expression and also the highest differences in CSF 
secretion and other body parameters described in Chapter 3. 
4.3.2 Gene expression profile of choroid plexus related to diet 
in 15w rats. 
MACE-RNAseq identified 15705 genes in our samples. Analysis of gene expression 
in HFD vs ND, HFD+PB vs ND and HFD+PB vs HFD was then carried out.  
I. HFD vs ND 
 Gene expression in HFD samples compared to ND as a function of log2fold change 



















































































































































































Figure 4.2. Distribution of differently expressed genes in HFD vs ND comparison. 
In (a) the proportion of each gene group compared to the total number of deregulated genes, in (b) volcano 
plot of relative expression and P value for each gene. n=3 
13757 genes were detected in the HFD vs ND comparison. From those, 128 were 
upregulated and 75 were downregulated. The functional classification of deregulated 
genes in HFD vs ND is shown in Figure 4.3.  
58 of the upregulated genes were selected by PANTHER in the HFD vs ND. The most 
common molecular function for upregulated genes appeared to be related to binding, 
including binding to nucleic acids and protein receptors. Analysis of the genes according to 
‘cellular process’ produced a higher number of hits and included proteins related to 
cytoskeleton organisation and nucleic acids such as the ATP-dependent DNA helicase Q5. 
Most of the proteins resulting from the upregulated genes in the HFD vs ND comparison 
were intracellular, and they belonged to a wide range of protein types. The most common 
ones were cytoskeletal proteins and hydrolases. 
 102 of the downregulated genes were selected by PANTHER. The most common 
molecular function in this group was related to catalytic activities, performed by proteins 




such as kinases and proteases. The most common biological function was related to cellular 
processes, including transcription factors and carrier proteins. The majority of 
downregulated genes resulted in intracellular proteins and the most common protein types 
were nucleic acid binding proteins and transcription factors. 




Figure 4.3. Functional classification of highly deregulated genes in the HFD vs ND comparison. 
Both up and downregulated genes were analysed using PANTHER to determine the (a) molecular function, 




























































































Functional classification of deregulated genes in HFD vs ND
58 genes
102 genes




A full list of deregulated genes in the HFD vs ND comparison and their functional 
classifications can be found in Appendix B, Table 0.5 and Table 0.6. 
Upregulated and downregulated pathways in the HFD vs ND comparison were 
obtained using DAVID Bioinformatics and are shown in Table 4.2. 
Table 4.2. Deregulated pathways in the HFD vs ND comparison.  
Highly deregulated genes were selected using the parameters explained above and, using two tools from 
DAVID Bioinformatics (GO Analysis: Biological Process and KEGG Pathway), up to ten relevant deregulated 
pathways were selected for each tool used. “Total” is the number of total affected pathways highlighted by 






Term Pathway No. transcripts P value 









Total 3    
KEGG 
Pathway 
rno04913 Ovarian steroidogenesis 3 0.012 
rno04918 Thyroid hormone synthesis 3 0.017 
Total 2    
     
DOWNREGULATED PATHWAYS 






Positive Regulation of 
Transcription from RNA 
Polymerase II Promoter 
15 0.003 
GO:0006355 








Negative Regulation of 
Neuron Differentiation 
4 0.009 
GO:0008104 Protein Localization 4 0.012 
GO:0000209 Protein Polyubiquitination 4 0.026 
GO:0043434 
Response to Peptide 
Hormone 
4 0.041 
GO:0048469 Cell Maturation 3 0.027 





Positive Regulation of 
Vasoconstriction 
3 0.029 
GO:0032570 Response to Progesterone 3 0.049 
Total 20    
KEGG Pathway ---- ---- ---- ---- 
Total 0    
 
A total of 5 differentially upregulated and 20 downregulated pathways were 
identified. The upregulated pathways picked up by DAVID bioinformatics from the HFD vs 
ND comparison were mostly related to hormones and to the cytoskeleton, while 
downregulated pathways were more varied. The pathways involving the greatest number 
of downregulated genes were related to nucleic acids. There were also pathways related 









II. HFD+PB vs ND 
Gene expression in HFD+PB samples compared to ND as a function of log2fold 
change and P value are shown in Figure 4.4. 
Figure 4.4. Distribution of differently expressed genes in the HFD+PB vs ND comparison. 
In (a) the proportion of each gene group compared to the total number of deregulated genes, in (b) volcano 
plot of relative expression and P value for each gene. n=3 
In HFD+PB vs ND comparison, 13588 genes were identified. From those, 514 were 
found to be downregulated and 43 upregulated. The functional classification of 
deregulated genes in HFD+PB vs ND can be found in Figure 4.5.  
PANTHER selected 34 of the highly upregulated genes and 419 of the highly 
downregulated genes. Amongst the upregulated genes, the most common molecular 
function was binding, including binding to proteins and binding to nucleic acids. The most 
common biological function in this group was related to cellular processes, such as 
cytoskeleton organisation and DNA repairing. The proteins in this group were mostly 
intracellular, and they belonged to a wide range of protein types, the most common of 
which were enzyme modulators and hydrolases.  
Highly downregulated genes produced proteins with a wider range of molecular 











binding. Most of these genes encoded proteins with biological functions regarding cellular 
processes, such as transcription and translation factors, and most of them were 
intracellular. The proteins from this group belonging to a wide range of protein classes, but 
the most common ones were hydrolases and enzyme modulators. 
A full list of deregulated genes in the HFD+PB vs ND comparison and their functional 
classifications can be found in Appendix B, Table 0.7 and Table 0.8. 
 




Figure 4.5. Functional classification of deregulated genes in the comparison HFD+PB vs ND.  
Both up and downregulated genes were analysed using PANTHER to determine the (a) molecular function, 
































































































Upregulated genes 34 genes
419 genes
Functional classification of deregulated genes in HFD+PB vs ND




Bioinformatic tools were used to select up and downregulated pathways in the 
HFD+PB vs ND comparison, and the results are shown in Table 4.3. 
A total of 6 differentially upregulated and 33 downregulated pathways were 
selected by DAVID bioinformatics for the HFD+PB vs ND comparison. The overexpressed 
pathways were related to DNA repairing, while downregulated pathways had varied 
functions. The pathways involving the highest number of downregulated proteins were 
related to transport and cell adhesion. Furthermore, pathways related to hormone 
response and various signalling pathways were also selected. 
Table 4.3. Deregulated pathways in the HFD+PB vs ND comparison. 
Highly deregulated genes were selected using the parameters explained above and, using two tools from 
DAVID Bioinformatics (GO Analysis: Biological Process and KEGG Pathway), up to ten relevant deregulated 
pathways were selected for each tool used. “Total” is the number of total affected pathways highlighted by 






Term Pathway No. transcripts P value 
GO:0006303 
Double-Strand Break Repair 




Response to Ionizing 
Radiation 
3 0.011 
GO:0033151 V(D)J Recombination 2 0.028 
GO:0033591 Response To L-Ascorbic Acid 2 0.032 
Total 4    
KEGG 
Pathway 
rno03450 Non-homologous end-joining 2 
 
0.025 
 Total 2    
 
DOWNREGULATED PATHWAYS 





GO:0006886 Intracellular Protein Transport 14 0.003 
GO:0007155 Cell Adhesion 14 0.019 
GO:0007264 












 Term Pathway No. transcripts P value 
GO:0006979 Response to Oxidative Stress 9 0.036 
GO:0009725 Response to Hormone 7 0.043 
GO:0030100 Regulation of Endocytosis 5 0.007 
GO:0030521 

















Total 20    
KEGG  
Pathway 
rno04014 RAS Signalling Pathway 12 2.23E-04 
rno04713 Circadian Entrainment 11 
1.03E-04 
rno04728 Dopaminergic Synapse 11 0.001 
rno04727 GABAergic Synapse 10 0.001 
rno04724 Glutamatergic Synapse 10 0.002 
rno04024 cAMP signalling pathway 10 0.041 
rno04540 Gap junction 9 0.001 
rno00190 Oxidative phosphorylation 9 0.021 
rno04725 Cholinergic synapse 7 
 
0.049 




Total 13    
 
  




III. HFD+PB vs HFD 
Gene expression in HFD+PB samples compared to HFD as a function of log2fold 
change and P value are shown in Figure 4.6. 
Figure 4.6. Distribution of differently expressed genes in HFD+PB vs HFD comparison. 
In (a) the proportion of each gene group compared to the total number of deregulated genes, in (b) volcano 
plot of relative expression and P value for each gene. n=3 
In the HFD+PB vs HFD comparison, 13120 genes were identified. From those, 377 
were found to be downregulated and 82 upregulated. The functional classification of 
deregulated genes in the HFD+PB vs HFD comparison can be found on Figure 4.7.  
PANTHER selected 65 genes from the group of highly upregulated genes of the 
HFD+PB vs HFD comparison. Most of these genes had molecular functions related to 
binding, including protein and nucleic acids, and catalytic activities. The most common 
biological functions were cellular processes, and most of them were components of the cell 
or the organelle. Enzyme modulators and hydrolases were the most common protein 
classes. 
PANTHER found information about proteins related to 302 of the highly deregulated 











proteins related to these genes performed binding functions, especially binding to proteins 
and binding to nucleic acids, and performed cellular processes with proteins such as 
transcription factors and traffic proteins. Most of these proteins were intracellular, and the 
most common protein classes were hydrolases and enzyme modulators. 
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Downregulated genes 302 genes
Upregulated genes 65 genes
Functional classification of deregulated genes in HFD+PB vs HFD
 
Figure 4.7. Functional classification of highly deregulated genes in the HFD+PB vs HFD comparison.  
Both highly up and downregulated genes were analysed using PANTHER to determine the (a) molecular 
function, (b) biological function, (c) cellular component and (d) protein class of their related proteins. n=3 
A full list of deregulated genes in the HFD+PB vs HFD comparison and their 
functional classifications can be found in Appendix B, Table 0.9 and Table 0.10. 





Using DAVID bioinformatic tools, up and downregulated pathways were selected 
and are shown in Table 4.4.  
Table 4.4. Deregulated pathways in the HFD+PB vs HFD comparison. 
Highly deregulated genes were selected using the parameters explained above and, using two tools from 
DAVID Bioinformatics (GO Analysis: Biological Process and KEGG Pathway), up to ten relevant deregulated 
pathways were selected for each tool used. “Total” is the number of total affected pathways highlighted by 






Term Pathway No. transcripts P value 
GO:0030154 Cell Differentiation 5 0.044 
GO:0019886 
Antigen Processing and 
Presentation of Exogenous 









Transport 3 0.046 
GO:0002506 
Polysaccharide Assembly 









Peptide Antigen Assembly 




Negative Regulation of 




Antigen Processing and 
Presentation of Peptide Or 
Polysaccharide Antigen Via 
MHC Class II 
2 0.039 
GO:0051085 
Chaperone Mediated Protein 
Folding Requiring Cofactor 
2 0.046 





























Total 3    











Negative Regulation of Cell 
Proliferation 
15 0.011 
GO:0007399 Nervous System Development 12 0.001 
GO:0007264 











GO:0051592 Response to Calcium Ion 6 0.022 
GO:0017158 













Positive Regulation of Glucose 
Import In Response To Insulin 
Stimulus 
4 0.002 
Total 72    
KEGG  
Pathway 
rno04014 Ras signalling pathway 10 0.020 
rno04024 cAMP signalling pathway 9 0.021 
rno04713 Circadian entrainment 8 0.002 
rno04728 Dopaminergic synapse 8 0.007 
rno04724 Glutamatergic synapse 7 0.015 
rno04727 GABAergic synapse 6 0.018 
rno04540 Gap junction 6 0.019 
rno05030 Cocaine addiction 5 0.008 
rno04721 Synaptic vesicle cycle 5 0.023 
Total 11    
 
A total of 14 differentially upregulated and 83 downregulated pathways were 
selected by DAVID bioinformatics for the HFD+PB vs HFD comparison. Upregulated 
pathways included cell differentiation and ion transport. Downregulated pathways 
included ion transport and various signalling pathways. 




IV. Differences in expression of genes related to CSF secretion 
 Ion transporters and channels and tight junction proteins expressed in human CP 
were selected from literature to analyse their gene expression changes in our study related 
to diet (Brown et al., 2004; Emerich et al., 2004; Kratzer et al., 2012; Praetorius and 
Damkier, 2017). Relative expression of genes related to these three categories is shown in 
Table 4.5. 
The largest differences in expression were found in the HFD+PB vs ND comparison, 
specifically amongst tight junction proteins. 
Out of 11 transporters analysed, only AQP1 and Slc4a5 were slightly overexpressed. 
Three transporters were highly downregulated, KCNA6, Slc4a10 and Aqp4. Three out of ten 
tight junctions proteins were upregulated, ZO-3, CLDN2 and CLDN22, although the 
difference in mRNA levels for all were < 1 therefore they were not considered highly 
deregulated. Four TJ genes were highly downregulated, ZO-1, Cadm1, CLDN11 and JAM3. 
Table 4.5. Relative gene expression in all three comparisons measured by MACE RNAseq of genes relevant 
to choroid plexus function related to CSF.  
Highlighted in red and bold lettering the downregulated genes for each specific comparison as determined 
by a significant P value; highlighted in green and bold lettering the upregulated genes for each specific 
comparison as determined by a significant P value. Underlined values mark deregulated genes with a log2fold 
change >1 or <-1.  
TRANSPORTERS 
Gene HFD vs ND  P value HFD+PB vs ND  P value HFD+PB vs HFD  P value 
Slc9a1 -0.239 0.705 0.195 0.579 0.434 0.354 
Kcna1 -0.472 0.686 -0.689 0.625 -0.217 0.932 
KCNA6 0.413 0.433 -1.457 0.004 -1.867 >0.001 
Slc12a2 -0.001 0.753 -0.491 0.224 -0.491 0.129 
Slc12a7 0.251 0.638 0.305 0.198 0.054 0.431 
AQP1 0.078 0.471 0.073 0.039 0.008 0.186 
Aqp4 -0.133 0.477 -3.373   0.021 -3.24 0.121 
Na+/K+ATPase1 0.134 0.598 0.022 0.852 -0.111 0.734 
Slc12a6 0.688 0.124 -0.330 0.925 -1.018 0.108 




Slc4a10 -0.721 0.110 -1.331 0.031 -0.610 0.577 
Slc4a2 0.078 0.926 0.151 0.076 0.073 0.095 
Slc4a5 0.619 0.017 0.494 0.009 0.125 0.823 
Slc4a7 0.670 0.817 -1.131 0.639 -1.801 0.464 
TIGHT JUNCTION PROTEINS 
Gene HFD vs ND  P value HFD+PB vs ND  P value HFD+PB vs HFD  P value 
ZO-1 -1.039 0.027 -1.437 0.014 -0.398 0.813 
ZO-2 -0.051 0.793 0.181 0.501 -0.232 0.357 
ZO-3 -0.239 0.510 0.285 0.045 0.524 0.010 
Cadm1 -0.743 0.246 -2.098 0.026 -1.355 0.286 
CLDN1 -0.074 0.496 -0.321 0.380 -0.246 0.846 
CLDN2 0.347 0.013 0.194 0.006 -0.154 0.777 
Cldn9 0.195 0.411 -0.014 0.446 -0.209 0.953 
CLDN11 0.079 0.853 -1.352 0.027 -1.431 0.043 
CLDN19 -0.024 0.930 -0.133 0.660 -0.109 0.729 
CLDN22 0.163 0.572 0.604 0.001 0.441 0.008 
Ocln -0.527 0.068 -0.438 0.181 0.089 0.625 
JAM3 -0.408 0.095 -1.068 0.001 -0.661 0.130 
 




V. Validation by qPCR 
The alteration of CP gene expression of key genes detected by MACE-RNASeq was 
validated by qPCR analysis using the same CP samples (Figure 4.8).  
Figure 4.8. Gene expression levels on a selection of genes of the CP of rats under three different diets. 
 *= P value<0.05, **= P value<0.01. n=3 
Gene expression levels of KCNA6 and ZO-1 appeared downregulated in both HFD 
and HFD+PB rats when compared to their ND control. CLDN2 expression levels were 
significantly higher in the HFD rats than in the ND rats, while JAM3 expression was 
significantly lower in HFD+PB when compared to HFD. 
Gene expression changes between HFD or HFD+PB and ND as measured by both 
MACE-RNAseq and qPCR were compared in Table 4.6. In the HFD vs ND comparison, the 
results of both techniques were similar: both detected a downregulation of ZO-1 and an 
upregulation of CLDN2 while the rest of the genes remained unchanged, except for KCNA6 
which was downregulated according to the qPCR. In the HFD+PB vs ND comparison, both 
techniques identified a decrease in expression levels of KCNA6 and ZO-1. However, the 
results of the qPCR suggested that the remaining tested genes were unchanged, while 































































Table 4.6. Gene expression level changes depending on diet on a selection of genes as measured by MACE-
RNAseq and qPCR. 
Due to the differences between techniques, results are indicated as level of gene expression change in either 




4.3.3 Protein expression of choroid plexus by 
immunohistochemistry on female rats related to diet 
The protein expression of ZO-1 and CLDN1 was studied further because they are 
essential TJ-forming proteins. AQP4 was not expected to be found in the CP samples taken 
from our rats because this gene is expressed in ependymal cells (Verkman et al., 2017; 
Trillo-Contreras et al., 2019). However, AQP4 expression was detected in our samples and 
it was decreased in HFD+PB vs ND, therefore its protein expression needed to be studied 
further. Photomicrograms of AQP4 staining in lateral ventricles of rats in brains from ND, 
HFD or HFD+PB rats can be found in Figure 4.9.a. No difference in intensity (Figure 4.9.b) 
or area of positive AQP4 staining relative to DAPI staining (Figure 4.9.c) was found between 




 HFD vs ND HFD+PB vs ND HFD vs ND HFD+PB vs ND 
 AQP1 = ↑ = = 
 AQP4 = ↓ = = 
 KCNA6 = ↓ ↓ ↓ 
 Slc4a10 = ↓ = = 
 ZO-1 ↓ ↓ ↓ ↓ 
 ZO-3 = ↑ = = 
 CLDN1 = = = = 
 CLDN2 ↑ ↑ ↑ = 
 JAM3 = ↓ = = 




Figure 4.9. Immunostaining of AQP4 in choroid plexus of female rats under different diets.  
(a) photomicrograms of images of AQP4 (green) and DAPI (red) staining in the lateral ventricle of ND, HFD 
and HFD+PB rats. (b) analysis of staining intensity and (c) area of AQP4 staining relative to DAPI. CTCF = 
corrected total cellular fluorescence,  n = 3 
 
Images of ZO-1 staining in lateral ventricles of rats under the different diets are 
shown in Figure 4.10.a. No differences in staining intensity (Figure 4.10.b) or relative area 
of ZO-1 staining (Figure 4.10.c) were observed related to diet. 
 






























































































































Figure 4.10. Immunostaining of ZO-1 in choroid plexus of female rats under different diets.  
(a) photomicrograms of images of ZO-1 (green) and DAPI (red) staining in the lateral ventricle of ND, HFD and 
HFD+PB rats. (b) analysis of staining intensity and (c) area of ZO-1 staining relative to DAPI. CTCF = corrected 
total cellular fluorescence, n=3 
The typical staining of CLDN1 observed in the lateral ventricles of the rats under ND, 
HFD or HFD+PB can be seen in Figure 4.11.a. There was a significant difference between 
intensity of staining between HFD and HFD+PB samples (Figure 4.11.b), but there was no 
difference in relative area of CLDN1 staining depending on diet (Figure 4.11.c). 
 





































































Figure 4.11. Immunostaining of CLDN1 in choroid plexus of female rats under different diets.  
(a) photomicrograms of images of CLDN1 (green) and DAPI (red) staining in the lateral ventricle of ND, HFD 
and HFD+PB rats. (b) analysis of staining intensity and (c) area of CLDN1 staining relative to DAPI. CTCF = 
corrected total cellular fluorescence, n=3, * = p value < 0.05 
 
4.4 Discussion 
Results shown in Chapter 3 demonstrated that diet and obesity influence CSF 
secretion in the female rat. The current study tested the hypothesis that this functional 
change was related to a diet-induced deregulation of gene and/or protein expression in the 
CP. A preliminary study was performed in which gene expression of select genes were 
compared between ND and HFD at 11w and 15w. The biggest difference was found to be 
between the 15w rats, therefore the following experiments were focused on studying 
possible changes between ND, HFD and HFD+PB at 15w. MACE-RNAseq analysis found that 
the HFD+PB group showed the largest changes in gene expression compared to the ND 
group, although those genes thought to be key for CSF dynamics were not altered. 




However, some tight junction proteins appeared downregulated. Furthermore, CLDN1 
immunostaining showed an increase of staining in HFD+PB when compared to HFD. 
HFD+PB had a decrease in expression levels of AQP7 and AQP9 compared to rats 
fed the ND. AQP7 is located on the apical membrane, which suggests a possible 
collaboration with AQP1 in CSF secretion, while the exact location of AQP9 within the CPEC 
is not known yet (Nazari et al., 2014; Patyal and Alvarez-Leefmans, 2016). Neither of these 
genes are thought to be essential for CSF secretion though, therefore the implication of 
their deregulation in CSF secretion is unknown. However, decreased levels of AQP7 and 
AQP9 could be a balance mechanism to decrease an already increased secretion of CSF. 
Nevertheless, more research is needed in order to investigate the extent at which these 
proteins collaborate on CSF secretion. 
HFD 15w rats showed an overexpression increase in mRNA levels of ATP1B1 while 
ATP1A1 and ATP1B2 remained unaltered. ATP1B1 function within the ATP1 family is 
thought to be related to stability and separation of this subunit from the heterodimer has 
been shown to irreversibly inactivate both transport and enzymatic activities of ATP1 
(McDonough, Geering and Farley, 1990). Consequently, an increased of expression of 
ATP1B1 would not affect ATP1 activity directly.  
The increase in Slc4a5 expression in HFD rats could be directly related to the 
differences in diet rather than the increase in body weight. In the renal epithelium, Slc4a5 
expression has been found to be increased following an intracellular sodium increase 
(Gildea et al., 2015). In the CP, Slc4a5 is essential for maintaining a stable pH in the CSF. 
While a lower expression of Slc4a5 has been shown to lead to altered CPEC, an 
overexpression of this gene has not been reported to significantly affect CPEC or CSF 
secretion on its own (Kao et al., 2011; Christensen et al., 2018) 
ERb was overexpressed in HFD15w when compared to ND of the same age. This 
protein can directly regulate transcription of specific target genes such as transthyretin, but 
it also requires a number of coregulatory proteins to function properly (Heldring et al., 
2007; Quintela et al., 2009; Wilson, Westberry and Trout, 2011; Paterni et al., 2014). In an 




ex vivo model of rabbit CP, oestrogen and progesterone were able to reduce CSF secretion 
on their own and in combination (Lindvall-Axelsson and Owman, 1989). A study of CP gene 
expression in ovariectomised female rodents reported upregulated levels of CSF secretion-
related genes, giving a further glimpse into the regulating role of sex hormones on CSF 
secretion (Santos et al., 2017). None of the genes analysed in our preliminary study 
appeared altered in their study, however. The total implication of sex hormones in CSF 
secretion is not well known yet, but the evidence points out to them being an important 
regulator. 
Due to the fact that the biggest difference in gene expression depending on diet 
was found on the 15w rats, the extensive gene expression analysis was performed on this 
group and the three available diets were tested. 
Gene expression from 15w ND, HFD and HFD+PB was analysed using the MACE-
RNAseq technique and compared between diet groups. HFD+PB vs ND was the comparison 
with the highest quantity of deregulated genes, which suggests that diet-induced obesity 
can alter gene expression levels in the CP. Dietary fat is a known gene expression regulator 
(Jump and Clarke, 1999; Jump, 2004; Siersbaek et al., 2017). Furthermore, CP is thought to 
be involved in lipid-related activities such as supplying brain tissue with polyunsaturated 
fatty acids and regulation of the sleep-inducing lipid oleamide, which could be affected by 
an increase in dietary fat (Bourrea et al., 1997; Egertová, Cravatt and Elphick, 2000; Raatz 
et al., 2001; Egertová et al., 2004). 
The most common biological functions amongst deregulated genes between diet 
groups were related to cell processes. The most common cell process in upregulated genes 
in all three comparisons was related to the cytoskeleton. Alterations in cytoskeletal-related 
proteins in the brain of rodents under a HFD have been previously reported, and it is 
thought to be a consequence of cell stress (Smine et al., 2017; McLean, Campbell, Langston, 
et al., 2019; McLean, Campbell, Sergi, et al., 2019). Amongst downregulated genes, the 
most common cell processes were related to gene transcription and carrier proteins.  




Using DAVID bioinformatics, deregulated pathways were analysed. Deregulated 
pathways in all comparisons were also characterised by increased pathways related to 
cellular structure and decreased pathways related to gene transcription and transport. 
However, other interesting pathways were also detected.  
HFD+PB group showed a deregulation in circadian pathways when compared to 
either HFD or ND. HFD has previously been reported as an alterator of the circadian clock, 
including changes on patterns of circulating levels of sex hormones (Kohsaka et al., 2007; 
Cano et al., 2008). The CP is highly influenced by circadian rhythms and sex hormone levels 
(Myung et al., 2018; Quintela et al., 2018; Yamaguchi et al., 2020). The extent at which an 
alteration of circadian rhythms would affect CSF secretion is not well explored yet. 
However, these alterations would certainly have an effect on CSF secretion rate, and 
further investigation into this topic is needed in order to understand this relationship 
better. 
Both HFD vs ND and HFD+PB vs ND showed a decrease in pathways related to 
hormonal response including the androgen receptor signalling pathway, which could be a 
compensatory mechanism to highly altered hormonal levels related to increased adiposity 
(Sidhu, Parikh and Burman, 2017; Varlamov, 2017; Volk et al., 2017). Cell adhesion 
pathways were also decreased, which could lead to an increase in permeability of the CP 
which could ultimately affect CSF dynamics (Wolburg and Paulus, 2010; Kant et al., 2018). 
Interestingly, HFD+PB vs ND showed a decrease in ion transmembrane transport. CSF 
secretion directly depends on ion transport across the BCSFB, therefore a decrease of this 
type of transport would cause a decrease in CSF secretion. However, HFD+PB rats had an 
increased secretion rate of CSF in Chapter 3. It is possible that the decrease in ion transport 
seen in this analysis is a compensatory mechanism caused by an increase of CSF secretion 
caused by other mechanisms, such as by an increase in paracellular permeability.  
Furthermore, several signalling pathways appeared downregulated in HFD+PB 
when compared to either ND or HFD. Whether they are directly related to the changes in 
CSF dynamics observed in HFD+PB rats in Chapter 3 is not known yet. However, it is a 
possibility. The cyclic adenosine 3′,5′-monophosphate (cAMP) signalling pathway, for 




example, has an essential role in cellular response to different neurotransmitters and 
hormones (Watson, Mayes and Watson, 2004; Sassone-Corsi, 2012). It is important to keep 
in mind that HFD+PB rats were found to have the highest rates of CSF secretion and also 
the highest concentration of testosterone in plasma, and that those two parameters 
correlated positively. Testosterone has been seen to increase fluid secretion and solute 
transport by increasing cAMP generation in kidney epithelial cells in vitro (Sandhu et al., 
1997). In CP, CSF secretion is increased by agents increasing intracellular cAMP (Saito and 
Wright, 1983). It is possible that testosterone could increase cAMP generation in CP 
epithelium, increasing CSF secretion, and the downregulation of the cAMP pathway 
observed in HFD+PB rats could be a compensatory mechanism to compensate for the big 
alteration caused by testosterone. Another downregulated signalling pathway was the 
renin angiotensin system (RAS). Sex hormones and especially testosterone have been 
shown to alter RAS activity in kidney epithelium (Fortepiani et al., 2003; Komukai, 
Mochizuki and Yoshimura, 2010). RAS controls fluid homeostasis, therefore an alteration 
in activity could alter fluid secretion (Kapsha and Severs, 1983; Savaskan, 2005). However, 
these are only speculations, and further research is needed in order to study the possible 
effect of testosterone on signalling pathways in the CP and, ultimately, in CSF secretion.  
As mentioned in the introduction, the roles that CP carries out regarding CSF 
secretion and integrity are dependent on proper functioning of molecular transporters and 
integrity of tight junction proteins. In the current experiment, it was found that HFD+PB 
highly decreased gene expression of two molecular transporters, KCNA6 and Slc4a10. The 
effect of decreased expression levels of KCNA6 in the CP functionality are not known. In 
animal models, deletion of the Slc4a10 gene in the CP results in a redistribution and altered 
polarisation of important proteins such as ATP1, AQP1 and Slc9a1 within the CPEC (Jacobs 
et al., 2008; Damkier and Praetorius, 2012; Christensen et al., 2020). This deletion can also 
lead to decreased total ion transport and thus a decrease in CSF secretion due to the lack 
of Na+ transport into the CSF (Jacobs et al., 2008; Christensen et al., 2013, 2020). However, 
it is important to note that these effects are seen in gene deletion in vivo models which are 
unable to express the Slc4a10 gene altogether, which is not the case of our animals. While 
the exact effect that decreased levels of Slc4a10 can have in CP function is unknown, this 




gene is still expressed therefore the effect might not be as dramatic as what was observed 
in Slc4a10 knock out animals.  
AQP1 expression was slightly increased in the HFD+PB vs ND comparison. However, 
as log2fold change<1, the difference in expression was not enough to be considered highly 
overexpressed. The same was also observed with three tight junction proteins, ZO-3, 
CLDN2 and CLDN22. By contrast, ZO-1, JAM3, Cadm1 and CLDN11 appeared highly 
downregulated in the HFD+PB group when compared to ND. ZO-1 is thought to be essential 
for epithelial barrier functionality, and its decrease has been linked with increased 
paracellular permeability in different epitheliums, including the CP (Scudamore et al., 1998; 
Guo et al., 2011; Kaur, Rathnasamy and Ling, 2016; Kim and Kim, 2017). JAM3 is thought to 
be important for CP integrity of TJs, and its deficiency has been linked with severe 
hydrocephalus in a mouse model as well as enlarged ventricles in a rare human condition 
caused by a mutated JAM3 leading to a non-functional protein (Mochida et al., 2010; Wyss 
et al., 2012). In animal models and human cases of neuroinflammation and Alzheimer’s 
disease, decreased tight junction protein expression in the CP is linked to increased leakage 
of the BCSFB and disruption of the barrier functions (Coisne and Engelhardt, 2011; Kooij et 
al., 2014; Brkic et al., 2015). Inflammation is thought to alter CP gene expression and 
functionality, including changes protein expression, barrier tightness and CSF secretion 
(Marques et al., 2007; Shrestha, Paul and Pachter, 2014; Kant et al., 2018). As mentioned 
in Chapter 1, diet-related obesity can be accompanied by general inflammation (Shaw et 
al., 2014; Ellulu et al., 2017; Stolarczyk, 2017). Furthermore, increased proinflammatory 
cytokines have been shown to increase CSF secretion in the rat using the ventriculo-
cisternal perfusion technique (Alimajstorovic, Pascual-Baixauli, et al., 2020). In the present 
study, the biggest alteration in tight junction protein expression was seen in our HFD+PB 
rats, which are also the group with highest BMI. It is possible that these rats were 
experiencing general inflammation, which might be promoting downregulation of these 
proteins. Another important characteristic of our HFD+PB rats is that they had increased 
levels of testosterone. Androgens have the ability to alter tight junction protein expression 
in some epithelia, such as prostate and seminiferous, and in the blood-testis barrier (Meng 
et al., 2005, 2011; Chakraborty et al., 2014). While the effect of androgens in tight junction 




proteins of the CP is not well studied yet, the fact that CPEC express AR indicates that 
androgen signalling might play a role in CP regulation, including being able to alter tight 
junction protein expression. Furthermore, IIH is characterised by female sex, obesity and 
higher levels of androgen levels (O’Reilly et al., 2019). According to our results, 
inflammation and androgen excess could both contribute to altering CSF dynamics by 
changing the expression of tight junction proteins. This possible increase in barrier leakage 
could lead to a higher paracellular passage of water, which could contribute to higher rates 
of CSF secretion.  
The samples analysed by MACE-RNAseq were also measured using qPCR in order to 
doublecheck the results obtained by the former technique. Both techniques are 
fundamentally different as their approach for gene expression measurement differs. MACE 
RNAseq appeared to be able to point out differences in gene expression that qPCR 
considered unchanged. However, neither of the results were contradictory – neither gene 
appeared as upregulated in one analysis and downregulated in the other. RNAseq is indeed 
considered to be more sensitive and precise than qPCR because it does not rely on the 
expression of housekeeping genes (Fassbinder-Orth, 2014; Nonis, De Nardi and Nonis, 
2014; Su et al., 2014; Pombo et al., 2017). However, it was important to also measure gene 
expression by qPCR in order to facilitate reproducibility by other researchers. qPCR is still 
the technique of choice nowadays for medium-throughput gene expression analysis in 
most laboratories, due to its relative low cost, time frame and difficulties to perform and 
analyse while maintaining analysis reliability.  
AQP4 is mainly found in the ependymal cells rather than CPEC, therefore its 
presence in our samples was not expected and it might mean that the extraction technique 
used yielded some contamination from the ventricle lining (Verkman et al., 2017; Trillo-
Contreras et al., 2019). However, MACE-RNAseq results showed that AQP4 was highly 
deregulated in HFD+PB when compared to ND, thus immunostaining of AQP4 protein was 
performed in order to analyse the difference of protein expression related to diet. AQP4 is 
thought to be important for CSF flow and water homeostasis in the brain ventricles, 
therefore a decrease in expression caused by diet could alter CSF dynamics (Speake, 




Freeman and Brown, 2003; Iliff et al., 2012). After performing immunostaining 
experiments, we can safely conclude that AQP4 is mainly expressed in the ventricle lining 
and its expression was not significantly changed by diet in our experiment.  
Immunostaining of CLDN1 showed an increase in intensity of staining in HFD+PB 
when compared to HFD. In the literature, ovariectomised rodents have been shown to have 
downregulated CLDN1 expression when compared to controls (Santos et al., 2017). 
However, the exact mechanism by which sex hormones could alter CLDN1 expression in CP 
has not been studied yet. Interestingly, oestradiol levels measured in Chapter 3 were 
increased in HFD rats and decreased in HFD+PB when compared to ND, following an 
opposite pattern to the intensity of CLDN1 staining detected in this chapter. However, 
whether oestradiol levels can alter CLDN1 expression in the CP cannot be concluded from 
these results. Furthermore, the increase in CLDN1 seen in HFD+PB could be due to other 
parameters not measured in this experiment, such as alteration in expression levels of 
other claudins as seen in intestinal epithelium (Sakaguchi et al., 2002; Yang et al., 2014).  
In summary, diet-induced obesity was able to alter gene expression in the CP of 
female rats. The most remarkable changes included a decrease in TJs gene expression. The 
biggest changes were seen in the rat group with highest testosterone plasma 
concentrations in Chapter 3. Due to this, the effect of testosterone in in a model of CP in 
vitro was investigated in Chapter 5.  




Chapter 5. Investigation into the Effects of 
Testosterone on Barrier Functionality of an In 
vitro Model of Choroid Plexus  
5.1 Introduction 
Sex hormones were firstly thought to mainly influence processes related to sex 
differentiation and reproduction (Moore, 1941, 1947; Jost, 1970). However, it has been 
shown that sex hormones can also affect a wide number of different physiological 
processes which are not directly related to sex or reproduction, such as the immune 
response, the circadian clock or food intake (Verthelyi, 2001; Pasquali, 2006; Quintela et 
al., 2015). Furthermore, sex hormone levels can be altered by several different 
mechanisms, including body fat composition. Specifically, obesity in women is known to 
increase testosterone levels, while in men, the opposite effect is observed (Evans et al., 
1983; Bray, 1997; Pasquali, 2006). 
Sex hormones have long been suspected to be potential key effectors for 
development of IIH, due to the demographics of this condition in the general population 
(see Section 1.3.4). The great majority of patients fall inside a very specific demographic 
group: overweight women of childbearing age (Radhakrishnan et al., 1993; Bidot and 
Bruce, 2015). Furthermore, conditions characterised by altered sex hormones such as PCOS 
and pregnancy or the use of hormonal oral contraceptives are linked to higher risk of 
developing IIH (Bagga et al., 2005; Glueck et al., 2005; Karmaniolou, Petropoulos and 
Theodoraki, 2011; Chen and Wall, 2014). Additionally, secondary intracranial hypertension 
in transgender individuals associated with testosterone treatment has been reported in the 
literature (Park et al., 2014; Bedolla, Buchanan and Hansen, 2017; Hornby et al., 2017).  
Little research has been developed in this area, however. While the possible role of 
sex hormones in IIH has long been speculated, most of the studies into this topic lack 
accuracy due to the very low numbers of studied patients and a failure to take menstrual 
cycle into account when obtaining and analysing the samples (Donaldson and Horak, 1982; 
Toscano et al., 1991). More recent research has shown a link between increased 




testosterone levels and IIH, especially in young onset (<25 years of age) patients (Klein et 
al., 2013; O’Reilly et al., 2019). An in vitro investigation into the effect of sex hormones on 
CSF secretion by the CP suggests that testosterone can increase secretion of CSF by 
increasing ATPase activity while progesterone and oestrogen are able to decrease secretion 
by a different but unknown mechanism (Lindvall-Axelsson and Owman, 1989; O’Reilly et 
al., 2019). In addition, the results from the previous Chapter show that the expression of 
some TJ proteins in the CP may be altered in diet-caused obesity, thereby suggesting 
alterations in the permeability of the CP. The effects of testosterone on permeability and 
gene expression of the CP have not yet been described. 
The research described in this chapter was aimed at exploring the effect of 
testosterone in an in vitro model of CP based on the immortalised rat choroid plexus 
epithelial cell line Z310. The morphology and gene expression of this cell line was first 
characterised, then, to establish the CP in vitro model, the culture conditions for growth of 
Z310 on a permeable membrane were optimised to identify those that would yield the 
tightest monolayer. Lastly, the effects of testosterone on cell morphology, gene expression 
and barrier functionality were studied in the optimised culture system.  
5.2 Materials and Methods 
All materials used were obtained from Sigma-Aldrich (Poole, Dorset, UK) unless 
otherwise specified. 
5.2.1 Cell culture 
The rat choroid plexus epithelium immortalised cell line Z310 was kindly provided 
by Dr Wei Zheng (Purdue University, West Lafayette, IN, USA) and was cultured following 
a protocol previously described in the literature (Zheng and Zhao, 2002). Briefly, cells were 
cultured in flasks in Dulbecco’s Modified Eagle Medium (DMEM, ThermoFisher Scientific, 
UK) with phenol red and supplemented with foetal calf serum (FBS, 10% v/v, ThermoFisher 
Scientific, UK), streptomycin (100µg/ml, ThermoFisher Scientific, UK), penicillin (100 U/ml, 
ThermoFisher Scientific, UK), gentamycin (40µg/ml) and epidermal growth factor (5µg/ml, 
ThermoFisher Scientific, UK) and maintained in a humidified incubator with 5% CO2/95% 




air v/v at 37oC. The culture medium was changed every two days and cells were passaged 
when 80% confluence was reached, typically twice a week. Cells were discarded after 8th 
passage, and all experiments were performed on cells between passage 5 and 7. 
The effect of testosterone in Z310 cells was studied. Testosterone-treated cells 
were incubated with either 0 (Control), 1, 3 or 10 ng/ml testosterone for 12h prior to the 
assay. For treatment with the androgen receptor antagonist flutamide, cells were 
incubated with 10µM of for 1h before testosterone was added in order to test whether the 
changes in gene expression and barrier functionality detected were due to testosterone. 
5.2.2 Gene expression analysis  
For gene expression analysis, cells were seeded at 2x105, grown until confluence 
and then washed with PBS three times. Cells were trypsinized for 10 min at 37o and, once 
they appeared round, birefringent and detached under the microscope, digestion was 
stopped by the addition of culture medium containing serum. Cells were then centrifuged 
at 200 xg for 10 min at 4oC to obtain a pellet, which was placed on ice. RNA was extracted 
immediately using the RNeasy Micro Kit (Qiagen, Manchester, UK) following 
manufacturer’s instructions. Reverse transcription was then performed using the High 
capacity cDNA Reverse Transcription Kit (Thermofisher Scientific, UK) and qPCR was carried 
out using the QuantiTect SYBR® Green PCR Kit (Qiagen, Manchester, UK) and KiCqStart® 
SyBR® Green predesigned primers for rat (Table 5.1, Table 4.1).  




Table 5.1. Sequences of primers used in qPCR analysis. 
 
For cell characterisation, gene expression relative to actin- β was normalised to 
GAPDH expression using Equation 5.1 (Kläs et al., 2010). Genes were selected based on 
either the results from Chapter 4 or from genes typically expressed in the choroid plexus 
(Szmydynger-Chodobska et al., 2007; Kläs et al., 2010). 
 
Equation 5.1. Calculation of relative expression levels of gene of interest. 
𝜟𝑪𝒕𝑮𝑶𝑰 = 𝑪𝒕𝑮𝑶𝑰 − 𝑪𝒕𝑨𝒄𝒕𝒊𝒏 𝜷  
𝑹𝒆𝒍𝒂𝒕𝒊𝒗𝒆 𝒆𝒙𝒑𝒓𝒆𝒔𝒔𝒊𝒐𝒏 𝒐𝒇 𝑮𝑶𝑰 = 𝟐−(𝜟𝑪𝒕𝑮𝑨𝑷𝑫𝑯 − 𝜟𝑪𝒕 𝑮𝑶𝑰)  
Where: 
Ct= Quantification cycle threshold 
GOI = Gene of Interest 
For analysis of the effect of testosterone on gene expression, expression relative to 
control was calculated using the 2-ΔΔCt method as previously described in the literature 
Gene Symbol Sequence 
Organic Anion Transporter 2 SLC22A7 
Forward 5’-TGGTATCCTTGGAGACTAAG 
Reverse 5’-CGTAGTAAAAGCAGCTTCAG 
Organic Anion Transporter 3 SLC22A8 
Forward 5’-GGTAGAAGAATTTGGAGTCAAC 
Reverse 5’-TTTCTGAAGGCACAAAGATG 
solute carrier organic anion transporter 










ATP-Dependent Phospholipid Transporter a ABCB1A 
Forward 5’-GCATTCTGGTATGGGACTT 
Reverse 5’-GTCTTTTCGAGACGGGTA 
ATP-Dependent Phospholipid Transporter b ABCB1B 
Forward 5’-CATTCTGCCGAGCGTTAC 
Reverse 5’-CCCGTGTAATAGTAGGCGTA 
Multi-Specific Organic Anion Transporter B ABCC4 
Forward 5’-CCATTCT GGTTATTCTGCTG 
Reverse 5’-TCAGATTGGTTATGAGGTCG 




(Livak and Schmittgen, 2001; Schmittgen and Livak, 2008). Cells with no testosterone nor 
flutamide treatment were used as control, and actin-β was used as reference gene. Genes 
were selected from the results of Section 4.3.2.IV.   
5.2.3 Study of Z310 monolayer barrier functionality 
In order to study the barrier characteristics of the cell monolayer, cells were 
cultured in a two-chamber system following a protocol previously described in the 
literature (Zheng and Zhao, 2002; Shi et al., 2008).  
Briefly, Corning™ Transwell™ inserts with either polyester or 
polytetrafluoroethylene (PTFE) 12 mm in diameter 0.4µm pore size permeable membrane 
were used (ThermoFisherScientific, UK).  
For optimisation of the rat CP model, different extracellular matrices and seeding 
numbers were first tested in order to find the culture conditions which yielded the tightest 
monolayer as measured by transepithelial electrical resistance (TEER). For collagen I 
coating, the insert was incubated with collagen I (100µg/ml, ThermoFisher Scientific, UK) 
at RT for 4 hours. For laminin coating, membranes were incubated with laminin (14µg/ml) 
for 15 min. For fibronectin coating, collagen I-pretreated membranes were incubated with 
fibronectin (5 μg/ml, ThermoFisher Scientific, UK) at RT for 1 hour. In all cases, excess liquid 
was removed after the incubation period and the membrane was left to air dry overnight 
at RT. 
In order to determine optimum cell seeding concentration, cells were seeded on 
collagen I pre-treated membranes at either 5x104, 2x105 or 4x105 cells per insert (1.13 cm2 
growing surface).  
The cell monolayer was typically formed 4-5 days after seeding, and it was 
determined by three criteria: cells forming a confluent monolayer without visible spaces 
when observed under an inverted light microscope; culture medium in the inner chamber 
being at least 2mm higher than that in the outer chamber and a constant TEER value across 
the insert (Zheng and Zhao, 2002; Shi et al., 2008). Cells were kept in confluency for a day 
before experiments were performed. 




I. Electrical resistance  
Electrical resistance of the barrier was estimated by TEER values. TEER was 
measured using an EVOM™ device coupled with an EndOhm chamber (World Precision 
Instruments, Hitchin, UK). The chamber was sterilised with 70% Ethanol for 10min at RT 
and then washed three times with autoclaved highly-purified water. The chamber was then 
filled with 1.5ml of pre-warmed culture medium. The insert was gently placed inside the 
chamber and filled with 500µl of pre-warmed medium. It was essential to avoid the 
formation of bubbles as they can affect TEER readings. The lid was placed over the insert 
and TEER was recorded three times per insert and averaged to increase measurement 
accuracy. 
II. Paracellular permeability 
Basolateral-to-apical paracellular permeability of the monolayer was calculated 
using 70kDa fluorescein isothiocyanate–Dextran (FITC-Dextran). Briefly, culture media was 
substituted by phenol red-free culture media 12h prior to the experiment. On the day of 
the experiment, the lower chamber was filled with phenol red-free media containing 
1mg/ml FITC-Dextran while the upper chamber did not contain any FITC-Dextran. Samples 
were collected from the upper chamber every 5 min for a total time of 30 min and 
measured using a spectrophotometer (Fluostar Optima, BMG labtech, Aylesbury, UK) with 
a 485nm excitation and 525nm emission wavelengths. Extracted samples were 
immediately replaced with fresh phenol red-free media and the dilution was calculated 
accordingly. The permeability coefficient (Pe) was calculated using Equation 5.2 (Dehouck 
et al., 1992; Tai et al., 2009). 
Equation 5.2. Permeability coefficient calculations 



















PS = Permeability surface area of epithelial monolayer 
sf = Surface area of filter 
me = slope of the curve corresponding to epithelial cells on filter 
mf = slope of the curve corresponding to empty filter 
5.2.4 Statistical analysis 
Each experiment consisted of 3 technical replicates averaged per biological 
replicate for a total of 3 biological replicates unless otherwise specified. All results are 
presented as average of biological replicates ± SEM. Normal distribution of data was 
confirmed by Q-Q plot. One-way ANOVA with Tukey Post Hoc test were used to analyse 
differences between groups for model optimisation and two-way ANOVA with Tukey Post 
Hoc tests to determine the effect of testosterone on Z310 cells. Statistical analysis was 
performed using GraphPad (Graphpad Software, 2019). 
5.3 Results 
5.3.1 Z310 characterisation  
Z310 were firstly characterised by morphological observation using phase-contrast 
microscopy. When the cells formed a confluent layer, they had a predominantly polygonal 
morphology (Figure 5.1). 






Figure 5.1. Morphology of Z310  
Cell morphology of Z310 monolayer was observed using phase-contrast microscopy. Cells were imaged 12h 
after confluence was reached. This is a representative image of a Z310 confluent monolayer. 
Z310 cells were further characterised by gene expression analysis. Genes typically 
expressed in the CP epithelium were selected and are shown in  
 
Figure 5.2. Analysed genes included: TJs, such as CLDN1 and ZO-1; transporters, 
such as ABCC4 and Slc4a10; water channels such as AQP1 and AQP4; and other genes 
expected to be expressed in the CP, such as TTR and AR. Z310 expressed all the analysed 
genes with the exception of OATP1a4, KCNA6 and AQP4. 





Figure 5.2. Gene expression in Z310 of genes typically expressed in CP. 
Cells were grown to confluence before RNA was extracted. Gene expression relative to actin-β was 
normalised to GAPDH expression for each gene studied. n=3 
A comparison of the expression of selected genes in Z310 and those from in vivo in 
the choroid plexus of female rats on a normal diet (ND 15w, determined using the MACE-
RNAseq technique and as reported in Chapter 4) is summarised in Table 5.2. Due to the 
differing techniques, results are only reported qualitatively, as expressed (+) or not 









































































































Table 5.2. Gene expression in Z310 cells and female rats.  
Summary of gene expression in Z310 cells (determined by qPCR) and in rat choroid plexus (Rat CP; 15w ND, 
determined by MACE-RNAseq). Genes were selected from (a) results of Chapter 4 or (b) genes typically 
expressed in the CP. + denotes gene detection, - denotes no detection. 
a) Gene Z310 Rat CP  b) Gene Z310 Rat CP 
 ATP1A1 + +   AR + + 
 CLDN1 + +   Slc22a7 + + 
 CLDN2 + +   Slc22a8 + + 
 ZO1 + +   OATP2b1 + + 
 ZO3 + +   OATP1a4 - + 
 JAM3 + +   ABCC4 + + 
 AQP1 + +   ABCB1a + - 
 AQP4 - +   ABCB1b + - 
 Slc4a10 + +   TTR + + 
 KCNA6 - +   
 
There were several differences between the expression profiles of the rat CP cell 
line and rat choroid plexus. Expression of AQP4, KCNA6 and OATP1a4, which were detected 
in rat CP, were not detected in Z310 cells, whilst ABCB1a and ABCB1b, which were not 
expressed in rat CP were in fact expressed by Z310 cells. 
5.3.2 CP Model optimisation 
In order to determine which surface and coating resulted in the optimal barrier 
properties for the model system, Z310 cells were cultured on two different membranes 
(PTFA and polyester) with four different pre-treatments (none, laminin, collagen I or 
collagen I with fibronectin). Once confluence was reached, TEER was recorded for the 
different parameters (Figure 5.3). 





Figure 5.3. Dependency of monolayer resistance on membrane material and coating. 
TEER was recorded for Z310 cultures grown to confluence on (a) PTFA or (b) polyester membranes in 
Transwells with one of four different matrices. n=3, *=P value < 0.05, **=P value < 0.01, ***=P value < 0.001, 
**** P value < 0.0001. 
Lack of coating yielded the lowest TEER values for both types of membranes. In 
PTFA inserts, laminin, collagen I and collagen I with fibronectin had significantly higher TEER 
values when compared to no coating, although there was no significant difference between 
these three coatings. While in polyester membranes lack of coating also showed 
significantly lower TEER values when compared to all the other treatments, there was also 
a difference between resistance recorded for cells grown on the other three matrices. 
Specifically, the monolayers cultured on both collagen I and collagen I with fibronectin 
showed significantly higher TEER than those cultured with a laminin coating. Polyester 
membranes with a collagen I coating gave the highest TEER values and hence were selected 






































































































Three different initial cell seeding numbers were tested in order to assess which 
resulted in the tightest monolayer. Three seeding numbers were tested, and their TEER 
values once confluency was reached are shown in Figure 5.4. Seeding of 5x104 cells / 
Transwell gave significantly lower TEER values once confluency was reached when 
compared to the other two cell seeding numbers. As a result, 2x105 cells / Transwell was 
























Number of cells seeded per well
 
Figure 5.4 Dependency of cell layer resistance on initial seeding number.  
Cells were seeded on collagen I pre-coated polyester membranes and grown to confluency. n=3, *=P value < 
0.05, **=P value < 0.01 
5.3.3 Effect of testosterone on morphology of Z310 
Three different testosterone concentrations were tested to investigate the possible 
effect of this hormone on morphology (Figure 5.5). No apparent differences in morphology 
were observed between different testosterone treatments and control. 







T 3ng/ml T 10ng/ml
 
Figure 5.5. Effect of testosterone on morphology of Z310 cells.  
Cells were cultured until confluence was reached. Then, cells were incubated with the concentrations of 
testosterone indicated for 12 h before images were taken. 
5.3.4 Effect of testosterone on gene expression of Z310 
The effect of testosterone was tested on Z310 cells using three different 
concentrations. The androgen receptor antagonist flutamide was used in order to assess 
which observed changes were due to testosterone action. Gene expression was measured 
in these cells and it is shown in Figure 5.6. 
Expression of ATP1A1, AQP1, Slc4a10, JAM3, CLDN1, CLDN2, ZO-1 and ZO-3 was 
analysed in this experiment. There was a significant dose-dependent increase in ATP1A1 
expression caused by all three concentrations of testosterone tested while just the highest 
concentration of testosterone was able to significantly increase AQP1 expression when 
compared to control. On the other hand, all three concentrations of testosterone greatly 
decreased Slc4a10 levels in Z310 cells. Furthermore, 3 and 10ng/ml of testosterone were 
both able to decrease ZO1 levels when compared to control while just the highest 
concentration decreased ZO3 expression levels significantly. None of the cells treated with 




flutamide showed any differences in gene expression, suggesting that testosterone induced 
gene expression changes detected. 
Figure 5.6. Gene expression levels of Z310 cells under different treatments with testosterone (T), with and 
without flutamide, relative to control.  
Cells were cultured until confluence was reached. Then, cells were incubated with a variable concentration 














































































































































































































































































































































































































































































before testosterone treatment. n=3, *=P value < 0.05, **=P value < 0.01, ***=P value < 0.001, **** p value 
< 0.0001. 
Testosterone-induced changes in gene expression relative to control in Z310 cells 
are summarised in Table 5.3, alongside a summary on gene expression changes in vivo in 
the choroid plexus of the female rat group showing the highest levels of testosterone, the 
HFD+PB 15w. Changes in expression of Z310 cells was measured by qPCR while changes in 
rats were measured using MACE-RNAseq and compared to female rats of the same age 
under ND. Due to the differing techniques, results are only reported qualitatively, as 
overexpressed (↑), unaltered (=) or downregulated (↓). 
Table 5.3. Gene expression in testosterone-treated Z310 cells and female rats.  
Summary of expression of selected genes in testosterone-treated Z310 cells (determined by qPCR) and in rat 
choroid plexus (Rat CP; HFD+PB 15w vs ND 15w, determined by MACE-RNAseq, as reported in Chapter 4). T 
stands for testosterone treatment. ↑ denotes increase in gene expression relative to their control, ↓ 
denotes decrease in gene expression relative to their control, = denotes no alteration. “Slightly” denotes that 
the p value was < 0.05, but log2fold change was between -1 and 1. 
 Gene Z310 1ng/ml T Z310 10ng/ml T Rat CP 
 AQP1 = ↑ Slightly ↑ 
 Slc4a10 = ↓ ↓ 
 ATP1A1 ↑ ↑ = 
 JAM3 = = ↓ 
 CLDN1 = = = 
 CLDN2 = = Slightly ↑ 
 ZO-1 = ↓ ↓ 
 ZO-3 = ↓ Slightly ↑ 
 
There were a number of differences between alterations by testosterone treatment 
on in vitro cells and changes in expression measured in rats. In cells treated with 1 ng/ml 
of testosterone, all analysed genes remained unchanged except for ATP1A1, which was 
upregulated. Cells treated with 10 ng/ml of testosterone showed an increase in expression 
of AQP1 and ATP1A1, while having a decrease in expression of Slc4a10, ZO-1 and ZO-3. The 
CP of rats belonging to the group with highest testosterone concentrations had a slight 




increase in expression levels of AQP1, CLDN2 and ZO-3. They also had a decrease in 
expression of Slc4a10, JAM3 and ZO-1.  
5.3.5 Effect of testosterone on Z310 barrier functionality 
Three different testosterone concentrations were tested to investigate the possible 
effect of this hormone the barrier functionality, specifically electrical resistance and 
permeability coefficient of the Z310 monolayer (Figure 5.7). 
Figure 5.7. Changes on barrier functionality depending on testosterone treatment. 
Barrier functionality was estimated by measuring (a) electrical resistance and (b) paracellular permeability of 
the monolayer. Cells were cultured on polyester membranes coated with collagen I until confluence was 
reached. Then, cells were incubated with the indicated concentrations of testosterone for 12 h before 
analysis was performed. Flutamide treatment was performed before testosterone treatment. After this, 
electrical resistance and permeability of the cell monolayer were measured. n=3,  *=P value < 0.05, **=P 
value < 0.01, ***=P value < 0.001, **** P value < 0.0001. 
The highest concentrations of testosterone (3 and 10 ng/ml respectively) caused a 
significant decrease in TEER values, suggesting that monolayer electrical resistance was 
decreased. Permeability was also increased in the samples treated with both 3 and 10 
ng/ml of testosterone. Neither electrical resistance nor permeability were altered in cells 

































































































































In order to investigate changes in CP caused by testosterone, an in vitro CP model 
was set up using Z310 cells. Firstly, cell characterisation was performed. Z310 presented a 
predominantly polygonal morphology and they expressed most of the genes typically 
expressed in CP, including transporters, water channels, and TJs, with the exception of 
OATP1a4, KCNA6 and AQP4. When compared to rat CP expression, the latter did express 
AQP4 and KCNA6. However, rat CP did not express ABCB1a and ABCB1b while Z310 did. 
The optimised CP model consisted of Z310 cells growing on a collagen I pre-coated 
polyester insert at a seeding concentration of 2·105 cells per insert (1.13 cm2 growing area). 
After confluence, cells were incubated with different concentrations of testosterone and 
gene expression, electrical resistance and paracellular permeability were measured. 
Testosterone treatment had the effect of increasing expression of AQP1 and ATP1A1, but 
reduced expression of Slc4a10, ZO-1 and ZO-3. Furthermore, testosterone treatment was 
also able to decrease monolayer electrical resistance and increase paracellular 
permeability. Pre-treatment with the AR antagonist Flutamide was able to prevent those 
changes from happening with testosterone treatment, which pointed out to testosterone 
being responsible for those changes. 
Characterisation of Z310 was performed by morphological observation and gene 
expression analysis. The observed morphology was very similar to that described in 
literature for this cell line (Zheng and Zhao, 2002; Monnot and Zheng, 2012). All genes 
reported in the literature as being expressed in Z310 were also detected in this study. 
However, Z310 has been reported to be deficient in Slc22a7, Slc22a8, CLDN2 and OATP2b1 
(Szmydynger-Chodobska et al., 2007; Shi et al., 2008; Kläs et al., 2010), while these genes 
were detected in our experiment. It is important to note that both primers and PCR systems 
were different in each report, which could explain the discrepancies in detected gene 
expressions between the current research and those reported in the literature. This was 
not researched further though, therefore no conclusions can be currently drawn. It is 
interesting to note that all four genes mentioned above that were detected in our 
experiment but not reported in the literature were also detected in the rat CP by RNAseq-
MACE, which points to the possibility that in our hands Z310 gene expression reflects more 




accurately the profile of expression in the choroid plexus in vivo than those mentioned 
above. The lack of AQP4 in Z310 when compared to rat CP was expected, as AQP4 is mainly 
expressed in the ependyma, and it is consistent with the reasoning that the CP samples 
analysed in Chapter 4 were contaminated with some ependymal cells.  
Z310 cells have already been used as a model of CP for several in vitro studies (Shi 
et al., 2008; Monnot and Zheng, 2013; Costa et al., 2016; Tomás et al., 2019), but it is 
important to keep in mind that this is an immortalised cell line. Due to the immortalisation 
process, which includes genetic manipulation, immortalised cell lines can present 
alterations in characteristics such as genotype and phenotype when compared to in vivo 
CPEC. Furthermore, serial passage can increase phenotypic and genotypic variation even 
more. These possible changes are the reason why characterisation of immortalised cells is 
essential before starting a new experiment. Thanks to this process, the degree of similarity 
between a prospective in vitro model and the in vivo cells / tissues can be studied and the 
suitability of the cells can be judged. Z310 not expressing KCNA6 or OATP1a4 while rat CP 
did, falls inside the expected differences between immortalised and in vivo cells. However, 
the fact that Z310 expressed ABCB1a and ABCB1b whereas rat CP did not, was unusual, 
especially so because ABCB1 has previously been detected in the CP of rats (Mercier et al., 
2004; Niehof and Borlak, 2009; Gazzin et al., 2011). As mentioned before, gene expression 
in Z310 and in rat CP were measured using different techniques therefore this discrepancy 
could be an artefact and no conclusions can be drawn with the present results. It is 
important to remember that qPCR and MACE-RNAseq use different approaches for gene 
expression measurements, therefore, when a discrepancy is found, further analysis using 
the same technique for both samples is needed in order to draw conclusions. In summary, 
Z310 cells and rat CP expressed most of the selected genes, therefore Z310 was determined 
to be a suitable in vitro model. 
The different materials, coatings and initial seeding numbers used in our research 
were selected based on published reports and compared to identify the conditions that 
yielded the tightest monolayer (Gath et al., 1997; Shi et al., 2008; Kläs et al., 2010). In vivo 
reported TEER values for CP epithelium range between 19 and 200 Ω·cm-2, while Z310 TEER 
reported values ranging between 25 and 100 Ω·cm-2 (Wright, 1972; Welch, 1975; Saito and 




Wright, 1983; Shi et al., 2008; Kläs et al., 2010). The TEER values obtained in our experiment 
were on the lower end of those reported, however they were stable and similar amongst 
replicates, therefore they were considered appropriate for our experiments. The 
differences in TEER values between reports could be related to the use of different 
equipment or even differences in temperature during TEER measurement (Srinivasan et al., 
2015). 
Testosterone was able to increase gene expression of ATP1A1. In vas deferens 
epithelium of orchiectomised rats, testosterone has been shown to cause increased fluid 
secretion by upregulating ATPase expression (Khadijah Ramli et al., 2018; Khadijah Ramli, 
Giribabu and Salleh, 2018). In the brain, testosterone has been shown to alter ATPase 
activity, including ATP1 in the CP (García, Cabezas and Pérez-González, 1985; Guerra et al., 
1987; O’Reilly et al., 2019). ATP1 activity was not measured in our experiment, however an 
increase of gene expression is consistent with an increase in activity. On the other hand, it 
has been observed that hypo and hyperkalaemia can alter ATP1 expression in the CP 
without altering CSF secretion, suggesting the presence of compensatory mechanisms to 
further regulate CSF secretion (Keep et al., 1997). Therefore, no specific conclusions can be 
drawn from our study about the effect that increased expression of ATP1 in the presence 
of testosterone might have on CSF secretion. 
Testosterone also increased AQP1 expression in Z310 cells. While the extent to 
which testosterone can alter gene and protein expression in CP has not been explored yet, 
it has been seen that testosterone can alter AQP1 expression in epithelium of uterus and 
proximal convoluted tubules of the kidney in female rats (Salleh et al., 2015; Loh, Giribabu 
and Salleh, 2017). In the present study, AQP1 appeared slightly increased in the CP of the 
group of rats having the highest levels of testosterone when compared to their control. In 
the CP, increased AQP1 has been linked to hydrocephalus and formation of hydrocephalic 
oedema in animal and in vitro models (Moon et al., 2006; Stępień et al., 2014; Sveinsdottir 
et al., 2014; Verkman et al., 2017), as well as to BCSFB disruption and increased intracranial 
pressure in hyponatremia in murine models (Kim and Jung, 2011, 2012). Our experiments 
showed that barrier functionality was altered by testosterone, however whether these 




parameters are directly altered by AQP1 expression or both are a result of a third effector, 
remains unknown.  
Testosterone was able to decrease Slc4a10 expression in Z310 cells. This decrease 
was also seen in the CP of female rats with the highest testosterone levels. Slc4a10 is 
important for CSF secretion and its deletion leads to an alteration of polarisation of the 
CPEC including alteration of expression patterns of other transporters, decreased CSF 
secretion and a decrease in brain ventricle size (Jacobs et al., 2008; Christensen et al., 2013, 
2020). While the decreased Slc4a10 expression seen in our cells after treatment with 
testosterone could lead one to hypothesise that CSF secretion would be decreased by 
testosterone, this parameter was not measured in our experiment; therefore the link 
between testosterone, Slc4a10 and CSF secretion in our CP model remains unexplored. It 
is possible that the decrease in Slc4a10 expression might be a compensatory mechanism 
to counteract increased CSF secretion driven by other gene or protein expression changes, 
however not enough data was obtained to draw any conclusions in this matter. 
Paracellular permeation in epithelial barriers is regulated by the protein 
composition of the barrier, especially tight junction location and expression, thus a 
decrease in expression of those can increase permeability and negatively affect barrier 
integrity (Gardner, 1995; Youakim and Ahdieh, 1999; Ahdieh, Vandenbos and Youakim, 
2001; Musch, Walsh-Reitz and Chang, 2006). In the CP, decreased or damaged tight 
junctions negatively impact barrier functionality, increasing paracellular permeability and 
thus allowing greater molecular leakage into CSF (Murphy and Johanson, 1985; Engelhardt 
and Sorokin, 2009; Johanson, Stopa and Mcmillan, 2011). Additionally, testosterone is 
known to regulate tight junctions in the epithelium of male reproductive organs (Meng et 
al., 2005, 2011; Chakraborty et al., 2014; Boivin and Schmidt-Ott, 2017). Testosterone has 
also been shown to perturb epidermal permeability in foetal murine skin (Kao et al., 2001). 
In our experiment, testosterone treatment was able to decrease ZO-1 and ZO-3 expression 
while also altering electrical resistance and permeability of the barrier, two effects that are 
most likely causally related. Testosterone also decreased gene expression of JAM3 and ZO-
1 in vivo in the group of female rats showing the highest concentrations of testosterone in 
plasma. Increased permeability of solutes into the CSF has been shown to have an effect 




on osmotic pressure, increasing CSF secretion by increasing water movement from blood 
to CSF (Palm et al., 1995; Damkier, Brown and Praetorius, 2013). Taking this into account, 
we theorised that the increase in CSF secretion observed in the rat group which also had 
higher levels of testosterone (HFD+PB 15w rats, see Chapter 4) could be caused by an 
alteration in TJs expression caused by increased levels of testosterone, amongst other 
things. 
In conclusion, in our in vitro model of CP, testosterone treatment altered gene 
expression and barrier functionality while maintaining cell morphology. The extent at 
which alteration of expression of certain genes such as AQP1 or Slc4a10 can have on barrier 
integrity is not well known yet. However, tight junctions are essential for maintaining 
barrier functions, therefore the decrease in ZO-1 and ZO-3 gene expression and decrease 
in barrier functionality are indeed related. It is theorized that the alteration in gene 
expression seen in HFD+PB 15w rats was affected, although not exclusively, by increased 
testosterone levels, which affected barrier permeability, allowing the passage of an 
increased amount of water, therefore contributing to the elevated CSF secretion rates seen 
in those animals. More work is needed in order to explore the relationship between 
testosterone levels and CSF dynamics in vivo. However, if testosterone is shown to increase 
CSF secretion in IIH patients, this alteration could most likely be treated with 
antiandrogens, a therapy which is already in use for the treatment of other hormonal-
related problems.




Chapter 6. General Discussion 
The present study was designed to explore the effects of diet on CSF secretion in 
the rat with the aim to unravel possible pathogenic mechanisms underlying IIH. Other 
parameters, such as sex and elevated proinflammatory mediators in CSF, were also studied. 
In summary, it was found that a HFD was able to increase both body weight and CSF 
secretion in males and female rats, although the differences related to diet appeared 
earlier in males than in females. However, the females fed a HFD showed a higher increase 
in CSF secretion than males. Furthermore, the addition of HC into the CSF of HFD male rats 
was able to potentiate HF-diet induced increase in CSF secretion. In females, intracranial 
pressure was increased by HFD, and weight was positively correlated with CSF secretion. 
Additionally, testosterone concentration in plasma also correlated positively with CSF 
secretion in females. The group showing the highest levels of CSF secretion rate, body 
weight and testosterone levels also had the highest deregulation in gene expression at the 
mRNA level. In that group, most of the genes related to CSF secretion remained unaltered; 
however, two transporters, Slc4a10 and Kcna6, and several TJs, including ZO-1, were 
downregulated. In vitro tests using a CP cell model showed that testosterone treatment 
altered gene expression of CPEC including decreased expression of TJs including ZO-1, 
Slc4a10, and overexpression of AQP1 and ATP1A1. Additionally, testosterone was also able 
to decrease barrier functionality in the in vitro CP model. 
IIH is a rare disease but its prevalence is increased in overweight women of 
childbearing age (Rowe and Sarkies, 1999; McCluskey et al., 2018). While the 
pathophysiology is not well known, it is thought that IIH is caused by an impairment of CSF 
dynamics influenced by the female sex and by either obesity or a factor causing obesity 
(Daniels et al., 2007; Markey et al., 2016; Zanello et al., 2018). In view of the results from 
the present study and previous studies reported in the literature, possible mechanisms 
underlying IIH have been summarised in Figure 6.1 and will be discussed below. 





Figure 6.1. Possible pathogenic mechanisms underlying Idiopathic Intracranial Hypertension.  
Upward arrows denote an increase while downward arrows denote a decrease. Red dashed lines and arrows 
mark direct contributors to raising ICP. Highlighted in purple are the findings of the present study and how 
they fit amongst the hypothesised mechanisms that contribute to the increased ICP characteristic of IIH. CSF 
= cerebrospinal fluid, ICP = Intracranial pressure (Sugerman et al., 1995; Biousse, Bruce and Newman, 2012; 
Kalani, Filippidis and Rekate, 2012; Lam, Alperin and Ranganathan, 2012; Paganini et al., 2017; Verkman et 
al., 2017; Bezerra, Ferreira and de Oliveira-Souza, 2018; Dokras et al., 2018; O’Reilly et al., 2019; 
Alimajstorovic, Pascual-Baixauli, et al., 2020) 
The CSF is mainly produced by CPEC, although the brain interstitium and meninges 
are thought to contribute on a smaller scale (Sakka, Coll and Chazal, 2011; Damkier, Brown 
and Praetorius, 2013; Orešković and Klarica, 2014). CSF fills the ventricular system and the 
cranial and spinal subarachnoid spaces. CSF generally flows from secretion sites towards 
drainage points. In large ventricles, CSF bulk flow is mostly driven by secretion and drainage 
rates, while in smaller spaces, such as the third ventricle, multi-ciliated ependymal cells 
appear to have a big role in circulation dynamics (Orešković and Klarica, 2014; Linninger et 




al., 2016; Abdelhamed et al., 2018; Eichele et al., 2020). CSF drainage is a complicated 
process that can occur through different sites, which fall into three functionally distinct 
categories: the arachnoid granulations, the perineural sheaths surrounding cranial and 
spinal nerves and the dural lymphatic vessels.  
Ninety per cent of IIH patients are overweight postpubescent premenopausal 
women. Additionally, IIH has been previously linked to use of hormonal oral contraceptives, 
PCOS and pregnancy. While IIH paediatric patients are a minority, it is important to note 
that, in children, sex does not appear to be a risk factor for developing IIH whereas obesity 
mainly increases the risk of recurrence (Stiebel-Kalish et al., 2014; Sheldon et al., 2016). 
This fits the hypothesis of sex hormones playing an important role in IIH pathophysiology, 
as the differences in sex hormone levels between men and women start being noticeable 
at puberty. While the influence of sex hormones on CSF dynamics and its contribution to 
IIH is not fully understood yet, it has been shown that IIH patients have higher androgen 
levels than healthy overweight women (Hornby et al., 2016; O’Reilly et al., 2019). 
Furthermore, sex hormones have been shown to alter CSF secretion in in vitro models of 
CP (Lindvall-Axelsson and Owman, 1989; O’Reilly et al., 2019).  
Plasma testosterone concentration positively correlated with CSF secretion rate of 
female rats in our research. It has previously been reported that testosterone can increase 
CSF secretion by increasing ATP1 activity (O’Reilly et al., 2019). In the current study, the rat 
group with highest CSF secretion rates and highest testosterone levels also had the highest 
difference in gene expression levels when compared to their controls, including a decrease 
in expression levels of two ion transporters and a small increase in AQP1. CSF secretion 
directly depends on ion transport across the BCSFB, therefore a decrease of expression this 
type of transport would cause a decrease in CSF secretion, but that was not the case. In 
vivo studies showed that these rats had the highest increase in CSF secretion when 
compared to their controls. It is possible that the decrease in ion transport seen in their 
CPEC is a compensatory mechanism caused by an increase of CSF secretion driven by other 
mechanisms, such as by an increase in paracellular permeability or increased water 
movement into CSF. Testosterone-treated cells also showed an increase in AQP1 
expression. AQP1 is essential for CSF secretion and its overexpression has been linked to 




increased CSF secretion in hydrocephalus models and to increased ICP in obese rats (Kalani, 
Filippidis and Rekate, 2012; Uldall et al., 2017; Castañeyra-Ruiz et al., 2019). 
The animal group with larger rats and higher testosterone levels also showed gene 
expression alteration of different signalling pathways which could have an effect on CSF 
secretion. For example, cAMP pathways appeared downregulated. Testosterone has been 
seen to increase fluid secretion and solute transport by increasing cAMP generation in 
kidney epithelial cells in vitro (Sandhu et al., 1997). It is possible that testosterone could 
increase cAMP generation in CP epithelium. In CP, CSF secretion is increased by agents 
increasing intracellular cAMP (Saito and Wright, 1983). This increase of CSF secretion by 
cAMP signalling pathway could be mediated by ATP1 and cAMP-activated anion channels, 
which would fit the results reported by O’Reilly et al about testosterone increasing ATP1 
activity (Jentsch et al., 2002; O’Reilly et al., 2019). Furthermore, the RAS pathway appeared 
altered in the CP of the rat group with highest CSF secretion rates in our study. RAS 
deregulation has been hypothesised as a contributor to altered CSF production levels in IIH 
(Brettschneider et al., 2011). However, it is possible that testosterone affects the CP and 
alters CSF dynamics in more than just one way. We found that testosterone was able to 
decrease barrier functionality of the CP in vitro. Furthermore, testosterone was also able 
to replicate gene expression alterations observed in the female rats with highest weight 
and testosterone levels. Both rats and testosterone treated Z310 cell line had a decreased 
expression of ZO-1 and Slc4a10. The CP of the rat group with the highest secretion rates 
had decreased expression of TJ and downregulated cell adhesion pathways. Barrier 
functionality is highly dependant on tight junction complexes, and decreased expression of 
these proteins are known to increase paracellular permeability (Ward, Tippin and Thakker, 
2000; Kratzer et al., 2012; Shen, 2012). The BCSFB is a highly regulated barrier, and a change 
in its permeability could have big effects for CSF dynamics, therefore it is possible that the 
differences in CSF secretion rates measured in the female rats and the changes in 
permeability observed in Z310 after testosterone treatment are the same mechanism. 
Increased CSF secretion has been previously linked to BCSF hyperpermeability in animal 
models of traumatic brain injury and hydrocephalus (Özevren, Deveci and Tuncer, 2018; 
Yang et al., 2019). If this was the case in our model, however, the CSF secretion observed 




in vivo would not strictly be such but rather an increase in permeability that would result 
in increased water flow across the CP epithelium into the ventricles, increasing CSF volume 
and ICP if drainage pathways are unable to compensate for the increase in flow. However 
it could also be considered increased CSF secretion because it would result in an increased 
flow of liquid through the BCSFB, which would lead to a higher passive rate of CSF 
production. 
Overweightness in humans is usually accompanied by elevated concentrations of 
proinflammatory mediators (Björntorp and Rosmond, 2000; Tchernof and Després, 2013; 
Shaw et al., 2014). It is speculated that an excess of these mediators might be behind the 
pathophysiology of IIH (Sinclair et al., 2008; Dhungana, Sharrack and Woodroofe, 2009a; 
Samancı et al., 2017). In our experiments, we found that the addition of HC into the CSF of 
overweight male rats increased CSF secretion. In females, HC and TNFα have been reported 
to increase CSF secretion in lean individuals, the former also being able to increase CSF 
secretion in diet-induced overweight females (Alimajstorovic, Pascual-Baixauli, et al., 
2020). The exact mechanisms by which obesity-related cytokines and adipokines can 
influence CSF secretion is not known yet. Proinflammatory mediators have been shown to 
be able to alter barrier permeability of the BCSFB. However, whether this alteration is due 
to a decrease in TJs, an increase in cell senescence or another mechanism is not well known 
yet (Coisne and Engelhardt, 2011; Ghersi-Egea et al., 2018; Johanson and Johanson, 2018). 
Furthermore, CCL2 was able to decrease CSF drainage in female rats, although the exact 
mechanism by which this happens has not been explored yet (Alimajstorovic, Pascual-
Baixauli, et al., 2020). 
IIH is most likely caused by a combination of factors, including an inadequate rate 
of CSF drainage (Julayanont et al., 2016; Mollan et al., 2016). As mentioned in Chapter 1, 
CSF gets absorbed by several different pathways, and it is currently unknown which, if any, 
is affected in IIH. Nevertheless, it is possible that the deregulation of more than one 
drainage pathway of CSF is involved in the development of IIH (Baykan, Ekizoğlu and 
Altiokka, 2015). 




Obesity can affect physiological processes due to the endocrine nature of adipose 
tissue but also because of physical effects caused by the increase in body mass (Lyon, Law 
and Hsueh, 2003; Watson and Pride, 2005; Coelho, Oliveira and Fernandes, 2013). It has 
been postulated that IIH is influenced by an increase in intra-abdominal pressure caused 
by obesity which would then increase venous pressure (Sugerman et al., 1995, 1997; 
Bloomfield et al., 1997). This change in venous pressure would decrease CSF drainage into 
the venous flow as this process is mainly driven by a pressure gradient from the ventricles 
outwards (Bono et al., 2008; Friedman, 2010). Impaired drainage would contribute to the 
increase of ICP with a further related increase in cerebral venous pressure by narrowing 
the sinuses to the point of stenosis (Jones and Gratton, 1989; Nedelmann, Kaps and 
Mueller-Forell, 2009; De Simone, Ranieri and Bonavita, 2010). It is thought that this positive 
feedback loop is self-limiting though: once the maximum stretching of the venous wall is 
reached, no additional narrowing could increase CSF pressure further. This would lead to a 
new balance at higher intracranial and venous pressures, which would remain stable for a 
longer period, even if the original cause of increased ICP disappeared (Mokri, 2001; 
Giridharan et al., 2018). However, according to this hypothesis, it would be possible to 
return to the original pressure balance by increasing CSF drainage. Indeed, it has been 
observed in IIH patients that surgical drainage of CSF, sometimes even after only one 
treatment, can resolve venous stenosis and improve the condition (De Simone et al., 2005; 
Horev et al., 2013; Shields et al., 2019). 
Venous sinus stenosis and impaired venous CSF drainage does not always result in 
increased ICP (Fargen, 2020). In these cases however, the glymphatic pathway could be 
acting as a compensatory mechanism to drain CSF at a rate high enough to prevent 
development of significant increase in ICP (Lenck et al., 2018). Nevertheless, in other 
circumstances the glymphatic pathway might become congested by an impaired flow of 
ISF. This could lead to diffuse stagnation of flow and solutes in the interstitium and/or 
paravascular spaces, congesting the glymphatic system and increasing ICP (Bezerra, 
Ferreira and de Oliveira-Souza, 2018; Mondejar and Patsalides, 2020). Authors defending 
this hypothesis base it on several observations, such as the smaller ventricular size 
observed in some IIH patients, the fact that obesity is associated with paravascular 




inflammation and lymphatic disturbance and also on the observation that, in Alzheimer’s 
disease, glymphatic dysfunction has been related to the deposition of β-amyloid molecules 
(Reid, Matheson and Teasdale, 1980; Bezerra, Ferreira and de Oliveira-Souza, 2018; Lenck 
et al., 2018). Nevertheless, the glymphatic dysfunction as cause of IIH hypothesis is 
relatively recent and further investigations are needed in order to further characterise its 
mechanisms and its influence in the development of IIH. 
Other drainage mechanisms thought to be impaired in IIH include reduced CSF 
drainage by the arachnoid villi, which would be decreased by the increased venous 
pressure mentioned above, and from the spinal canal, which CSF volume would appear 
reduced in IIH (Glueck et al., 2005; Alperin et al., 2012; Lam, Alperin and Ranganathan, 
2012; Mondejar and Patsalides, 2020). However, the reason why the spinal canal 
compliance appears reduced in this condition has not been explored yet. 
According to the results obtained in the present study, we hypothesise that an 
obesity-related increase in testosterone plasma concentration contributes to the 
development of IIH by increasing CSF production and paracellular permeability of the 
BCSFB.  
6.1 Future Work 
Future work on this subject should include a bigger study on the effects of factors 
such as diet and altered hormonal levels on ICP. Future in vivo experiments could test 
different diets to induce overweightness, such as high-carbohydrate low-fat or cafeteria 
diet. It would be interesting to observe whether there is a difference in CSF dynamics or 
hormonal levels depending on the ingredients of the diet. Additionally, the use of different 
formulations of HFD could also result in different levels of overweightness, providing an 
easy tool to study the relationship between body weight or weight gain and CSF dynamics. 
Furthermore, it would be very interesting to study the relationship between increased 
permeability of BCSF and CSF dynamics, including ICP.  
Following our results, it would be extremely interesting to explore the effects of 
increased testosterone levels in the female rat. Experiments to test barrier permeability, 




ICP, CSF secretion rates and gene expression, especially that of TJs and AQP1, should be 
included. It would also be interesting to note if increased testosterone levels affect food 
intake, body weight and body fat composition. These experiments should include animals 
treated with anti-androgens such as flutamide. Furthermore, it would be interesting to 
observe the effect of anti-androgens on the animal model established in our project in 
order to see if parameters such as weight gain, CSF secretion rate or ICP are altered; if that 
was the case, it would be an indicator that testosterone directly affects these factors. 
Additionally, testing how testosterone can alter barrier functionality and gene 
expression of other in vitro models of CP, including human cells, would be beneficial. By 
using different cell lines, the validity of our results could be tested. If our results could be 
replicated in other cells lines, it would be more likely that they are reproducing molecular 
mechanisms happening in vivo. In the future, if testosterone is found to be a direct 
contributor to IIH, anti-androgens would be an ideal treatment due to their specificity and 
also because antiandrogens have long been used to treat other health issues in women, 
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Table 0.1. Further information about Rat and Mouse No.1 Maintenance Diet. 




Table 0.2. Further information about Rodent Maintenance Atwater Fuel Energy High Fat Diet. 
 






Table 0.3. Further information about Western Rodent Diet.  
  













Table 0.4. Further information about "Grandessa Peanut Butter Crunchy". 
Nutrient Typical Values per 100g 
Energy 2552kJ / 616 kcal 
Fat 50g 
of which saturates 9.5g 
Carbohydrate 12g 






Ingredients: Peanuts (95%), Palm Oil, Sugar, Peanut Oil, Sea Salt. 





I. Deregulated genes in HFD vs ND comparison 
Table 0.5. Highly upregulated genes in HFD rats when compared to ND and their functional classification as determined by PANTHER bioinformatics. 
Genes were determined to be highly deregulated if they had a log2 fold change (log2FC) > 1 and a P value < 0.05. “Hit” refers to whether the gene was found by PANTHER. 
HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Cga 6.839 0.014 Yes 
hormone activity 
(GO:0005179). 
cellular aromatic compound 
metabolic process 
(GO:0006725). 
regulation of lipid 
biosynthetic process 
(GO:0046890). 
positive regulation of 
biosynthetic process 
(GO:0009891). 
cellular modified amino acid 
metabolic process 
(GO:0006575). 
steroid biosynthetic process 
(GO:0006694). 
hormone metabolic process 
(GO:0042445). 












HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Slc17a6 4.499 0.000 No ———— ———— ———— ———— 
Dclre1c 3.544 0.013 Yes 
5'-3' exonuclease activity 
(GO:0008409). 










double-strand break repair 






Pomc 3.479 0.000 No ———— ———— ———— ———— 
RGD1561730 3.406 0.035 Yes 
signaling receptor binding 
(GO:0005102). 
———— ———— ———— 
LOC10090965
7 
3.254 0.039 Yes ———— ———— ———— 





3.254 0.039 Yes ———— ———— ———— chaperone (PC00072). 




HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Fam83h 3.172 0.006 Yes ———— ———— ———— ———— 
Pinlyp 3.084 0.002 Yes ———— ———— ———— 
scaffold/adaptor protein 
(PC00226). 
Adra1b 2.959 0.020 No ———— ———— ———— ———— 
Adra1b 2.959 0.020 No ———— ———— ———— ———— 
Asb13 2.892 0.048 Yes ———— ———— ———— ———— 
Ctla2a 2.892 0.048 Yes 
cysteine-type endopeptidase 
activity (GO:0004197). 
proteolysis involved in 




























Ccl9 2.821 0.032 Yes 




cytokine receptor binding 
(GO:0005126). 










innate immune response 
(GO:0045087). 
positive regulation of ERK1 
and ERK2 cascade 
(GO:0070374). 









HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 







positive regulation of 
GTPase activity 
(GO:0043547). 
Mkrn2os 2.821 0.020 Yes ———— ———— ———— ———— 
Krt14 2.567 0.018 Yes ———— ———— ———— ———— 




HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Hnf1b 2.544 0.021 Yes 
DNA-binding transcription 
factor activity (GO:0003700). 
RNA polymerase II 
regulatory region sequence-
specific DNA binding 
(GO:0000977). 
positive regulation of 
transcription, DNA-
templated (GO:0045893). 
transcription by RNA 
polymerase II (GO:0006366). 
regulation of transcription 





Golm1 2.460 0.019 Yes ———— ———— ———— ———— 
Mical1 2.445 0.004 Yes ———— ———— ———— ———— 





























binding protein (PC00130). 




HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






Cyp1b1 2.406 0.047 No ———— ———— ———— ———— 




RNA splicing factor 
(PC00148). 
Tubg2 2.219 0.048 Yes 
GTP binding (GO:0005525). 
 structural molecule activity 
(GO:0005198). 
mitotic spindle organization 
(GO:0007052). 


















HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Etnk2 2.082 0.032 Yes ———— ———— ———— kinase (PC00137). 
Tcea3 1.976 0.045 Yes ———— ———— ———— 
general transcription factor 
(PC00259). 
Oas1a 1.945 0.018 No ———— ———— ———— ———— 
Nefh 1.945 0.028 No ———— ———— ———— ———— 
Wdr5b 1.890 0.040 Yes 
histone binding 
(GO:0042393). 





Akap1 1.890 0.006 No ———— ———— ———— ———— 
Hpdl 1.820 0.019 Yes ———— ———— ———— oxygenase (PC00177). 
Larp7 1.820 0.003 No ———— ———— ———— ———— 




Vegfb 1.805 0.007 Yes 
growth factor activity 
(GO:0008083). 
growth factor receptor 
binding (GO:0070851). 















positive regulation of 
angiogenesis (GO:0045766). 




growth factor (PC00112). 




HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
cellular response to growth 
factor stimulus 
(GO:0071363). 
positive regulation of 
protein phosphorylation 
(GO:0001934). 




myeloid leukocyte migration 
(GO:0097529). 
positive regulation of 
epithelial cell proliferation 
(GO:0050679). 




HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






———— hydrolase (PC00121). 
LOC691083 1.598 0.040 Yes 
hydrolase activity, acting on 
ester bonds (GO:0016788). 
———— ———— ———— 
Susd2 1.590 0.011 Yes ———— ———— ———— ———— 






———— hydrolase (PC00121). 
LOC10369011
6 
1.472 0.010 No ———— ———— ———— ———— 
Adcy5 1.466 0.019 No ———— ———— ———— ———— 




HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Tril 1.457 0.011 Yes 
lipopolysaccharide binding 
(GO:0001530). 
toll-like receptor signaling 
pathway (GO:0002224). 




immune effector process 
(GO:0002252). 
regulation of cytokine 
production (GO:0001817). 
















HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 









Recql5 1.431 0.008 Yes 
3'-5' DNA helicase activity 
(GO:0043138). 
DNA biosynthetic process 
(GO:0071897). 









DNA helicase (PC00011). 
Cxcl17 1.412 0.003 Yes ———— ———— ———— ———— 




HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Crlf1 1.410 0.022 Yes 
cytokine binding 
(GO:0019955). 
cytokine receptor activity 
(GO:0004896). 
———— 
leaflet of membrane bilayer 
(GO:0097478). 





Fam198b 1.389 0.001 Yes ———— ———— ———— ———— 
Ccdc136 1.380 0.025 Yes ———— ———— ———— 
scaffold/adaptor protein 
(PC00226). 
Tsen54 1.358 0.049 Yes 




tRNA splicing, via 
endonucleolytic cleavage 
and ligation (GO:0006388). 
catalytic complex 
(GO:1902494). 
nuclear part (GO:0044428). 
endoribonuclease 
(PC00094). 
Acap3 1.354 0.027 Yes ———— ———— ———— ———— 




HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Fbxw9 1.352 0.005 Yes ———— 
maturation of 5.8S rRNA 
(GO:0000460). 






preribosome, large subunit 
precursor (GO:0030687). 
———— 
Slc44a3 1.346 0.010 No ———— ———— ———— ———— 







Sncg 1.337 0.000 No ———— ———— ———— ———— 
Ppp1r42 1.314 0.032 Yes ———— ———— ———— ———— 
Zfp688 1.312 0.019 Yes ———— ———— ———— ———— 
Htatip2 1.305 0.005 Yes ———— ———— ———— ———— 




HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Prune1 1.263 0.040 Yes 
pyrophosphatase activity 
(GO:0016462). 




cellular catabolic process 
(GO:0044248). 
oxoacid metabolic process 
(GO:0043436). 
cytoplasm (GO:0005737). ———— 
Zscan10 1.227 0.001 Yes ———— ———— ———— ———— 
Gjb6 1.209 0.035 Yes ———— ———— ———— gap junction (PC00105). 
Mob3b 1.201 0.022 Yes ———— ———— ———— kinase activator (PC00138). 
Gprasp2 1.201 0.003 Yes ———— ———— ———— ———— 
Nat8f1 1.190 0.018 No ———— ———— ———— ———— 
RGD1306502 1.188 0.045 Yes ———— ———— ———— ———— 




HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






Tubb6 1.163 0.045 Yes 
GTP binding (GO:0005525). 
structural molecule activity 
(GO:0005198). 







Prorsd1 1.148 0.008 Yes ———— ———— ———— ———— 
Ptprn 1.122 0.020 Yes ———— ———— ———— ———— 






Tpp1 1.115 0.009 No ———— ———— ———— ———— 
St6galnac2 1.083 0.007 Yes ———— ———— ———— ———— 
Blvra 1.083 0.033 No ———— ———— ———— ———— 
Patj 1.063 0.001 Yes ———— ———— ———— ———— 




HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
LOC10368994
9 




Sv2a 1.027 0.004 Yes ———— ———— 
integral component of 
membrane (GO:0016021). 
plasma membrane region 
(GO:0098590). 






Gpx3 1.012 0.003 No ———— ———— ———— ———— 




HFD vs ND – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Agl 1.007 0.005 Yes 
transferase activity, 
















1.007 0.047 Yes ———— ———— ———— ———— 
 
  




Table 0.6. Highly downregulated genes in HFD rats when compared to ND and their functional classification as determined by PANTHER bioinformatics. 
Genes were determined to be highly deregulated if they had a log2 fold change (log2FC) < -1 and a P value < 0.05. “Hit” refers to whether the gene was found by PANTHER. 
HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Junb -3.869 0.005 No ———— ———— ———— ———— 
RGD1560608 -3.669 0.019 Yes ———— ———— ———— ———— 
Dtwd1 -3.615 0.007 No ———— ———— ———— ———— 




mitotic DNA damage 
checkpoint (GO:0044773). 
mitotic nuclear division 
(GO:0140014). 
signal transduction in 
response to DNA damage 
(GO:0042770). 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 







Slc35f5 -3.239 0.004 Yes 
secondary carrier 
transporter (PC00258). 
———— ———— ———— 
Tmem178a -3.236 0.028 Yes ———— ———— ———— ———— 
Pxdc1 -3.165 0.005 Yes ———— ———— ———— ———— 








HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




nucleus (GO:0005634). ———— 
telomere maintenance 
(GO:0000723). 
double-strand break repair 
(GO:0006302). 
Fam167b -2.823 0.002 Yes ———— ———— ———— ———— 
Grip1 -2.822 0.042 Yes ———— ———— ———— ———— 
Rc3h2 -2.725 0.043 Yes ———— ———— ———— ———— 
LOC688553 -2.725 0.003 Yes ———— ———— ———— ———— 
B3galt4 -2.725 0.027 Yes ———— ———— ———— ———— 
Gramd4 -2.721 0.045 Yes ———— ———— ———— ———— 
Meis2 -2.618 0.018 Yes 
homeodomain transcription 
factor (PC00119). 
———— ———— ———— 
Gria3 -2.618 0.015 Yes ———— ———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Exo5 -2.615 0.045 Yes ———— nucleus (GO:0005634). ———— 
interstrand cross-link repair 
(GO:0036297). 









Shprh -2.502 0.035 Yes ———— ———— ———— ———— 
Negr1 -2.461 0.007 No ———— ———— ———— ———— 




Cttnbp2 -2.441 0.045 Yes ———— ———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 








cellular response to DNA 
damage stimulus 
(GO:0006974). 
Ube2d1 -2.402 0.001 Yes 
ubiquitin-protein ligase 
(PC00234). 










HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Ttc8 -2.331 0.017 Yes ———— 
BBSome (GO:0034464). 




intraciliary transport particle 
(GO:0030990). 




involved in cilium assembly 
(GO:0035735). 
non-motile cilium assembly 
(GO:1905515). 
vesicle targeting, trans-Golgi 




ciliary transition zone 
assembly (GO:1905349). 
protein localization to cilium 
(GO:0061512). 
Fam193a -2.285 0.027 Yes ———— ———— ———— ———— 
Ptgs1 -2.285 0.011 Yes ———— ———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Acap2 -2.189 0.016 Yes ———— ———— ———— ———— 
Efemp1 -2.165 0.031 Yes ———— ———— ———— ———— 
Med1 -2.149 0.011 Yes 
general transcription factor 
(PC00259). 
———— ———— ———— 
LOC499643 -2.087 0.018 Yes ———— ———— ———— ———— 
RGD1359508 -2.086 0.035 Yes ———— ———— ———— ———— 
Nampt -2.054 0.005 Yes transferase (PC00220). ———— ———— ———— 
Tradd -2.032 0.006 Yes ———— ———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Nr2f1 -2.021 0.003 Yes 
C4 zinc finger nuclear 
receptor (PC00169). 
nucleus (GO:0005634). ———— 
negative regulation of 
transcription by RNA 





transcription by RNA 
polymerase II (GO:0006366). 
positive regulation of 
transcription by RNA 
polymerase II (GO:0045944). 
Arntl -1.962 0.029 No ———— ———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Gar1 -1.947 0.017 Yes 














Rpgr -1.935 0.002 Yes ———— ———— ———— ———— 
RGD1565323 -1.918 0.046 No ———— ———— ———— ———— 











poly (A). tail shortening 
(GO:0000289). 
Zfp189 -1.871 0.029 Yes ———— ———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
LOC680227 -1.871 0.032 No ———— ———— ———— ———— 
LOC10834832
6 
-1.856 0.006 Yes 
transfer/carrier protein 
(PC00219). 











Cav1 -1.843 0.016 No ———— ———— ———— ———— 
Cbfb -1.797 0.002 Yes 
DNA-binding transcription 
factor (PC00218). 
RNA polymerase II 
transcription factor complex 
(GO:0090575). 
———— 
transcription by RNA 
polymerase II (GO:0006366). 
regulation of transcription 
by RNA polymerase II 
(GO:0006357). 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Klf15 -1.775 0.009 Yes 
C2H2 zinc finger 
transcription factor 
(PC00248). 
nucleus (GO:0005634). ———— 
transcription by RNA 
polymerase II (GO:0006366). 
regulation of transcription 
by RNA polymerase II 
(GO:0006357). 
Ube2ql1 -1.775 0.046 Yes 
ubiquitin-protein ligase 
(PC00234). 
———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Brwd1 -1.743 0.007 Yes ———— nucleus (GO:0005634). ———— 






transcription by RNA 
polymerase II (GO:0006366). 
regulation of transcription 
by RNA polymerase II 
(GO:0006357). 
















HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Dgkb -1.725 0.004 No ———— ———— ———— ———— 
Rapgef2 -1.699 0.019 Yes 
guanyl-nucleotide exchange 
factor (PC00113). 
———— ———— ———— 
Camkk2 -1.694 0.015 Yes ———— ———— ———— ———— 
Mlh3 -1.601 0.021 Yes 
DNA binding protein 
(PC00009). 





Fam135a -1.590 0.025 Yes ———— ———— ———— 
cellular lipid metabolic 
process (GO:0044255). 
Herc3 -1.580 0.009 Yes ———— ———— ———— ———— 
Dusp6 -1.548 0.000 Yes ———— cytosol (GO:0005829). ———— 




Gnl3 -1.542 0.036 Yes ———— nucleolus (GO:0005730). ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Tmem117 -1.536 0.025 Yes ———— ———— ———— 
intrinsic apoptotic signaling 
pathway in response to 
endoplasmic reticulum 
stress (GO:0070059). 




snRNA 3'-end processing 
(GO:0034472). 
RGD1563354 -1.502 0.010 Yes ———— ———— ———— ———— 
Zfp280d -1.502 0.034 Yes 
C2H2 zinc finger 
transcription factor 
(PC00248). 
nucleus (GO:0005634). ———— 
transcription, DNA-
templated (GO:0006351). 
regulation of transcription, 
DNA-templated 
(GO:0006355). 
Arpp21 -1.492 0.001 Yes ———— ———— ———— ———— 
Mpdz -1.475 0.007 Yes ———— ———— ———— ———— 
Jag1 -1.441 0.034 Yes ———— ———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Galns -1.435 0.043 Yes hydrolase (PC00121). ———— ———— ———— 




cell population proliferation 
(GO:0008283). 
negative regulation of cell 
population proliferation 
(GO:0008285). 
mitotic nuclear division 
(GO:0140014). 
negative regulation of 
mitotic cell cycle 
(GO:0045930). 
Ehmt1 -1.420 0.039 Yes ———— ———— ———— ———— 
Sclt1 -1.419 0.020 Yes ———— ———— ———— ———— 










HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




cell motility (GO:0048870). 









Htr2a -1.401 0.042 Yes 
G-protein coupled receptor 
(PC00021). 
dendrite (GO:0030425). 
integral component of 
plasma membrane 
(GO:0005887). 







G protein-coupled receptor 
signaling pathway, coupled 
to cyclic nucleotide second 
messenger (GO:0007187). 
response to drug 
(GO:0042493). 
activation of phospholipase 
C activity (GO:0007202). 
chemical synaptic 
transmission (GO:0007268). 
sequestering of calcium ion 
(GO:0051208). 
phospholipase C-activating G 
protein-coupled receptor 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
signaling pathway 
(GO:0007200). 
release of sequestered 
calcium ion into cytosol 
(GO:0051209). 




nuclear pore (GO:0005643). 
———— ———— 
Eed -1.346 0.034 Yes 
chromatin/chromatin-




PcG protein complex 
(GO:0031519). 
———— 
negative regulation of 
transcription by RNA 
polymerase II (GO:0000122). 
transcription by RNA 
polymerase II (GO:0006366). 
chromatin silencing 
(GO:0006342). 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Dnajc21 -1.332 0.030 Yes ———— ———— ———— ———— 
Fat3 -1.332 0.049 No ———— ———— ———— ———— 
Ptprz1 -1.310 0.015 Yes ———— ———— ———— ———— 
Rcor1 -1.296 0.019 Yes 
DNA-binding transcription 




region DNA binding 
(GO:0044212). 











HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 

















endosome to Golgi 
(GO:0042147). 
Gin1 -1.275 0.029 Yes ———— ———— ———— ———— 
LOC10091050
6 
-1.275 0.050 No ———— ———— ———— ———— 
Epsti1 -1.268 0.045 Yes ———— ———— ———— ———— 
Rdh5 -1.268 0.001 Yes dehydrogenase (PC00092). ———— ———— ———— 












response to cytokine 
(GO:0034097). 




cellular protein metabolic 
process (GO:0044267). 
negative regulation of 
endopeptidase activity 
(GO:0010951). 
negative regulation of 
protein catabolic process 
(GO:0042177). 
negative regulation of 
cellular catabolic process 
(GO:0031330). 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
response to hormone 
(GO:0009725). 
cellular catabolic process 
(GO:0044248). 
Nkapd1 -1.258 0.016 Yes ———— ———— ———— ———— 
Tmem38b -1.253 0.046 Yes ———— ———— ———— ———— 
Lrrc20 -1.239 0.006 Yes ———— ———— ———— ———— 
Ddx42 -1.239 0.044 Yes ———— nucleus (GO:0005634). ———— ———— 
Azin1 -1.224 0.004 Yes ———— ———— ———— ———— 
Slc25a51 -1.222 0.030 Yes ———— ———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Qrich1 -1.218 0.015 Yes 
zinc finger transcription 
factor (PC00244). 
nucleus (GO:0005634). ———— 





transcription by RNA 
polymerase II (GO:0006366). 
regulation of transcription 
by RNA polymerase II 
(GO:0006357). 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 

















cell cycle (GO:0007049). 
negative regulation of 
molecular function 
(GO:0044092). 
Ddn -1.206 0.008 No ———— ———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Hdac9 -1.205 0.009 Yes 
histone modifying enzyme 
(PC00261). 
———— ———— ———— 
Qser1 -1.200 0.027 Yes ———— ———— ———— ———— 
Gcc2 -1.184 0.021 Yes ———— ———— ———— ———— 




———— ———— ———— 
Setd2 -1.176 0.041 Yes ———— ———— ———— ———— 
Capn7 -1.165 0.044 Yes ———— ———— ———— ———— 
Plppr4 -1.165 0.042 No ———— ———— ———— ———— 
Pter -1.139 0.016 Yes hydrolase (PC00121). ———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




cell population proliferation 
(GO:0008283). 
negative regulation of cell 
population proliferation 
(GO:0008285). 
mitotic nuclear division 
(GO:0140014). 
negative regulation of 
mitotic cell cycle 
(GO:0045930). 
Lrif1 -1.130 0.032 No ———— ———— ———— ———— 
Zbtb11 -1.123 0.035 Yes ———— ———— ———— ———— 
Vegfa -1.114 0.004 No ———— ———— ———— ———— 
Fam91a1 -1.105 0.003 Yes ———— ———— ———— ———— 
Esrrg -1.094 0.021 Yes ———— ———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Fam149a -1.087 0.042 Yes ———— ———— ———— ———— 
Pole4 -1.080 0.003 Yes 













regulation of transcription, 
DNA-templated 
(GO:0006355). 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 





neuron part (GO:0097458). 
nucleoplasm (GO:0005654). 
———— 





transcription by RNA 
polymerase II (GO:0006366). 
regulation of transcription 
by RNA polymerase II 
(GO:0006357). 










HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




plasma membrane region 
(GO:0098590). 




involved in cilium assembly 
(GO:0035735). 
vesicle targeting, trans-Golgi 




ciliary transition zone 
assembly (GO:1905349). 
protein localization to cilium 
(GO:0061512). 
RT1-Ba -1.061 0.000 Yes ———— ———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Arcn1 -1.059 0.044 Yes 






COPI vesicle coat 
(GO:0030126). 
———— 






transport, Golgi to 
endoplasmic reticulum 
(GO:0006890). 
Plpp4 -1.058 0.015 Yes phosphatase (PC00181). ———— ———— ———— 
Jade1 -1.055 0.041 Yes 
zinc finger transcription 
factor (PC00244). 
———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Lyar -1.051 0.046 Yes 
RNA processing factor 
(PC00147). 
nucleolus (GO:0005730). ———— 
negative regulation of 
transcription by RNA 
polymerase II (GO:0000122). 
transcription by RNA 
polymerase II (GO:0006366). 
rRNA processing 
(GO:0006364). 
Grp -1.047 0.036 Yes ———— ———— ———— ———— 
Phf2 -1.041 0.048 Yes ———— ———— ———— ———— 
Ptcra -1.040 0.004 Yes ———— ———— ———— ———— 
Tjp1 -1.039 0.027 Yes tight junction (PC00214). ———— ———— ———— 
LOC10017491
0 
-1.038 0.016 Yes ———— ———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Dyrk2 -1.033 0.040 Yes 
non-receptor tyrosine 














Dcdc2 -1.033 0.040 Yes ———— 
microtubule organizing 
center (GO:0005815). 








Omg -1.012 0.033 Yes ———— ———— ———— ———— 




HFD VS ND – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
















II. Deregulated genes in HFD+PB vs ND comparison 
Table 0.6. Highly upregulated genes in HFD+PB rats when compared to ND and their functional classification as determined by PANTHER bioinformatics. 
Genes were determined to be highly deregulated if they had a log2 fold change (log2FC) > 1 and a P value < 0.05. “Hit” refers to whether the gene was found by PANTHER. 
HFD+PB vs ND – UPREGULATED GENES 
Gene Symbol log2FC  P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Npb 3.282 0.002 Yes 
G protein-coupled receptor 
binding (GO:0001664). 





Dclre1c 3.036 0.036 Yes 
5'-3' exonuclease activity 
(GO:0008409). 










double-strand break repair 






Zmynd15 3.036 0.037 Yes ———— ———— ———— ———— 




HFD+PB vs ND – UPREGULATED GENES 
Gene Symbol log2FC  P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Zfp267 3.036 0.024 Yes ———— ———— ———— 
C2H2 zinc finger 
transcription factor 
(PC00248). 
Itga2 2.603 0.040 Yes ———— ———— ———— ———— 
Pla2g1b 2.567 0.017 Yes ———— ———— ———— phospholipase (PC00186). 












Pth1r 2.449 0.005 Yes 
G protein-coupled peptide 
receptor activity 
(GO:0008528). 
peptide hormone binding 
(GO:0017046). 
———— ———— ———— 
Ints13 2.349 0.031 Yes ———— ———— ———— ———— 




HFD+PB vs ND – UPREGULATED GENES 
Gene Symbol log2FC  P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Golm1 2.243 0.020 Yes ———— ———— ———— ———— 
Neto2 2.186 0.017 No ———— ———— ———— ———— 
Adgra3 2.127 0.046 Yes ———— ———— ———— ———— 
Tiam1 2.127 0.034 Yes 
Rac GTPase binding 
(GO:0048365). 
Rho guanyl-nucleotide 
exchange factor activity 
(GO:0005089). 
positive regulation of 
axonogenesis (GO:0050772). 











Slc36a1 2.058 0.013 Yes 
amino acid transmembrane 
transporter activity 
(GO:0015171). 
amino acid transmembrane 
transport (GO:0003333). 
———— 
amino acid transporter 
(PC00046). 




HFD+PB vs ND – UPREGULATED GENES 
Gene Symbol log2FC  P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Fcgr2b 2.035 0.001 Yes ———— ———— ———— 
immunoglobulin receptor 
superfamily (PC00124). 
Sipa1 1.865 0.006 Yes ———— ———— ———— 
GTPase-activating protein 
(PC00257). 
Crip3 1.791 0.037 Yes ———— ———— ———— 
actin or actin-binding 
cytoskeletal protein 
(PC00041). 
Doc2a 1.728 0.017 Yes ———— ———— ———— ———— 
Ccdc187 1.672 0.037 Yes ———— ———— ———— 
non-motor microtubule 
binding protein (PC00166). 




HFD+PB vs ND – UPREGULATED GENES 
Gene Symbol log2FC  P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Xrcc4 1.631 0.047 Yes ———— 
positive regulation of 
catalytic activity 
(GO:0043085). 
double-strand break repair 
via nonhomologous end 
joining (GO:0006303). 
response to ionizing 
radiation (GO:0010212). 
nuclear part (GO:0044428). 
DNA repair complex 
(GO:1990391). 
———— 
Larp7 1.602 0.004 No ———— ———— ———— ———— 
Eloa 1.478 0.013 No ———— ———— ———— ———— 
Insig2 1.451 0.036 Yes ———— ———— ———— ———— 
St6galnac2 1.450 0.000 Yes ———— ———— ———— ———— 
Rhbdl2 1.450 0.016 Yes ———— ———— ———— ———— 
Sez6l 1.385 0.007 Yes ———— ———— ———— ———— 
RGD1305347 1.374 0.006 Yes ———— ———— ———— ———— 
Zfp426 1.342 0.014 Yes ———— ———— ———— ———— 




HFD+PB vs ND – UPREGULATED GENES 
Gene Symbol log2FC  P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Xbp1 1.309 0.011 No ———— ———— ———— ———— 
Nrg4 1.280 0.012 No ———— ———— ———— ———— 
Sntb2 1.280 0.039 Yes ———— ———— 




Tpp1 1.259 0.001 No ———— ———— ———— ———— 
Capn1 1.244 0.024 No ———— ———— ———— ———— 
Cyren 1.155 0.029 Yes ———— ———— ———— ———— 
Lexm 1.128 0.030 Yes ———— ———— ———— ———— 
Gli4 1.106 0.049 Yes ———— ———— ———— 
C2H2 zinc finger 
transcription factor 
(PC00248). 
Cys1 1.088 0.017 No ———— ———— ———— ———— 




HFD+PB vs ND – UPREGULATED GENES 
Gene Symbol log2FC  P value Hit? Molecular Function Biological Function Cellular Component Protein Class 







regulation of chromosome 
organization (GO:0033044). 












Cyp11a1 1.072 0.038 No ———— ———— ———— ———— 




HFD+PB vs ND – UPREGULATED GENES 
Gene Symbol log2FC  P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Tubb6 1.058 0.030 Yes 
GTP binding (GO:0005525). 
structural molecule activity 
(GO:0005198). 







Ppih 1.035 0.029 Yes 
catalytic activity, acting on a 
protein (GO:0140096). 
drug binding (GO:0008144). 
peptide binding 
(GO:0042277). 







Frem3 1.015 0.017 Yes ———— ———— ———— ———— 




HFD+PB vs ND – UPREGULATED GENES 
Gene Symbol log2FC  P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Zfat 1.005 0.018 Yes 
DNA binding (GO:0003677). 
DNA-binding transcription 
factor activity (GO:0003700). 
transcription, DNA-
templated (GO:0006351). 













Table 0.7. Highly downregulated genes in HFD+PB rats when compared to ND and their functional classification as determined by PANTHER bioinformatics. 
Genes were determined to be highly deregulated if they had a log2 fold change (log2FC) < -1 and a P value < 0.05. “Hit” refers to whether the gene was found by PANTHER. 
HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Ptprz1 -5.524 0.000 No ———— ———— ———— ———— 
Pter -4.524 0.000 Yes ———— ———— ———— hydrolase (PC00121). 
Fam84a -4.176 0.007 Yes ———— ———— ———— ———— 
Lpar1 -4.113 0.000 Yes ———— ———— ———— 
G-protein coupled receptor 
(PC00021). 
Scai -3.990 0.007 Yes 
transcription corepressor 
activity (GO:0003714). 
———— nucleus (GO:0005634). ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Gpr88 -3.968 0.000 Yes 
G protein-coupled receptor 
activity (GO:0004930). 
cellular response to light 
stimulus (GO:0071482). 
response to external 
stimulus (GO:0009605). 
G protein-coupled receptor 
signaling pathway 
(GO:0007186). 
detection of stimulus 
(GO:0051606). 
integral component of 
plasma membrane 
(GO:0005887). 
G-protein coupled receptor 
(PC00021). 
Wasf1 -3.943 0.000 Yes ———— ———— ———— 
non-motor actin binding 
protein (PC00165). 
Vwa1 -3.940 0.024 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Ldb2 -3.940 0.010 Yes 







negative regulation of 






transcription by RNA 
polymerase II 
(GO:0006366). 
positive regulation of 












HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Grm3 -3.940 0.009 Yes 
G protein-coupled receptor 
activity (GO:0004930). 
glutamate receptor activity 
(GO:0008066). 
amino acid binding 
(GO:0016597). 
adenylate cyclase activity 
(GO:0004016). 
G protein-coupled receptor 
signaling pathway 
(GO:0007186). 









integral component of 
plasma membrane 
(GO:0005887). 
G-protein coupled receptor 
(PC00021). 
RT1-N3 -3.887 0.012 Yes 
peptide binding 
(GO:0042277). 
signaling receptor binding 
(GO:0005102). 
T cell mediated immunity 
(GO:0002456). 
positive regulation of 
adaptive immune response 
(GO:0002821). 
———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Fgf12 -3.887 0.009 Yes ———— ———— ———— growth factor (PC00112). 














synaptic vesicle cycle 
(GO:0099504). 
dendrite (GO:0030425). 
plasma membrane region 
(GO:0098590). 
synaptic vesicle membrane 
(GO:0030672). 
vacuole (GO:0005773). 
integral component of 
organelle membrane 
(GO:0031301). 
neuron projection terminus 
(GO:0044306). 
———— 
B3gat2 -3.833 0.027 No ———— ———— ———— ———— 
Chia -3.833 0.020 No ———— ———— ———— ———— 
Dtwd1 -3.833 0.007 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Scn4b -3.776 0.009 Yes ———— ———— ———— 
scaffold/adaptor protein 
(PC00226). 








Tbc1d8b -3.717 0.045 Yes 
GTPase activity 
(GO:0003924). 
GTPase activator activity 
(GO:0005096). 














HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 





exchange factor activity 
(GO:0017112). 












Btbd17 -3.690 0.002 Yes ———— ———— ———— ———— 








HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 












microtubule binding motor 
protein (PC00156). 
Tmem178a -3.454 0.027 No ———— ———— ———— ———— 
Wdr89 -3.454 0.022 Yes ———— ———— ———— ———— 
Adhfe1 -3.454 0.013 Yes 
oxidoreductase activity, 
acting on the CH-OH group 
of donors, NAD or NADP as 
acceptor (GO:0016616). 
———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Rab40b -3.421 0.008 Yes ———— 






















Omg -3.367 0.000 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 

















DNA incision (GO:0033683). 
nucleus (GO:0005634). ———— 
Ncam1 -3.202 0.000 No ———— ———— ———— ———— 
Tmem229a -3.180 0.015 Yes ———— ———— ———— ———— 
Ifrd1 -3.135 0.007 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 

































Gad2 -3.134 0.001 Yes ———— ———— ———— decarboxylase (PC00089). 
RGD1565323 -3.132 0.024 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Gpr37 -3.113 0.001 Yes 











negative regulation of 
adenylate cyclase activity 
(GO:0007194). 
positive regulation of MAPK 
cascade (GO:0043410). 














HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Nap1l5 -3.073 0.008 Yes ———— ———— ———— 
chromatin/chromatin-
binding, or -regulatory 
protein (PC00077). 





cell death (GO:0008219). 
signal transduction 
(GO:0007165). 






growth factor (PC00112). 
Dpf1 -3.009 0.006 No ———— ———— ———— ———— 
Vsnl1 -2.995 0.000 Yes ———— ———— ———— ———— 
Ntm -2.993 0.029 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 









———— ligase (PC00142). 
Grin2b -2.983 0.004 No ———— ———— ———— ———— 
Arhgef16 -2.943 0.042 Yes ———— ———— ———— ———— 
Edil3 -2.924 0.028 Yes ———— ———— ———— oxidoreductase (PC00176). 












ATP-binding cassette (ABC). 
transporter (PC00003). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Rasa2 -2.890 0.027 Yes ———— ———— ———— 
GTPase-activating protein 
(PC00257). 






mitotic spindle organization 
(GO:0007052). 
mitotic nuclear division 
(GO:0140014). 






















HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Gng8 -2.871 0.008 Yes 
protein binding 
(GO:0005515). 





leaflet of membrane bilayer 
(GO:0097478). 
plasma membrane protein 
complex (GO:0098797). 
extrinsic component of 






Dtna -2.851 0.001 Yes ———— ———— ———— ———— 
Prkar2b -2.836 0.034 Yes ———— ———— ———— ———— 
S100a3 -2.836 0.019 Yes ———— ———— ———— 
calmodulin-related 
(PC00061). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Meis2 -2.836 0.018 Yes ———— ———— ———— 
homeodomain transcription 
factor (PC00119). 
Arpp21 -2.835 0.000 Yes ———— ———— ———— ———— 
Gng13 -2.811 0.001 Yes ———— ———— ———— 
heterotrimeric G-protein 
(PC00117). 
Frrs1l -2.797 0.016 Yes ———— ———— ———— ———— 
Cav1 -2.797 0.005 No ———— ———— ———— ———— 








Fam131b -2.790 0.001 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Usp18 -2.780 0.033 Yes 
thiol-dependent ubiquitin-










Ctrb1 -2.779 0.047 No ———— ———— ———— ———— 
Gatm -2.779 0.040 No ———— ———— ———— ———— 
Enpp4 -2.778 0.000 Yes ———— ———— ———— 
nucleotide phosphatase 
(PC00173). 




















HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 





RNA splicing factor 
(PC00148). 








cellular protein metabolic 
process (GO:0044267). 











Tspan2 -2.699 0.002 Yes ———— ———— 








HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Mal -2.689 0.001 Yes 
structural molecule activity 
(GO:0005198). 
myelination (GO:0042552). 
integral component of 
membrane (GO:0016021). 
membrane traffic protein 
(PC00150). 
Arhgap21 -2.659 0.009 Yes ———— ———— ———— ———— 
Cttnbp2 -2.659 0.043 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 





involved in cilium assembly 
(GO:0035735). 
vesicle targeting, trans-





ciliary transition zone 
assembly (GO:1905349). 
protein localization to 
cilium (GO:0061512). 
BBSome (GO:0034464). 




plasma membrane region 
(GO:0098590). 
———— 
Thrsp -2.637 0.044 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Pik3c2b -2.637 0.029 Yes 
phosphotransferase 






















Pcdha6 -2.637 0.005 No ———— ———— ———— ———— 















HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Diaph3 -2.595 0.047 No ———— ———— ———— ———— 
LOC10369487
0 






sodium ion transport 
(GO:0006814). 






Ak5 -2.549 0.029 Yes ———— ———— ———— 
nucleotide kinase 
(PC00172). 
Kif5a -2.547 0.000 No ———— ———— ———— ———— 
Taf5 -2.542 0.008 Yes ———— ———— ———— ———— 












HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Tph2 -2.528 0.040 Yes 
oxidoreductase activity, 
acting on paired donors, 
with incorporation or 










Phlda1 -2.504 0.046 No ———— ———— ———— ———— 
Lrp12 -2.493 0.004 Yes ———— ———— ———— ———— 
RGD1308544 -2.485 0.011 Yes ———— ———— ———— ———— 
Matk -2.480 0.009 Yes ———— ———— ———— ———— 
Gpm6b -2.480 0.001 No ———— ———— ———— ———— 






myelin protein (PC00161). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 







Esm1 -2.456 0.012 Yes ———— ———— ———— ———— 
Smyd4 -2.456 0.001 Yes ———— ———— ———— ———— 
Ptn -2.444 0.000 Yes 
growth factor activity 
(GO:0008083). 
———— ———— growth factor (PC00112). 
Sst -2.442 0.001 Yes ———— 








Nfyb -2.432 0.002 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Rit2 -2.428 0.004 Yes 








Ras protein signal 
transduction (GO:0007265). 






small GTPase (PC00208). 
Efnb3 -2.421 0.019 Yes 












Carmil2 -2.398 0.014 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Ttc9b -2.391 0.002 Yes ———— ———— ———— ———— 
Snapc1 -2.383 0.038 Yes 
sequence-specific DNA 
binding (GO:0043565). 
transcription by RNA 
polymerase III 
(GO:0006383). 
transcription by RNA 
polymerase II 
(GO:0006366). 
nuclear transcription factor 
complex (GO:0044798). 
———— 
Efemp1 -2.383 0.031 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Rxfp2 -2.368 0.022 Yes 












G protein-coupled receptor 
signaling pathway 
(GO:0007189). 






integral component of 
plasma membrane 
(GO:0005887). 
G-protein coupled receptor 
(PC00021). 
Ercc6 -2.357 0.044 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Magohb -2.345 0.027 Yes ———— RNA splicing (GO:0008380). 
exon-exon junction 
complex (GO:0035145). 
catalytic step 2 spliceosome 
(GO:0071013). 








HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




























HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Zfp280d -2.305 0.012 Yes 










C2H2 zinc finger 
transcription factor 
(PC00248). 
Gdap1l1 -2.304 0.033 Yes ———— 











Tubb3 -2.284 0.001 Yes 
GTP binding (GO:0005525). 
structural molecule activity 
(GO:0005198). 











HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Kpna2 -2.265 0.041 Yes 
signal sequence binding 
(GO:0005048). 
NLS-bearing protein import 





nuclear pore (GO:0005643). 
nucleoplasm (GO:0005654). 
transporter (PC00227). 
Klhl5 -2.265 0.019 Yes ———— ———— ———— 
scaffold/adaptor protein 
(PC00226). 
Gria3 -2.250 0.028 No ———— ———— ———— ———— 





C2H2 zinc finger 
transcription factor 
(PC00248). 
Gad1 -2.222 0.001 Yes ———— ———— ———— decarboxylase (PC00089). 
Ptpn5 -2.222 0.006 No ———— ———— ———— ———— 
Ptcra -2.211 0.000 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 





Agap2 -2.203 0.000 Yes ———— ———— nucleus (GO:0005634). ———— 
LOC361016 -2.199 0.001 No ———— ———— ———— ———— 




plasma membrane region 
(GO:0098590). 



















G1/S transition of mitotic 
cell cycle (GO:0000082). 
apoptotic process 
(GO:0006915). 
positive regulation of 
apoptotic process 
(GO:0043065). 















HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
regulation of multicellular 
organismal process 
(GO:0051239). 






Tsc22d2 -2.180 0.022 Yes ———— ———— ———— ———— 




transcription by RNA 
polymerase II 
(GO:0006366). 
positive regulation of 








binding, or -regulatory 
protein (PC00077). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Fastkd3 -2.170 0.035 Yes ———— ———— ———— ———— 
Grin1 -2.165 0.001 Yes 
ligand-gated ion channel 
activity (GO:0015276). 






Penk -2.162 0.000 Yes 









plasma membrane region 
(GO:0098590). 





Cep290 -2.161 0.007 Yes ———— ———— ———— ———— 
Ddn -2.160 0.000 No ———— ———— ———— ———— 
Lgi4 -2.157 0.014 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




Vps37a -2.135 0.014 Yes ———— 
ubiquitin-dependent 
protein catabolic process 
via the multivesicular body 
sorting pathway 
(GO:0043162). 
multivesicular body sorting 
pathway (GO:0071985). 
protein targeting to 
membrane (GO:0006612). 
protein targeting to vacuole 
(GO:0006623). 
protein catabolic process in 
the vacuole (GO:0007039). 










HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Tubb2b -2.135 0.003 Yes 
GTP binding (GO:0005525). 















Akr1c14 -2.134 0.037 Yes 
carboxylic acid binding 
(GO:0031406). 
oxidoreductase activity, 
acting on the CH-OH group 
of donors, NAD or NADP as 
acceptor (GO:0016616). 
oxidoreductase activity, 
acting on paired donors, 
with incorporation or 
reduction of molecular 
oxygen, NAD (P).H as one 
donor, and incorporation of 
one atom of oxygen 
(GO:0016709). 










drug metabolic process 
(GO:0017144). 
steroid metabolic process 
(GO:0008202). 




cytosol (GO:0005829). reductase (PC00198). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
hormone metabolic process 
(GO:0042445). 
ammonium ion metabolic 
process (GO:0097164). 
Calb1 -2.112 0.005 Yes 
calcium ion binding 
(GO:0005509). 
positive regulation of 
synaptic transmission 
(GO:0050806). 
regulation of synaptic 
plasticity (GO:0048167). 
regulation of cytosolic 



















HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Olig1 -2.108 0.000 No ———— ———— ———— ———— 
Rnf139 -2.104 0.000 Yes 









Cadm1 -2.098 0.026 No ———— ———— ———— ———— 
Elovl2 -2.098 0.013 Yes 
transferase activity, 
transferring acyl groups 
other than amino-acyl 
groups (GO:0016747). 
fatty acid biosynthetic 
process (GO:0006633). 












Tmem59l -2.078 0.001 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Mlc1 -2.077 0.046 Yes ———— 
regulation of response to 
stress (GO:0080134). 














HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




chloride channel activity 
(GO:0005254). 








nervous system process 
(GO:0050877). 
integral component of 
plasma membrane 
(GO:0005887). 




ligand-gated ion channel 
(PC00141). 
Dennd4a -2.073 0.014 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Dgkd -2.073 0.033 Yes 
phosphotransferase 










———— kinase (PC00137). 













Rnf146 -2.061 0.000 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






protein catabolic process 
(GO:0043161). 
regulation of proteasomal 
ubiquitin-dependent 
protein catabolic process 
(GO:0032434). 
response to endoplasmic 
reticulum stress 
(GO:0034976). 
protein modification by 












Fbxl12 -2.042 0.032 Yes 
ubiquitin protein ligase 
activity (GO:0061630). 
G2/M transition of mitotic 
cell cycle (GO:0000086). 
response to external 
stimulus (GO:0009605). 















SCF ubiquitin ligase 
complex (GO:0019005). 
———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
response to light stimulus 
(GO:0009416). 






binding protein (PC00166). 
Rab3b -2.042 0.002 Yes ———— 






















HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Cbs -2.041 0.046 Yes 
drug binding (GO:0008144). 








alpha-amino acid metabolic 
process (GO:1901605). 
sulfur compound metabolic 
process (GO:0006790). 




cytoplasm (GO:0005737). lyase (PC00144). 
Sparcl1 -2.037 0.001 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Stx1b -2.029 0.001 Yes 
SNARE binding 
(GO:0000149). 



















SNARE protein (PC00034). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Hsd11b1 -2.028 0.010 Yes 
oxidoreductase activity, 
acting on the CH-OH group 




organic cyclic compound 
catabolic process 
(GO:1901361). 
lipid catabolic process 
(GO:0016042). 
steroid metabolic process 
(GO:0008202). 
———— ———— 
Ampd3 -2.022 0.039 No ———— ———— ———— ———— 
Gria2 -2.017 0.011 No ———— ———— ———— ———— 
Lamp5 -2.009 0.049 Yes ———— 
establishment of protein 
localization to organelle 
(GO:0072594). 













HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Mt1m -2.000 0.014 Yes 
metal ion binding 
(GO:0046872). 
cellular zinc ion 
homeostasis (GO:0006882). 
response to cadmium ion 
(GO:0046686). 
response to toxic substance 
(GO:0009636). 
cellular response to 
chemical stimulus 
(GO:0070887). 














SCF ubiquitin ligase 
complex (GO:0019005). 
———— 
Gjc1 -1.995 0.000 Yes ———— ———— ———— gap junction (PC00105). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Acap2 -1.993 0.029 Yes ———— ———— ———— ———— 
Fam212b -1.983 0.035 Yes 





protein kinase inhibitor 
activity (GO:0004860). 
———— nucleus (GO:0005634). ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Rnf144b -1.983 0.019 Yes 
ubiquitin-like protein 
conjugating enzyme binding 
(GO:0044390). 


















Togaram1 -1.983 0.001 Yes ———— ———— ———— 
non-motor microtubule 
binding protein (PC00166). 
Opalin -1.976 0.027 Yes ———— ———— 









HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 















Ina -1.971 0.038 No ———— ———— ———— ———— 
Herc3 -1.968 0.006 Yes ———— ———— ———— ———— 
Rundc3a -1.952 0.001 Yes ———— 
cGMP-mediated signaling 
(GO:0019934). 
positive regulation of 
intracellular signal 
transduction (GO:1902533). 
cytosol (GO:0005829). ———— 
Mbtps2 -1.942 0.006 Yes ———— ———— ———— metalloprotease (PC00153). 
Mettl25 -1.942 0.034 Yes ———— ———— ———— 
RNA methyltransferase 
(PC00033). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 














plasma membrane region 
(GO:0098590). 
———— 
Grp -1.942 0.002 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Dagla -1.942 0.040 Yes ———— 






















HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 












Fem1c -1.921 0.002 Yes ———— ———— ———— ———— 
RGD1307100 -1.919 0.005 Yes ———— ———— ———— ———— 
Dhx36 -1.907 0.006 Yes RNA binding (GO:0003723). ———— nucleus (GO:0005634). RNA helicase (PC00032). 
Rbp4 -1.907 0.033 Yes ———— ———— ———— 
transfer/carrier protein 
(PC00219). 
Bcat1 -1.898 0.000 Yes 
transferase activity 
(GO:0016740). 














HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Tril -1.889 0.017 Yes 
lipopolysaccharide binding 
(GO:0001530). 
toll-like receptor signaling 
pathway (GO:0002224). 




immune effector process 
(GO:0002252). 
regulation of cytokine 
production (GO:0001817). 












Ngdn -1.889 0.012 Yes ———— 
maturation of SSU-rRNA 
from tricistronic rRNA 







RNA binding protein 
(PC00031). 
Synm -1.889 0.011 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Adgrb2 -1.884 0.008 Yes 









G protein-coupled receptor 
signaling pathway 
(GO:0007189). 
activation of adenylate 
cyclase activity 
(GO:0007190). 
integral component of 
plasma membrane 
(GO:0005887). 
G-protein coupled receptor 
(PC00021). 
Mbp -1.883 0.035 Yes ———— ———— ———— ———— 
Ppat -1.882 0.039 Yes ———— ———— ———— transferase (PC00220). 
Evi2a -1.876 0.003 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Sfxn1 -1.862 0.026 No ———— ———— ———— ———— 
Ddx50 -1.861 0.003 Yes ———— ———— nucleolus (GO:0005730). ———— 
Nefl -1.857 0.001 Yes ———— ———— ———— ———— 
Nfrkb -1.857 0.038 Yes ———— ———— ———— 
chromatin/chromatin-




-1.857 0.033 Yes ———— ———— ———— ———— 
Apod -1.855 0.027 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 










regulation of calcium ion 
transport (GO:0051924). 
regulation of cation 
transmembrane transport 
(GO:1904062). 







Nap1l3 -1.851 0.013 Yes ———— ———— ———— 
chromatin/chromatin-
binding, or -regulatory 
protein (PC00077). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Sash1 -1.851 0.013 Yes ———— ———— ———— ———— 
Stk26 -1.848 0.025 Yes ———— ———— ———— ———— 
Tbc1d23 -1.848 0.007 Yes ———— ———— ———— ———— 
Chrm4 -1.836 0.030 No ———— ———— ———— ———— 
Tmem87b -1.835 0.011 Yes ———— ———— ———— 
G-protein coupled receptor 
(PC00021). 
Bbs10 -1.835 0.012 Yes ———— ———— ———— ———— 




Htr2a -1.829 0.024 Yes 

















G protein-coupled receptor 
signaling pathway, coupled 
to cyclic nucleotide second 
messenger (GO:0007187). 
response to drug 
(GO:0042493). 
activation of phospholipase 
C activity (GO:0007202). 
chemical synaptic 
transmission (GO:0007268). 
sequestering of calcium ion 
(GO:0051208). 
phospholipase C-activating 
G protein-coupled receptor 
dendrite (GO:0030425). 
integral component of 
plasma membrane 
(GO:0005887). 
plasma membrane region 
(GO:0098590). 
G-protein coupled receptor 
(PC00021). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
signaling pathway 
(GO:0007200). 
release of sequestered 
calcium ion into cytosol 
(GO:0051209). 
Cd24 -1.828 0.000 Yes ———— ———— ———— ———— 






serine protease (PC00203). 
S100b -1.816 0.002 Yes ———— ———— ———— 
calmodulin-related 
(PC00061). 
Lrif1 -1.807 0.010 No ———— ———— ———— ———— 
Spata18 -1.798 0.015 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Dhx9 -1.790 0.009 Yes 
RNA binding (GO:0003723). 
3'-5' DNA helicase activity 
(GO:0043138). 
regulation of mRNA 
processing (GO:0050684). 





positive regulation of 







RNA helicase (PC00032). 





mRNA cleavage factor 
complex (GO:0005849). 
RNA splicing factor 
(PC00148). 
Mag -1.783 0.008 Yes 









superfamily cell adhesion 
molecule (PC00125). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Gja1 -1.783 0.001 Yes ———— ———— ———— gap junction (PC00105). 
Mobp -1.781 0.000 Yes 
actin binding (GO:0003779). 
myosin binding 
(GO:0017022). 
Rab GTPase binding 
(GO:0017137). 
———— 
cortical actin cytoskeleton 
(GO:0030864). 
myelin protein (PC00161). 
Sptbn2 -1.769 0.006 No ———— ———— ———— ———— 







Cpped1 -1.767 0.004 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 










Cav2 -1.754 0.035 No ———— ———— ———— ———— 










Abhd17b -1.749 0.004 Yes ———— ———— ———— serine protease (PC00203). 
Cenpe -1.744 0.014 Yes ———— 
mitotic metaphase plate 
congression (GO:0007080). 
———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Btg1 -1.738 0.006 Yes ———— 
cell population proliferation 
(GO:0008283). 
negative regulation of cell 
population proliferation 
(GO:0008285). 
mitotic nuclear division 
(GO:0140014). 
negative regulation of 





Usp53 -1.720 0.015 Yes ———— 
sensory perception of 
sound (GO:0007605). 






RGD1563354 -1.720 0.010 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Rasgrp3 -1.720 0.024 Yes ———— ———— ———— 
guanyl-nucleotide exchange 
factor (PC00113). 
Rab30 -1.719 0.040 Yes ———— ———— ———— ———— 










maintenance of epithelial 













cell-cell adherens junction 
(GO:0005913). 
cell cortex (GO:0005938). 
apical junction complex 
(GO:0043296). 
apical plasma membrane 
(GO:0016324). 
———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
establishment of organelle 
localization (GO:0051656). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 









active ion transmembrane 
transporter activity 
(GO:0022853). 










sodium ion transmembrane 
transport (GO:0035725). 





export from cell 
(GO:0140352). 
———— 
primary active transporter 
(PC00068). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Camk2b -1.710 0.001 No ———— ———— ———— ———— 
Armc8 -1.703 0.006 Yes ———— 
proteasome-mediated 
ubiquitin-dependent 







Nedd9 -1.701 0.002 Yes ———— 
actin filament organization 
(GO:0007015). 
transmembrane receptor 
















HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Gopc -1.698 0.012 Yes ———— ———— ———— 
membrane traffic protein 
(PC00150). 
Usp32 -1.696 0.000 Yes ———— ———— ———— 
cysteine protease 
(PC00081). 
Fam49a -1.693 0.028 Yes ———— ———— ———— ———— 
Klhl13 -1.689 0.014 Yes ———— ———— midbody (GO:0030496). ———— 
Slc1a3 -1.680 0.012 No ———— ———— ———— ———— 
Atl2 -1.679 0.040 Yes 















HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Rp2 -1.675 0.002 Yes 
GTPase activity 
(GO:0003924). 











Gpr149 -1.671 0.048 Yes 






integral component of 
plasma membrane 
(GO:0005887). 




G-protein coupled receptor 
(PC00021). 




L-amino acid transport 
(GO:0015807). 




amino acid transporter 
(PC00046). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 









active ion transmembrane 
transporter activity 
(GO:0022853). 










sodium ion transmembrane 
transport (GO:0035725). 





export from cell 
(GO:0140352). 
———— 
primary active transporter 
(PC00068). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 









Fez1 -1.662 0.000 Yes ———— ———— 
cytoplasm (GO:0005737). 




Slc30a4 -1.658 0.001 No ———— ———— ———— ———— 
Nrcam -1.650 0.046 No ———— ———— ———— ———— 
Cpox -1.650 0.034 Yes 
oxidoreductase activity 
(GO:0016491). 
heme biosynthetic process 
(GO:0006783). 
cytoplasm (GO:0005737). oxidase (PC00175). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Tapt1 -1.638 0.026 Yes ———— 
maintenance of location 
(GO:0051235). 












Scaf8 -1.638 0.010 No ———— ———— ———— ———— 




Nipbl -1.637 0.016 Yes 
chromatin binding 
(GO:0003682). 
regulation of cellular 
localization (GO:0060341). 




mitotic sister chromatid 
cohesion (GO:0007064). 









positive regulation of 






binding, or -regulatory 
protein (PC00077). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
polymerase II 
(GO:0045944). 
positive regulation of 
mitotic cell cycle 
(GO:0045931). 
establishment of protein 
localization to organelle 
(GO:0072594). 
positive regulation of 
molecular function 
(GO:0044093). 
positive regulation of 
organelle organization 
(GO:0010638). 
regulation of mitotic sister 
chromatid segregation 
(GO:0033047). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Tspan12 -1.637 0.015 Yes ———— 
cellular response to growth 
factor stimulus 
(GO:0071363). 
regulation of cellular 
response to growth factor 
stimulus (GO:0090287). 
transmembrane receptor 
protein tyrosine kinase 
signaling pathway 
(GO:0007169). 
regulation of signal 
transduction (GO:0009966). 




Akap11 -1.634 0.000 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 















Yars2 -1.624 0.015 Yes 
ligase activity 
(GO:0016874). 
catalytic activity, acting on 
a tRNA (GO:0140101). 
cellular amino acid 
metabolic process 
(GO:0006520). 





Pcp4 -1.621 0.000 Yes ———— ———— ———— ———— 
Stmn3 -1.621 0.000 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Usp38 -1.620 0.040 Yes 
thiol-dependent ubiquitin-










Tagln3 -1.620 0.031 Yes ———— ———— ———— 
non-motor actin binding 
protein (PC00165). 








integral component of 
plasma membrane 
(GO:0005887). 
primary active transporter 
(PC00068). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Mt2A -1.614 0.001 Yes 
metal ion binding 
(GO:0046872). 
cellular zinc ion 
homeostasis (GO:0006882). 
response to cadmium ion 
(GO:0046686). 
response to toxic substance 
(GO:0009636). 
cellular response to 
chemical stimulus 
(GO:0070887). 





Schip1 -1.610 0.009 Yes ———— ———— ———— ———— 
Krt10 -1.609 0.042 Yes ———— ———— ———— ———— 
Slc2a13 -1.609 0.026 Yes ———— ———— ———— ———— 
Marcks -1.607 0.001 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 







Ccdc153 -1.606 0.000 Yes ———— ———— ———— ———— 
Ivns1abp -1.603 0.002 Yes ———— ———— ———— 
scaffold/adaptor protein 
(PC00226). 
Sp1 -1.603 0.012 Yes 
DNA-binding transcription 
factor activity, RNA 
polymerase II-specific 
(GO:0000981). 
transcription by RNA 
polymerase II 
(GO:0006366). 
regulation of transcription 
by RNA polymerase II 
(GO:0006357). 
nucleus (GO:0005634). 
C2H2 zinc finger 
transcription factor 
(PC00248). 
Hdac9 -1.603 0.004 Yes ———— ———— ———— 
histone modifying enzyme 
(PC00261). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Phyhip -1.602 0.013 Yes ———— ———— ———— ———— 
Psd -1.599 0.000 No ———— ———— ———— ———— 
Sfpq -1.594 0.010 Yes 
transcription regulatory 
region sequence-specific 
DNA binding (GO:0000976). 
transcription, DNA-
templated (GO:0006351). 
regulation of transcription, 
DNA-templated 
(GO:0006355). 
mRNA splicing, via 
spliceosome (GO:0000398). 
nucleus (GO:0005634). 
RNA binding protein 
(PC00031). 

















Bcan -1.594 0.004 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 

























serine protease (PC00203). 
Fam204a -1.594 0.004 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






Dync2h1 -1.590 0.001 No ———— ———— ———— ———— 
Lmo4 -1.589 0.003 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Tmed7 -1.586 0.034 Yes ———— 





















vesicle coat protein 
(PC00235). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




regulation of axonogenesis 
(GO:0050770). 
stress-activated protein 




mitotic nuclear division 
(GO:0140014). 
activation of protein kinase 
activity (GO:0032147). 
signal transduction by 
protein phosphorylation 
(GO:0023014). 
regulation of mitotic cell 
cycle (GO:0007346). 
cytoplasm (GO:0005737). ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Eif5a2 -1.585 0.007 Yes 
translation regulator 
activity (GO:0045182). 
RNA binding (GO:0003723). 





translation initiation factor 
(PC00224). 
Susd1 -1.583 0.001 Yes ———— ———— ———— 
extracellular matrix 
glycoprotein (PC00100). 




BMP signaling pathway 
(GO:0030509). 










HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
















Trim23 -1.568 0.028 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
















Pank3 -1.562 0.001 Yes 
phosphotransferase 
















HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Golga7 -1.560 0.000 Yes 
catalytic activity, acting on 














C1d -1.558 0.001 Yes ———— ———— ———— 
transcription cofactor 
(PC00217). 




Synj1 -1.556 0.014 Yes 
phosphatase activity 
(GO:0016791). 
SH3 domain binding 
(GO:0017124). 
small molecule catabolic 
process (GO:0044282). 

















perinuclear region of 
cytoplasm (GO:0048471). 
phosphatase (PC00181). 




HFD+PB vs ND - DOWNREGULATED 





nervous system process 
(GO:0050877). 
behavior (GO:0007610). 
Srgn -1.550 0.017 Yes ———— ———— ———— ———— 
Cwf19l2 -1.543 0.013 Yes ———— 





U5 snRNP (GO:0005682). 
———— 
Rnf216 -1.543 0.011 Yes ———— ———— ———— 
ubiquitin-protein ligase 
(PC00234). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Adcyap1r1 -1.541 0.037 Yes 
G protein-coupled peptide 
receptor activity 
(GO:0008528). 
peptide hormone binding 
(GO:0017046). 
———— ———— ———— 
Ipo7 -1.540 0.000 Yes ———— 









Ptp4a3 -1.539 0.018 Yes ———— ———— nucleus (GO:0005634). ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 













growth cone (GO:0030426). 
cytoplasm (GO:0005737). 
plasma membrane region 
(GO:0098590). 
———— 
Csmd2 -1.535 0.002 Yes ———— ———— ———— ———— 
Lrrc4b -1.535 0.009 Yes ———— ———— ———— ———— 
Scgb2b24 -1.532 0.012 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Enoph1 -1.527 0.036 Yes 
phosphatase activity 
(GO:0016791). 
alpha-amino acid metabolic 
process (GO:1901605). 
sulfur compound metabolic 
process (GO:0006790). 
drug metabolic process 
(GO:0017144). 
cellular amino acid 
biosynthetic process 
(GO:0008652). 
———— phosphatase (PC00181). 
Faim2 -1.527 0.003 Yes ———— ———— ———— ———— 
Ermn -1.519 0.005 Yes ———— ———— ———— ———— 
Azin1 -1.519 0.002 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Sox10 -1.517 0.015 Yes 
DNA-binding transcription 
activator activity, RNA 
polymerase II-specific 
(GO:0001228). 
negative regulation of 
transcription by RNA 
polymerase II 
(GO:0000122). 
morphogenesis of an 
epithelium (GO:0002009). 
transcription by RNA 
polymerase II 
(GO:0006366). 
positive regulation of 




Rnf111 -1.516 0.015 Yes 














HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Gramd1c -1.513 0.000 Yes ———— ———— ———— ———— 
Ngef -1.513 0.010 No ———— ———— ———— ———— 
Krt26 -1.504 0.033 Yes ———— ———— ———— ———— 
Ash1l -1.500 0.003 Yes ———— ———— ———— ———— 
Baalc -1.497 0.016 Yes ———— ———— cytoplasm (GO:0005737). ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Gng3 -1.496 0.007 Yes 
protein binding 
(GO:0005515). 





leaflet of membrane bilayer 
(GO:0097478). 
plasma membrane protein 
complex (GO:0098797). 
extrinsic component of 










HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Ets2 -1.490 0.008 Yes 
DNA-binding transcription 





transcription by RNA 
polymerase II 
(GO:0006366). 
regulation of transcription 




























HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Gng2 -1.488 0.001 Yes 
protein binding 
(GO:0005515). 





leaflet of membrane bilayer 
(GO:0097478). 
plasma membrane protein 
complex (GO:0098797). 
extrinsic component of 






Dlgap3 -1.488 0.013 No ———— ———— ———— ———— 




Lzts1 -1.485 0.045 Yes ———— ———— ———— ———— 
Sclt1 -1.485 0.028 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




Magi2 -1.483 0.049 No ———— ———— ———— ———— 
Cse1l -1.478 0.002 Yes 
transporter activity 
(GO:0005215). 
protein import into nucleus 
(GO:0006606). 









Med14 -1.476 0.008 Yes 
transcription coregulator 
activity (GO:0003712). 
transcription by RNA 
polymerase II 
(GO:0006366). 
regulation of transcription 
by RNA polymerase II 
(GO:0006357). 




general transcription factor 
(PC00259). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Cnrip1 -1.474 0.018 Yes 




negative regulation of 













cellular protein metabolic 
process (GO:0044267). 







RGD1308601 -1.474 0.007 Yes 
ubiquitin protein ligase 
activity (GO:0061630). 
ubiquitin-dependent 
protein catabolic process 
(GO:0006511). 
———— ———— 
Sult4a1 -1.470 0.009 Yes ———— ———— ———— ———— 
Fkbp3 -1.469 0.000 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Rnase4 -1.457 0.039 Yes 
ribonuclease activity 
(GO:0004540). 
———— ———— ———— 










membrane traffic protein 
(PC00150). 
Kcna6 -1.457 0.004 No ———— ———— ———— ———— 
Prim1 -1.457 0.009 Yes 





DNA biosynthetic process 
(GO:0071897). 
RNA biosynthetic process 
(GO:0032774). 
———— primase (PC00189). 
Cnih2 -1.452 0.001 Yes ———— ———— ———— 
membrane traffic protein 
(PC00150). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Mt-nd5 -1.448 0.000 Yes ———— ———— ———— oxidoreductase (PC00176). 




Scn1b -1.445 0.045 Yes 
molecular function 
regulator (GO:0098772). 
cation channel activity 
(GO:0005261). 
sodium ion transmembrane 
transporter activity 
(GO:0015081). 




regulation of metal ion 
transport (GO:0010959). 








sodium ion transmembrane 
transport (GO:0035725). 
cardiac muscle contraction 
(GO:0060048). 
integral component of 
plasma membrane 
(GO:0005887). 
plasma membrane protein 
complex (GO:0098797). 
cation channel complex 
(GO:0034703). 
voltage-gated ion channel 
(PC00241). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
regulation of cation 
transmembrane transport 
(GO:1904062). 
regulation of ion 
transmembrane transporter 
activity (GO:0032412). 
Prc1 -1.438 0.036 Yes ———— ———— ———— 
non-motor microtubule 
binding protein (PC00166). 
Tjp1 -1.437 0.014 Yes ———— ———— ———— tight junction (PC00214). 
Ppfia3 -1.433 0.036 No ———— ———— ———— ———— 
Clk1 -1.430 0.038 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Tnrc6b -1.430 0.000 Yes ———— 
regulation of mRNA 
catabolic process 
(GO:0061013). 
gene silencing by miRNA 
(GO:0035195). 





positive regulation of 
cellular catabolic process 
(GO:0031331). 
nuclear-transcribed mRNA 




RNA binding protein 
(PC00031). 
Gtf2b -1.418 0.045 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Sycp3 -1.418 0.020 Yes ———— 
spermatid development 
(GO:0007286). 





Gnao1 -1.413 0.004 Yes 




















leaflet of membrane bilayer 
(GO:0097478). 
plasma membrane protein 
complex (GO:0098797). 
extrinsic component of 








Tcf7l2 -1.410 0.005 Yes 
transcription regulatory 






regulation of insulin 
secretion (GO:0050796). 




positive regulation of cell 
communication 
(GO:0010647). 




canonical Wnt signaling 
pathway (GO:0060070). 











HFD+PB vs ND - DOWNREGULATED 




positive regulation of 
protein secretion 
(GO:0050714). 
regulation of transcription 
by RNA polymerase II 
(GO:0006357). 
Htra1 -1.408 0.030 Yes ———— ———— ———— serine protease (PC00203). 
LOC10834817
5 
-1.402 0.000 Yes RNA binding (GO:0003723). ———— nucleus (GO:0005634). 
RNA splicing factor 
(PC00148). 
Mospd2 -1.395 0.041 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






microtubule (GO:0005874). ———— 















protein modifying enzyme 
(PC00260). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 







Snrpf -1.388 0.032 Yes RNA binding (GO:0003723). ———— ———— 
RNA splicing factor 
(PC00148). 
Sec23b -1.381 0.001 Yes 
GTPase activity 
(GO:0003924). 






ER to Golgi transport vesicle 
membrane (GO:0012507). 





vesicle coat protein 
(PC00235). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Zfp365 -1.378 0.025 Yes ———— ———— ———— ———— 
Dhx32 -1.370 0.021 Yes RNA binding (GO:0003723). ———— 
spliceosomal complex 
(GO:0005681). 
RNA helicase (PC00032). 
Ahnak -1.367 0.010 Yes RNA binding (GO:0003723). 
RNA splicing (GO:0008380). 






Ublcp1 -1.362 0.030 No ———— ———— ———— ———— 
Rammet -1.361 0.013 Yes ———— ———— ———— ———— 
Fbxo38 -1.357 0.030 Yes ———— ———— ———— ———— 
Pitrm1 -1.357 0.041 Yes ———— ———— ———— metalloprotease (PC00153). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Cbr4 -1.354 0.002 Yes 
oxidoreductase activity, 
acting on the CH-OH group 






fatty acid biosynthetic 
process (GO:0006633). 
———— oxidoreductase (PC00176). 






Cldn11 -1.352 0.027 No ———— ———— ———— ———— 
Tbc1d5 -1.352 0.000 Yes 
GTPase activity 
(GO:0003924). 
GTPase activator activity 
(GO:0005096). 














HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Cherp -1.352 0.023 Yes ———— 
cellular calcium ion 
homeostasis (GO:0006874). 
perinuclear region of 
cytoplasm (GO:0048471). 
RNA binding protein 
(PC00031). 






regulation of intracellular 
pH (GO:0051453). 





Slc44a1 -1.322 0.034 No ———— ———— ———— ———— 












positive regulation of 
signaling (GO:0023056). 





positive regulation of 
multicellular organismal 
process (GO:0051240). 
response to starvation 
(GO:0042594). 
regulation of system 
process (GO:0044057). 
perinuclear region of 
cytoplasm (GO:0048471). 
———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
action potential 
(GO:0001508). 













general transcription factor 
(PC00259). 
Ankrd40 -1.312 0.008 Yes ———— ———— ———— ———— 
Nelfa -1.312 0.016 Yes ———— ———— ———— ———— 
Crym -1.310 0.018 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Arih1 -1.310 0.011 Yes 
ubiquitin-like protein 
conjugating enzyme binding 
(GO:0044390). 


















Rbm3 -1.308 0.004 No ———— ———— ———— ———— 
Tmem126a -1.302 0.001 Yes ———— ———— ———— ———— 
Khdrbs3 -1.297 0.024 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Heatr5a -1.294 0.041 Yes ———— 

























Lrrc8c -1.285 0.018 Yes ———— ———— ———— 
scaffold/adaptor protein 
(PC00226). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Nudcd2 -1.280 0.008 Yes 









ST7 -1.279 0.022 Yes ———— ———— ———— ———— 
Syt14 -1.276 0.043 Yes ———— ———— ———— ———— 
Dbndd2 -1.270 0.001 Yes ———— ———— ———— ———— 
Tmem38a -1.270 0.024 No ———— ———— ———— ———— 









plasma membrane region 
(GO:0098590). 
———— 




Syt4 -1.269 0.048 Yes 









regulation of response to 
stimulus (GO:0048583). 












regulation of exocytosis 
(GO:0017157). 















HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
cellular response to 
chemical stimulus 
(GO:0070887). 
Srsf2 -1.267 0.001 Yes RNA binding (GO:0003723). 
mRNA cis splicing, via 
spliceosome (GO:0045292). 
regulation of alternative 
mRNA splicing, via 
spliceosome (GO:0000381). 






RNA splicing factor 
(PC00148). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Trappc8 -1.262 0.028 Yes ———— 
autophagosome assembly 
(GO:0000045). 
endoplasmic reticulum to 
Golgi vesicle-mediated 
transport (GO:0006888). 










phagophore assembly site 
(GO:0000407). 








Cxcl14 -1.259 0.004 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Eef1a2 -1.257 0.000 Yes 
translation regulator 
activity (GO:0045182). 








Rhot1 -1.255 0.028 Yes 
GTP binding (GO:0005525). 
GTPase activity 
(GO:0003924). 
organelle transport along 
microtubule (GO:0072384). 







integral component of 
mitochondrial outer 
membrane (GO:0031307). 
small GTPase (PC00208). 
Nsf -1.250 0.025 No ———— ———— ———— ———— 
Selenos -1.248 0.000 No ———— ———— ———— ———— 




Moxd1 -1.248 0.003 Yes 
copper ion binding 
(GO:0005507). 
oxidoreductase activity, 
acting on paired donors, 
with incorporation or 







organic cyclic compound 
catabolic process 
(GO:1901361). 
cellular nitrogen compound 
biosynthetic process 
(GO:0044271). 




















HFD+PB vs ND - DOWNREGULATED 














Ndrg1 -1.245 0.019 Yes ———— 
signal transduction 
(GO:0007165). 
cytoplasm (GO:0005737). serine protease (PC00203). 
Galnt11 -1.244 0.010 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Pllp -1.244 0.032 Yes 
structural molecule activity 
(GO:0005198). 
myelination (GO:0042552). 
integral component of 
membrane (GO:0016021). 
membrane traffic protein 
(PC00150). 
Qrich1 -1.243 0.028 Yes 
DNA-binding transcription 
factor activity, RNA 
polymerase II-specific 
(GO:0000981). 





transcription by RNA 
polymerase II 
(GO:0006366). 
regulation of transcription 
by RNA polymerase II 
(GO:0006357). 
nucleus (GO:0005634). 
zinc finger transcription 
factor (PC00244). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Usp25 -1.243 0.019 Yes 
thiol-dependent ubiquitin-














HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Bbs9 -1.239 0.015 Yes ———— 
intraciliary transport 
involved in cilium assembly 
(GO:0035735). 
vesicle targeting, trans-





ciliary transition zone 
assembly (GO:1905349). 





plasma membrane region 
(GO:0098590). 
———— 
Fam216b -1.238 0.010 Yes ———— ———— ———— ———— 
Clpx -1.236 0.020 Yes ———— ———— ———— ———— 
Zfp266 -1.234 0.045 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Socs5 -1.234 0.027 Yes 
phosphotransferase 
















Nrxn2 -1.232 0.015 No ———— ———— ———— ———— 
Sh3glb1 -1.228 0.002 Yes ———— ———— ———— ———— 









respiratory chain complex I 
(GO:0045271). 
oxidoreductase (PC00176). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 

















Ndn -1.222 0.000 Yes ———— ———— ———— 
scaffold/adaptor protein 
(PC00226). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Osbp -1.216 0.003 Yes 
sterol binding 
(GO:0032934). 
lipid transporter activity 
(GO:0005319). 
———— 
perinuclear region of 
cytoplasm (GO:0048471). 




























HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Matr3 -1.211 0.001 No ———— ———— ———— ———— 
Tank -1.211 0.019 Yes ———— ———— ———— ———— 
Cltrn -1.211 0.000 Yes ———— ———— ———— ———— 









establishment of protein 






vesicle budding from 
membrane (GO:0006900). 
synaptic vesicle transport 
(GO:0048489). 




regulation of synapse 

















membrane traffic protein 
(PC00150). 




HFD+PB vs ND - DOWNREGULATED 











Ptk2b -1.205 0.036 Yes 
protein tyrosine kinase 
activity (GO:0004713). 
signaling receptor binding 
(GO:0005102). 






epidermal growth factor 






regulation of cell adhesion 
(GO:0030155). 









extrinsic component of 
cytoplasmic side of plasma 
membrane (GO:0031234). 
plasma membrane region 
(GO:0098590). 
———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Ctxn1 -1.204 0.003 Yes ———— ———— ———— ———— 
Bok -1.203 0.029 Yes 
protein homodimerization 
activity (GO:0042803). 
extrinsic apoptotic signaling 
pathway (GO:0097191). 
intrinsic apoptotic signaling 






Gtf2a2 -1.198 0.004 Yes 
transcription coactivator 
activity (GO:0003713). 
TBP-class protein binding 
(GO:0017025). 
RNA polymerase II 
preinitiation complex 
assembly (GO:0051123). 
positive regulation of DNA-
binding transcription factor 
activity (GO:0051091). 
positive regulation of 
transcription by RNA 
polymerase II 
(GO:0045944). 
RNA polymerase II 
transcription factor 
complex (GO:0090575). 
RNA polymerase II, 
holoenzyme (GO:0016591). 
general transcription factor 
(PC00259). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 





kinase signaling cascade 
(GO:0031098). 





activation of protein kinase 
activity (GO:0032147). 
signal transduction by 
protein phosphorylation 
(GO:0023014). 
regulation of mitotic cell 
cycle (GO:0007346). 
cytoplasm (GO:0005737). ———— 
Cdh13 -1.190 0.032 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Mt-nd3 -1.189 0.013 Yes ———— ———— ———— oxidoreductase (PC00176). 
Mdm1 -1.188 0.024 Yes ———— ———— ———— ———— 
Ttc30b -1.187 0.014 No ———— ———— ———— ———— 
Vps13d -1.186 0.032 Yes ———— 
maintenance of location 
(GO:0051235). 
protein localization to Golgi 
apparatus (GO:0034067). 




extrinsic component of 
membrane (GO:0019898). 
———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 


















intercellular signal molecule 
(PC00207). 




transport, cytochrome c to 
oxygen (GO:0006123). 
ATP synthesis coupled 
proton transport 
(GO:0015986). 
———— oxidase (PC00175). 
Timm9 -1.178 0.004 Yes ———— ———— ———— 
primary active transporter 
(PC00068). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
















Farp1 -1.172 0.047 Yes 
Rac GTPase binding 
(GO:0048365). 
Rho guanyl-nucleotide 
exchange factor activity 
(GO:0005089). 
———— ———— ———— 












lipid storage (GO:0019915). 
plasma lipoprotein particle 
clearance (GO:0034381). 
regulation of localization 
(GO:0032879). 











leaflet of membrane bilayer 
(GO:0097478). 
external side of plasma 
membrane (GO:0009897). 
serine protease (PC00203). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Herc2 -1.170 0.027 Yes ———— ———— ———— 
guanyl-nucleotide exchange 
factor (PC00113). 
Gtf2f2 -1.170 0.000 No ———— ———— ———— ———— 
Ttyh1 -1.168 0.001 Yes 
ion gated channel activity 
(GO:0022839). 





ion channel (PC00133). 
Hif1a -1.166 0.000 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Gpd1 -1.160 0.021 Yes 
oxidoreductase activity, 
acting on the CH-OH group 













cytosol (GO:0005829). dehydrogenase (PC00092). 
Ogn -1.156 0.021 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 















Trafd1 -1.153 0.043 No ———— ———— ———— ———— 
Rpgr -1.153 0.034 Yes ———— ———— ———— ———— 
Psip1 -1.153 0.033 No ———— ———— ———— ———— 





transcription by RNA 
polymerase II 
(GO:0006366). 
regulation of transcription 
by RNA polymerase II 
(GO:0006357). 









HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Ptma -1.152 0.000 Yes ———— ———— ———— ———— 
Tubb4a -1.151 0.041 Yes 
GTP binding (GO:0005525). 
structural molecule activity 
(GO:0005198). 







Camkv -1.150 0.018 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
























extracellular matrix protein 
(PC00102). 
Ptprn -1.148 0.035 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Syn1 -1.146 0.002 Yes ———— 
neurotransmitter secretion 
(GO:0007269). 















Myadm -1.144 0.019 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
LOC10368998
3 
-1.140 0.001 Yes 












pigment metabolic process 
(GO:0042440). 
nucleobase-containing 









HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Tbc1d1 -1.135 0.026 Yes 
GTPase activity 
(GO:0003924). 
GTPase activator activity 
(GO:0005096). 










Ep400 -1.135 0.018 Yes ———— ———— ———— ———— 
Nxt1 -1.135 0.042 Yes ———— 













HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Taf4b -1.128 0.008 Yes 
DNA binding (GO:0003677). 
transcription factor binding 
(GO:0008134). 
transcription by RNA 
polymerase II 
(GO:0006366). 
positive regulation of 
transcription by RNA 
polymerase II 
(GO:0045944). 
transcription factor TFIID 
complex (GO:0005669). 
general transcription factor 
(PC00259). 
39326.000 -1.125 0.008 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Arid1a -1.121 0.019 Yes 
nucleosome binding 
(GO:0031491). 





transcription by RNA 
polymerase II 
(GO:0006366). 
regulation of transcription 






neuron part (GO:0097458). 
nucleoplasm (GO:0005654). 
———— 
Zcchc24 -1.117 0.039 No ———— ———— ———— ———— 
Plekha1 -1.114 0.039 Yes 
protein binding 
(GO:0005515). 
———— cytoplasm (GO:0005737). ———— 
Plcl1 -1.112 0.012 No ———— ———— ———— ———— 
Ldlr -1.111 0.032 No ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 





































HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 





cytoplasmic side of 
membrane (GO:0098562). 

















HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Rabgap1 -1.106 0.015 Yes 
GTPase activity 
(GO:0003924). 
GTPase activator activity 
(GO:0005096). 










Hydin -1.106 0.005 Yes ———— ———— ———— ———— 




Sema4d -1.102 0.025 Yes 
receptor ligand activity 
(GO:0048018). 
negative regulation of 
locomotion (GO:0040013). 
neural crest cell 
differentiation 
(GO:0014033). 
regulation of cell size 
(GO:0008361). 
negative regulation of 
cellular component 
movement (GO:0051271). 





transcription by RNA 
polymerase II 
(GO:0006366). 











cell surface receptor 
signaling pathway 
(GO:0007166). 





negative regulation of 
transcription by RNA 
polymerase II 
(GO:0000122). 










regulation of axonogenesis 
(GO:0050770). 
regulation of cell growth 
(GO:0001558). 
negative regulation of 




negative regulation of 
cellular component 
organization (GO:0051129). 




positive regulation of cell 
migration (GO:0030335). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Vegfa -1.102 0.011 No ———— ———— ———— ———— 




Rhob -1.096 0.015 Yes 
GTP binding (GO:0005525). 














maintenance of cell polarity 
(GO:0007163). 
actin filament organization 
(GO:0007015). 















small GTPase (PC00208). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Htr2c -1.095 0.000 No ———— ———— ———— ———— 
Ubqln2 -1.090 0.007 Yes 
polyubiquitin modification-









cytosol (GO:0005829). ———— 
Dock8 -1.089 0.036 Yes ———— ———— ———— 
guanyl-nucleotide exchange 
factor (PC00113). 
LOC499219 -1.087 0.032 Yes ———— ———— ———— 
P53-like transcription factor 
(PC00253). 
Pphln1 -1.086 0.011 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Dek -1.085 0.016 Yes 
histone binding 
(GO:0042393). 
regulation of double-strand 
break repair (GO:2000779). 




binding, or -regulatory 
protein (PC00077). 
Kcnab1 -1.084 0.007 Yes ———— ———— ———— ———— 
Bcas2 -1.080 0.003 Yes ———— ———— 
catalytic step 2 spliceosome 
(GO:0071013). 
U5 snRNP (GO:0005682). 
Prp19 complex 
(GO:0000974). 
RNA splicing factor 
(PC00148). 
Ube3a -1.076 0.047 Yes ———— ———— ———— ———— 













HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Rad17 -1.070 0.045 Yes 





DNA damage checkpoint 
(GO:0000077). 
DNA repair (GO:0006281). 
G2/M transition of mitotic 
cell cycle (GO:0000086). 
mitotic nuclear division 
(GO:0140014). 










regulation of biological 
quality (GO:0065008). 
cytoplasm (GO:0005737). ———— 





transporting ATP synthase 
complex (GO:0005753). 
ATP synthase (PC00002). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Jam3 -1.068 0.001 Yes ———— ———— ———— ———— 
Zfp513 -1.068 0.031 Yes 
RNA polymerase II 
regulatory region sequence-
specific DNA binding 
(GO:0000977). 













C2H2 zinc finger 
transcription factor 
(PC00248). 
Tmem212 -1.067 0.016 Yes ———— ———— ———— transporter (PC00227). 
Dnaaf1 -1.066 0.021 Yes ———— ———— ———— ———— 




Lgals3 -1.066 0.013 Yes 








positive regulation of 
calcium ion transport 
(GO:0051928). 
extrinsic apoptotic signaling 
pathway (GO:0097191). 
negative regulation of 
transport (GO:0051051). 
endocytosis (GO:0006897). 















plasma membrane part 
(GO:0044459). 
extracellular matrix protein 
(PC00102). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
negative regulation of 




regulation of endocytosis 
(GO:0030100). 
negative regulation of 
cellular component 
organization (GO:0051129). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Actl6a -1.063 0.029 Yes 
chromatin binding 
(GO:0003682). 







transcription by RNA 
polymerase II 
(GO:0006366). 
regulation of transcription 









actin and actin related 
protein (PC00039). 
Slc6a20 -1.058 0.030 No ———— ———— ———— ———— 
Atp6v1h -1.057 0.013 Yes ———— ———— ———— ATP synthase (PC00002). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Tbl1x -1.056 0.030 Yes 
transcription corepressor 
activity (GO:0003714). 





regulation of transcription 





Ranbp2 -1.055 0.028 Yes 
GTPase activity 
(GO:0003924). 
GTPase activator activity 
(GO:0005096). 






nuclear pore (GO:0005643). 
scaffold/adaptor protein 
(PC00226). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 


















Rtn4 -1.053 0.000 Yes ———— ———— ———— ———— 








HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Tubb2a -1.051 0.013 Yes 
GTP binding (GO:0005525). 















Rab21 -1.050 0.002 Yes 
GTPase activity 
(GO:0003924). 














HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 





Hint3 -1.045 0.031 No ———— ———— ———— ———— 
Svbp -1.045 0.018 Yes ———— 
protein secretion 
(GO:0009306). 





apical part of cell 
(GO:0045177). 
———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Snx5 -1.044 0.005 Yes 
phosphatidylinositol 
binding (GO:0035091). 
cytoskeletal protein binding 
(GO:0008092). 













Trappc2 -1.041 0.044 Yes ———— ———— ———— 
membrane traffic protein 
(PC00150). 
S100a6 -1.041 0.001 Yes ———— ———— ———— 
calmodulin-related 
(PC00061). 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 





cellular response to stress 
(GO:0033554). 
transcription by RNA 
polymerase II 
(GO:0006366). 
positive regulation of 









Lrp6 -1.031 0.002 Yes ———— ———— ———— apolipoprotein (PC00052). 
Fgf13 -1.029 0.015 Yes ———— ———— ———— growth factor (PC00112). 
Scg5 -1.020 0.002 No ———— ———— ———— ———— 
LOC680885 -1.011 0.008 Yes ———— ———— ———— ———— 




HFD+PB vs ND - DOWNREGULATED 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Sub1 -1.006 0.001 Yes 
transcription coactivator 
activity (GO:0003713). 
positive regulation of 
transcription initiation from 
RNA polymerase II 
promoter (GO:0060261). 
transcription initiation from 





general transcription factor 
(PC00259). 
Fam174a -1.003 0.021 Yes ———— ———— ———— ———— 








III. Deregulated genes in the HFD+PB vs HFD comparison 
Table 0.8. Highly upregulated genes in HFD+PB rats when compared to HFD and their functional classification as determined by PANTHER bioinformatics. 
Genes were determined to be highly deregulated if they had a log2 fold change (log2FC) > 1 and a P value < 0.05. “Hit” refers to whether the gene was found by PANTHER. 
HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Rhbdl2 4.365 0.000 Yes ———— ———— ———— ———— 
Tyk2 3.780 0.005 Yes ———— ———— ———— ———— 
Slc35f5 3.537 0.002 Yes ———— ———— ———— 
secondary carrier 
transporter(PC00258) 









Col6a5 3.480 0.019 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






positive regulation of 
axonogenesis(GO:0050772). 











Mettl27 3.365 0.016 Yes ———— ———— ———— methyltransferase(PC00155) 






RGD1560608 3.239 0.041 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Kri1 3.239 0.030 Yes ———— 




maturation of SSU—rRNA 
from tricistronic rRNA 
transcript (SSU—rRNA, 5.8S 
rRNA, LSU—
rRNA)(GO:0000462). 
cleavage involved in rRNA 
processing(GO:0000469). 
maturation of 5.8S rRNA 
from tricistronic rRNA 



















































HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
B3galt4 3.104 0.007 No ———— ———— ———— ———— 
Zfp267 2.949 0.033 Yes ———— ———— ———— 
C2H2 zinc finger 
transcription 
factor(PC00248) 
Syk 2.949 0.050 No ———— ———— ———— ———— 
Slc36a1 2.783 0.011 Yes 
amino acid transmembrane 
transporter 
activity(GO:0015171) 





Ccdc17 2.783 0.013 Yes ———— ———— ———— ———— 
Adamts2 2.783 0.012 Yes ———— ———— ———— metalloprotease(PC00153) 




HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 















HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Traf3ip1 2.590 0.031 Yes ———— 




involved in cilium 
assembly(GO:0035735). 
vesicle targeting, trans—





ciliary transition zone 
assembly(GO:1905349). 

















HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
B3gntl1 2.590 0.023 Yes ———— ———— ———— 
glycosyltransferase(PC00111
) 




Ryr1 2.590 0.023 No ———— ———— ———— ———— 
Tmem102 2.589 0.008 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Ttc8 2.519 0.013 Yes ———— 
intraciliary transport 










ciliary transition zone 
assembly(GO:1905349). 












Pla2g1b 2.483 0.020 Yes ———— ———— ———— phospholipase(PC00186) 




HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Prss36 2.445 0.013 No ———— ———— ———— ———— 
AABR0707274
8.1 
2.367 0.041 Yes ———— ———— ———— ———— 
Clcnkb 2.367 0.048 No ———— ———— ———— ———— 




HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Rrh 2.367 0.002 Yes 
G protein—coupled receptor 
activity(GO:0004930) 
cellular response to light 
stimulus(GO:0071482). 
response to external 
stimulus(GO:0009605). 



















Uros 2.367 0.031 Yes 
hydro—lyase 
activity(GO:0016836) 









HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Trpm7 2.215 0.004 No ———— ———— ———— ———— 






















regulation of cellular protein 
catabolic 
process(GO:1903362). 
positive regulation of 
multi—organism 
process(GO:0043902). 
negative regulation of blood 
coagulation(GO:0030195). 





















































positive regulation of 
molecular 
function(GO:0044093). 
positive regulation of 
signaling(GO:0023056). 
signaling(GO:0023052). 
regulation of gene 
expression(GO:0010468). 
negative regulation of 
molecular 
function(GO:0044092). 





regulation of cellular 
localization(GO:0060341). 



















cellular protein catabolic 
process(GO:0044257). 














positive regulation of 
organelle 
organization(GO:0010638). 









negative regulation of 





















HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
vesicle budding from 
membrane(GO:0006900). 
vesicle fusion(GO:0006906). 








regulation of multicellular 
organismal 
development(GO:2000026) 
Slc30a2 2.004 0.038 No ———— ———— ———— ———— 
Armc6 1.870 0.003 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 







Cd68 1.783 0.020 Yes ———— 











Slc39a4 1.783 0.016 No ———— ———— ———— ———— 
LOC680227 1.782 0.016 No ———— ———— ———— ———— 
Phf12 1.782 0.015 Yes ———— ———— ———— 
chromatin/chromatin—
binding, or —regulatory 
protein(PC00077) 




HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
















LOC499643 1.708 0.040 Yes ———— ———— ———— ———— 
Tradd 1.567 0.022 Yes ———— ———— ———— ———— 
Sntb2 1.560 0.028 Yes ———— ———— 




Zfp106 1.548 0.008 Yes ———— ———— ———— ———— 










HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Rnf170 1.483 0.011 Yes ———— ———— ———— ———— 
Ptp4a1 1.461 0.013 Yes ———— ———— nucleus(GO:0005634) ———— 

















cellular protein metabolic 
process(GO:0044267). 
negative regulation of 
endopeptidase 
activity(GO:0010951). 
negative regulation of 
protein catabolic 
process(GO:0042177). 












HFD+PB vs HFD – UPREGULATED GENES 





Rps6ka3 1.434 0.042 Yes 
protein serine/threonine 
kinase activity(GO:0004674) 
———— ———— ———— 
Rapgef2 1.426 0.043 Yes ———— ———— ———— 
guanyl—nucleotide 
exchange factor(PC00113) 
Secisbp2 1.367 0.010 No ———— ———— ———— ———— 
Mturn 1.367 0.033 Yes ———— ———— ———— ———— 
Cebpa 1.319 0.049 No ———— ———— ———— ———— 
Eloa 1.313 0.031 No ———— ———— ———— ———— 
Lrp5 1.306 0.048 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 





transforming growth factor 
beta receptor signaling 
pathway(GO:0007179). 
cellular response to 
stress(GO:0033554). 
regulation of neuron 
differentiation(GO:0045664)
. 
regulation of transforming 










HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 














negative regulation of 
transcription by RNA 
polymerase II(GO:0000122). 
















Yes ———— ———— ———— ———— 
Sez6l 1.209 0.014 Yes ———— ———— ———— ———— 
Plekhg5 1.197 0.033 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Vps33b 1.185 0.032 Yes ———— ———— ———— 
membrane trafficking 
regulatory protein(PC00151) 
Xbp1 1.169 0.026 No ———— ———— ———— ———— 
Fam234b 1.145 0.031 Yes ———— ———— ———— ———— 
Ccdc137 1.145 0.029 Yes ———— ———— ———— ———— 






Yes ———— ———— ———— 
major histocompatibility 
complex protein(PC00149) 
Fcgr2b 1.104 0.037 Yes ———— ———— ———— 
immunoglobulin receptor 
superfamily(PC00124) 
Laptm5 1.097 0.001 Yes ———— ———— ———— transporter(PC00227) 




HFD+PB vs HFD – UPREGULATED GENES 






Yes ———— ———— ———— 
scaffold/adaptor 
protein(PC00226) 
Nthl1 1.082 0.048 Yes 








———— DNA glycosylase(PC00010) 
Zfp426 1.082 0.044 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 







regulation of chromosome 
organization(GO:0033044). 
















HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Frem3 1.069 0.012 Yes ———— ———— ———— ———— 






non—motor actin binding 
protein(PC00165) 







Smpdl3b 1.063 0.049 Yes 






















HFD+PB vs HFD – UPREGULATED GENES 






























No ———— ———— ———— ———— 




HFD+PB vs HFD – UPREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Lyar 1.005 0.026 Yes DNA binding(GO:0003677) 
negative regulation of 
transcription by RNA 
polymerase II(GO:0000122). 














Table 0.9. Highly downregulated genes in HFD+PB rats when compared to HFD and their functional classification as determined by PANTHER bioinformatics. 
Genes were determined to be highly deregulated if they had a log2 fold change (log2FC) < -1 and a P value < 0.05. “Hit” refers to whether the gene was found by PANTHER. 
HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






cellular aromatic compound 
metabolic 
process(GO:0006725). 
regulation of lipid 
biosynthetic 
process(GO:0046890). 
positive regulation of 
biosynthetic 
process(GO:0009891). 







organic hydroxy compound 
metabolic 
process(GO:1901615) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 












Vwa1 -4.303 0.005 No ———— ———— ———— ———— 





leaflet of membrane 
bilayer(GO:0097478). 
plasma membrane protein 
complex(GO:0098797). 
extrinsic component of 












HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Tbc1d8b -4.215 0.023 Yes ———— ———— ———— ———— 
Ptprz1 -4.215 0.029 No ———— ———— ———— ———— 
Gjb2 -4.122 0.008 Yes gap junction(PC00105) ———— ———— ———— 
Fam84a -4.022 0.014 Yes ———— ———— ———— ———— 
Jakmip1 -4.022 0.016 Yes ———— ———— ———— ———— 









establishment of cell 
polarity(GO:0030010). 












HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Mfap2 -4.022 0.014 Yes ———— ———— ———— ———— 
Nap1l5 -3.990 0.000 Yes 
chromatin/chromatin—
binding, or —regulatory 
protein(PC00077) 
———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 








involved in cilium 
assembly(GO:0035735). 
vesicle targeting, trans—






ciliary transition zone 
assembly(GO:1905349). 
protein localization to 
cilium(GO:0061512) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
































HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 







negative regulation of 




transcription by RNA 
polymerase II(GO:0006366). 
positive regulation of 
transcription by RNA 
polymerase II(GO:0045944) 
Zfp92 -3.800 0.015 Yes chaperone(PC00072) ———— ———— ———— 
Chia -3.800 0.040 No ———— ———— ———— ———— 




transcription by RNA 
polymerase II(GO:0006366). 
regulation of transcription 
by RNA polymerase 
II(GO:0006357) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Agt -3.677 0.001 Yes decarboxylase(PC00089) ———— ———— ———— 
Svop -3.675 0.047 Yes ———— ———— ———— ———— 
Fgf12 -3.675 0.038 Yes growth factor(PC00112) ———— ———— ———— 




positive regulation of 
transcription, DNA—
templated(GO:0045893). 
transcription by RNA 
polymerase II(GO:0006366). 
regulation of transcription 
by RNA polymerase 
II(GO:0006357) 
Pomc -3.594 0.001 No ———— ———— ———— ———— 
Slc13a3 -3.540 0.009 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 















response to amino 
acid(GO:0043200). 
TOR signaling(GO:0031929). 
cellular response to 
starvation(GO:0009267). 
cellular response to 
organonitrogen 
compound(GO:0071417). 
cellular response to 
oxygen—containing 
compound(GO:1901701). 
positive regulation of TOR 
signaling(GO:0032008) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Ncam1 -3.504 0.000 No ———— ———— ———— ———— 
Btbd17 -3.466 0.008 Yes ———— ———— ———— ———— 







Akap1 -3.439 0.000 No ———— ———— ———— ———— 
Rit2 -3.419 0.000 Yes 
phosphodiesterase(PC0018
5) 
cytoplasm(GO:0005737) ———— ———— 
Crlf1 -3.410 0.000 Yes ———— ———— ———— ———— 




———— ———— ———— 
Thrsp -3.387 0.001 No ———— ———— ———— ———— 




Tril -3.347 0.000 Yes 















transcription by RNA 
polymerase II(GO:0006366). 
positive regulation of cell 
differentiation(GO:0045597
). 
response to organic cyclic 
compound(GO:0014070). 
positive regulation of 
transcription by RNA 
polymerase II(GO:0045944). 
cell cycle(GO:0007049). 




regulation of cell 
population 
proliferation(GO:0042127). 
response to mechanical 
stimulus(GO:0009612). 
negative regulation of 

















HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
regulation of cell 
cycle(GO:0051726). 
response to organonitrogen 
compound(GO:0010243) 
Lpar1 -3.306 0.023 Yes lyase(PC00144) ———— ———— ———— 
Wasf1 -3.306 0.036 Yes nucleotide kinase(PC00172) ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 












negative regulation of 
adenylate cyclase 
activity(GO:0007194). 
positive regulation of MAPK 
cascade(GO:0043410). 





Nrip1 -3.218 0.017 Yes ———— ———— ———— ———— 











































HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




























HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
















protein localization to 
plasma 
membrane(GO:0072659) 
Rassf5 -3.125 0.024 Yes 
scaffold/adaptor 
protein(PC00226) 
———— ———— ———— 
Arhgap21 -3.125 0.002 Yes ———— ———— ———— ———— 
Grin2b -3.105 0.001 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




Icam5 -3.092 0.010 Yes ———— ———— ———— ———— 
Fam131b -3.066 0.000 No ———— ———— ———— ———— 
Clcn2 -3.026 0.021 Yes ———— 




Gpr88 -3.026 0.034 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 














involved in cilium 
assembly(GO:0035735). 
vesicle targeting, trans—






ciliary transition zone 
assembly(GO:1905349). 
protein localization to 
cilium(GO:0061512) 
Hnmt -3.026 0.023 No ———— ———— ———— ———— 










HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 








Gjb6 -2.995 0.000 Yes ———— ———— ———— ———— 
Ak5 -2.954 0.009 Yes 
RNA splicing 
factor(PC00148) 





Tmem59l -2.943 0.000 No ———— ———— ———— ———— 














negative regulation of 
locomotion(GO:0040013). 
neural crest cell 
differentiation(GO:0014033
). 
regulation of cell 
size(GO:0008361). 
negative regulation of 
cellular component 
movement(GO:0051271). 






cell surface receptor 
signaling 
pathway(GO:0007166). 









regulation of cell 
growth(GO:0001558). 
negative regulation of 
response to external 
stimulus(GO:0032102). 











HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
positive regulation of cell 
migration(GO:0030335) 
Cdkn2c -2.919 0.037 Yes ———— ———— ———— ———— 




Dhx57 -2.919 0.044 Yes ———— ———— ———— ———— 






positive regulation of 
GTPase 
activity(GO:0043547) 
Scamp5 -2.919 0.025 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 










Hmgxb4 -2.880 0.012 Yes ———— ———— ———— ———— 
Gng8 -2.880 0.018 Yes 
membrane traffic 
protein(PC00150) 
integral component of 
membrane(GO:0016021) 
———— myelination(GO:0042552) 







transcription by RNA 
polymerase II(GO:0006366). 
positive regulation of 
transcription by RNA 
polymerase II(GO:0045944) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






















regulation of cytokine 
production(GO:0001817) 
Frrs1l -2.880 0.013 Yes 
ubiquitin—protein 
ligase(PC00234) 
———— ———— ———— 
Mmrn2 -2.803 0.036 Yes 
ubiquitin—protein 
ligase(PC00234) 
———— ———— ———— 
Mical1 -2.802 0.007 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
LOC10091140
2 
-2.742 0.026 Yes ———— 
endosome(GO:0005768). 











Resp18 -2.730 0.000 Yes ———— ———— ———— ———— 









regulation of response to 
stress(GO:0080134). 
response to osmotic 
stress(GO:0006970) 
Cdca7 -2.678 0.043 Yes ———— nucleus(GO:0005634) ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Lgi4 -2.677 0.001 Yes 
immunoglobulin 




———— cell adhesion(GO:0007155) 







RGD1308544 -2.651 0.005 Yes ———— 
mitochondrial membrane 
part(GO:0044455). 







Vsnl1 -2.642 0.000 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Lgr4 -2.632 0.021 Yes ———— ———— ———— 
axon 
guidance(GO:0007411) 




cell surface receptor 
signaling 
pathway(GO:0007166) 







cellular protein metabolic 
process(GO:0044267). 
negative regulation of 
endopeptidase 
activity(GO:0010951) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
















Rgs4 -2.620 0.001 Yes 
GTPase—activating 
protein(PC00257) 
———— ———— ———— 
Tial1 -2.611 0.012 Yes 
scaffold/adaptor 
protein(PC00226) 
———— ———— ———— 
Ttc9b -2.603 0.001 Yes ———— ———— ———— ———— 









regulation of insulin 
secretion(GO:0050796). 











canonical Wnt signaling 
pathway(GO:0060070). 
transcription by RNA 
polymerase II(GO:0006366). 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
muscle structure 
development(GO:0061061). 
positive regulation of 
protein 
secretion(GO:0050714). 
regulation of transcription 
by RNA polymerase 
II(GO:0006357) 












Kif5a -2.498 0.000 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 














HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 































HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 











protein localization to 
organelle(GO:0033365) 






Frmd6 -2.439 0.050 Yes ———— cytoskeleton(GO:0005856) ———— 
actomyosin structure 
organization(GO:0031032) 
Shoc2 -2.439 0.050 Yes ———— ———— ———— 
tRNA 
methylation(GO:0030488) 
Prss23 -2.439 0.048 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






regulation of RNA 
splicing(GO:0043484) 
Cck -2.437 0.000 Yes ———— ———— ———— ———— 













Gtdc1 -2.388 0.030 Yes ———— ———— ———— 
transcription, DNA—
templated(GO:0006351). 
negative regulation of 









extrinsic apoptotic signaling 
pathway via death domain 
receptors(GO:0008625). 
positive regulation of NF—
kappaB transcription factor 
activity(GO:0051092) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Enpp4 -2.387 0.018 Yes 
nucleotide 
phosphatase(PC00173) 
———— ———— ———— 
Nfyb -2.387 0.007 Yes ———— ———— ———— ———— 
Matk -2.387 0.013 Yes ———— ———— ———— ———— 
Chgb -2.377 0.001 Yes ———— cytoplasm(GO:0005737) ———— 








Tubb2b -2.375 0.001 Yes 
G—protein coupled 
receptor(PC00021) 
———— ———— ———— 
Omg -2.355 0.027 Yes ———— midbody(GO:0030496) ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






Nptxr -2.353 0.012 No ———— ———— ———— ———— 









HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Tspan2 -2.333 0.021 Yes small GTPase(PC00208) ———— ———— 










Smyd4 -2.333 0.012 Yes ———— nucleus(GO:0005634) ———— ———— 
Elavl2 -2.333 0.008 No ———— ———— ———— ———— 
Stmn3 -2.322 0.000 No ———— ———— ———— ———— 
Wfdc1 -2.317 0.009 Yes ———— ———— ———— ———— 
Mgst2 -2.306 0.035 Yes 
extracellular matrix 
glycoprotein(PC00100) 
———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Mal -2.305 0.024 Yes 
scaffold/adaptor 
protein(PC00226) 
———— ———— ———— 
Cox18 -2.288 0.017 Yes transporter(PC00227) 





chain complex IV 
assembly(GO:0033617). 
protein insertion into 
mitochondrial inner 
membrane(GO:0045039) 
Fastkd3 -2.288 0.024 Yes 
G—protein coupled 
receptor(PC00021) 




cellular response to light 
stimulus(GO:0071482). 











HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Crnkl1 -2.288 0.014 No ———— ———— ———— ———— 






















Syngr3 -2.253 0.002 Yes transporter(PC00227) ———— ———— ———— 
Fn1 -2.218 0.046 No ———— ———— ———— ———— 
Apod -2.212 0.010 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Nefl -2.193 0.000 Yes ———— ———— ———— ———— 
Dtna -2.165 0.025 Yes ———— ———— ———— ———— 
Glmn -2.144 0.039 Yes 
ubiquitin—protein 
ligase(PC00234) 
cytoplasm(GO:0005737) ———— ———— 
Slf2 -2.144 0.045 Yes ———— ———— ———— ———— 








cellular protein metabolic 
process(GO:0044267). 
negative regulation of 
endopeptidase 
activity(GO:0010951) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 















Apba2 -2.124 0.022 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 











sodium ion transmembrane 
transport(GO:0035725). 







Disp2 -2.111 0.020 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Mmd2 -2.109 0.020 Yes 
G—protein coupled 
receptor(PC00021) 
———— ———— ———— 















Olig1 -2.078 0.000 No ———— ———— ———— ———— 
Tagln3 -2.066 0.006 Yes ———— ———— ———— ———— 





























HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 







positive regulation of 
GTPase 
activity(GO:0043547) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




modulation of chemical 
synaptic 
transmission(GO:0050804). 
regulation of system 
process(GO:0044057). 
regulation of signaling 
receptor 
activity(GO:0010469) 






positive regulation of 
GTPase 
activity(GO:0043547) 
Sparcl1 -2.059 0.004 No ———— ———— ———— ———— 




Rprml -2.054 0.023 Yes ———— 
focal 
adhesion(GO:0005925). 




extrinsic component of 


















regulation of cell 
adhesion(GO:0030155). 
regulation of cell 
population 
proliferation(GO:0042127) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 











regulation of calcium ion 
transport(GO:0051924). 
regulation of cation 
transmembrane 
transport(GO:1904062). 
regulation of ion 
transmembrane transporter 
activity(GO:0032412) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 







cellular protein metabolic 
process(GO:0044267). 
negative regulation of 
endopeptidase 
activity(GO:0010951) 




cellular zinc ion 
homeostasis(GO:0006882). 
response to cadmium 
ion(GO:0046686). 
response to toxic 
substance(GO:0009636). 









HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Bcat1 -2.031 0.000 Yes 
membrane traffic 
protein(PC00150) 
integral component of 
membrane(GO:0016021) 
———— myelination(GO:0042552) 
Synm -2.025 0.031 Yes ———— ———— ———— ———— 
S1pr5 -2.025 0.017 Yes ———— 




Lhx2 -2.025 0.037 No ———— ———— ———— ———— 
Cpped1 -2.011 0.002 Yes RNA helicase(PC00032) nucleus(GO:0005634) ———— ———— 
Nudt21 -1.995 0.025 Yes 
heterotrimeric G—
protein(PC00117) 
———— ———— ———— 
LOC10036536
3 




transcription by RNA 
polymerase II(GO:0006366). 
positive regulation of 
transcription by RNA 
polymerase II(GO:0045944) 
Ptprr -1.995 0.036 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Apoc1 -1.995 0.042 No ———— ———— ———— ———— 
Gad1 -1.983 0.011 Yes decarboxylase(PC00089) ———— ———— ———— 
Cbs -1.972 0.042 Yes ———— ———— ———— ———— 
Gria2 -1.972 0.029 No ———— ———— ———— ———— 
Adap1 -1.967 0.007 Yes ———— ———— ———— ———— 




regulation of metal ion 
transport(GO:0010959). 
sodium ion transmembrane 
transport(GO:0035725). 
regulation of cation 
transmembrane 
transport(GO:1904062). 
regulation of ion 
transmembrane transporter 
activity(GO:0032412) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 












Mbtps2 -1.955 0.020 Yes metalloprotease(PC00153) ———— ———— ———— 
Mt-nd4l -1.955 0.017 Yes ———— ———— ———— ———— 
Gng13 -1.955 0.043 Yes metalloprotease(PC00153) ———— ———— ———— 
Adora1 -1.954 0.043 Yes 
G—protein coupled 
receptor(PC00021) 
———— ———— ———— 
Rbp4 -1.954 0.049 Yes ———— ———— ———— ———— 
Ubap1l -1.954 0.041 Yes acetyltransferase(PC00038) ———— ———— ———— 
Ptpn5 -1.954 0.047 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Ccdc136 -1.943 0.015 Yes 
scaffold/adaptor 
protein(PC00226) 
———— ———— ———— 















regulation of response to 
stimulus(GO:0048583). 














regulation of ion 
transport(GO:0043269). 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
cellular response to 
chemical 
stimulus(GO:0070887) 




Vegfb -1.940 0.018 Yes 
voltage—gated ion 
channel(PC00241) 
integral component of 
plasma 
membrane(GO:0005887). 







regulation of metal ion 
transport(GO:0010959). 
















HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
regulation of cation 
transmembrane 
transport(GO:1904062). 
regulation of ion 
transmembrane transporter 
activity(GO:0032412) 
















HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 












Osbpl8 -1.934 0.044 Yes ———— ———— ———— ———— 
Mag -1.918 0.006 Yes 
G—protein coupled 
receptor(PC00021) 
———— ———— ———— 
Slc43a2 -1.918 0.018 Yes ———— ———— ———— 
neutral amino acid 
transport(GO:0015804) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






regulation of mRNA 
catabolic 
process(GO:0061013). 
gene silencing by 
miRNA(GO:0035195). 















HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 













Gja1 -1.903 0.000 Yes gap junction(PC00105) ———— ———— ———— 
Adgrb2 -1.887 0.023 Yes ———— ———— ———— ———— 
Spata18 -1.881 0.010 No ———— ———— ———— ———— 
Rundc3a -1.873 0.002 Yes ———— 
integral component of 
plasma 
membrane(GO:0005887) 
———— cell adhesion(GO:0007155) 
Mt1m -1.870 0.026 Yes kinase(PC00137) ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




Kcna6 -1.867 0.000 No ———— ———— ———— ———— 
Ptn -1.864 0.002 Yes 
general transcription 
factor(PC00259) 
———— ———— ———— 
Sfxn1 -1.861 0.032 No ———— ———— ———— ———— 













Adcyap1r1 -1.850 0.016 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 













protein catabolic process 
via the multivesicular body 
sorting 
pathway(GO:0043162). 
multivesicular body sorting 
pathway(GO:0071985). 
protein catabolic process in 
the vacuole(GO:0007039) 
Dhx36 -1.842 0.023 Yes ———— ———— ———— ———— 
Klhl13 -1.832 0.005 Yes 
GTPase—activating 
protein(PC00257) 
———— ———— ———— 
Dlgap3 -1.803 0.007 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




























ciliary transition zone 
assembly(GO:1905349). 
protein localization to 
cilium(GO:0061512) 
Arhgef28 -1.802 0.037 Yes metalloprotease(PC00153) ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






Ras protein signal 
transduction(GO:0007265). 
positive regulation of 
neuron projection 
development(GO:0010976) 
Zfp292 -1.802 0.038 Yes oxidoreductase(PC00176) ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 

































HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






negative regulation of 
signaling receptor 
activity(GO:2000272) 
Rap1gap -1.762 0.018 Yes 
G—protein coupled 
receptor(PC00021) 
———— ———— ———— 
Bcan -1.758 0.008 No ———— ———— ———— ———— 
Fem1c -1.754 0.042 Yes ———— ———— ———— ———— 
RragB -1.748 0.036 Yes ———— ———— ———— ———— 
















HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 













Sptbn2 -1.724 0.005 No ———— ———— ———— ———— 
Patj -1.723 0.000 Yes ———— ———— ———— ———— 
Rasgrf1 -1.709 0.021 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






positive regulation of 
GTPase 
activity(GO:0043547) 
Togaram1 -1.703 0.042 Yes 
non—motor microtubule 
binding protein(PC00166) 
———— ———— ———— 
Tcf7l2 -1.682 0.001 Yes ———— ———— ———— ———— 
Fxyd7 -1.677 0.011 Yes ———— cytosol(GO:0005829) ———— 
cGMP—mediated 
signaling(GO:0019934). 
positive regulation of 
intracellular signal 
transduction(GO:1902533) 
Agap2 -1.673 0.001 Yes ———— ———— ———— ———— 
Ndrg1 -1.665 0.004 Yes serine protease(PC00203) cytoplasm(GO:0005737) ———— 
signal 
transduction(GO:0007165) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Mb21d2 -1.665 0.029 Yes ———— ———— ———— ———— 























regulation of response to 
stimulus(GO:0048583). 














regulation of ion 
transport(GO:0043269). 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
cellular response to 
chemical 
stimulus(GO:0070887) 
Wscd1 -1.649 0.000 Yes ———— ———— ———— ———— 













Snrpf -1.646 0.021 Yes 
RNA splicing 
factor(PC00148) 
———— ———— ———— 
Camk2b -1.646 0.002 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Mtfmt -1.642 0.006 Yes ———— ———— ———— ———— 












Slc1a3 -1.630 0.025 No ———— ———— ———— ———— 
Akap11 -1.626 0.001 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Mobp -1.620 0.001 Yes ———— ———— ———— 
anatomical structure 
formation involved in 
morphogenesis(GO:004864
6). 







Mtrf1 -1.616 0.049 Yes ———— ———— ———— ———— 
Magi2 -1.616 0.040 No ———— ———— ———— ———— 
Amn1 -1.613 0.009 Yes nucleotide kinase(PC00172) ———— ———— ———— 
Sncb -1.606 0.002 No ———— ———— ———— ———— 
Ngef -1.596 0.021 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Mapk8ip2 -1.596 0.028 Yes ———— ———— ———— 




Trim34 -1.587 0.032 Yes ———— ———— ———— ———— 
RGD1311745 -1.580 0.028 Yes ———— ———— ———— ———— 
Dguok -1.566 0.016 Yes 
phosphatase 
modulator(PC00184) 
———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Eef1a2 -1.565 0.000 Yes phosphatase(PC00181) ———— ———— 


















cellular protein metabolic 
process(GO:0044267). 
negative regulation of 
endopeptidase 
activity(GO:0010951) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Hcrt -1.563 0.025 Yes ———— ———— ———— ———— 
Pls3 -1.563 0.004 No ———— ———— ———— ———— 
Ptp4a3 -1.556 0.029 Yes ———— nucleus(GO:0005634) ———— ———— 



















HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
























HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Prim1 -1.540 0.012 Yes kinase activator(PC00138) 
transcription factor TFIIH 
core complex(GO:0000439). 
transcription factor TFIIH 
holo complex(GO:0005675) 
———— 
phosphorylation of RNA 
polymerase II C—terminal 
domain(GO:0070816). 







Mum1 -1.540 0.040 Yes ———— ———— ———— 





Dnm1 -1.539 0.002 Yes oxidoreductase(PC00176) ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
S100b -1.529 0.014 Yes 
calmodulin—
related(PC00061) 
———— ———— ———— 
Gng2 -1.529 0.003 Yes ———— ———— ———— 
T cell mediated 
immunity(GO:0002456). 
positive regulation of 
adaptive immune 
response(GO:0002821) 
Acad10 -1.523 0.030 Yes ———— 








Pcsk6 -1.523 0.016 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 

























HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Abhd17b -1.503 0.047 Yes translation factor(PC00223) ———— ———— 
translational 
elongation(GO:0006414) 
Tubb4a -1.499 0.008 Yes ———— ———— ———— ———— 
























HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Pllp -1.481 0.012 Yes ———— ———— ———— ———— 























regulation of ion 
transport(GO:0043269). 
regulation of response to 
stimulus(GO:0048583). 
vesicle fusion to plasma 
membrane(GO:0099500). 




response to calcium 
ion(GO:0051592). 




HFD+PB vs HFD – DOWNREGULATED GENES 









cellular response to 
chemical 
stimulus(GO:0070887) 
Cadm3 -1.452 0.046 Yes ———— ———— ———— ———— 
Phyhip -1.452 0.038 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Irgm -1.452 0.034 Yes 




transcription by RNA 
polymerase II(GO:0006366). 
regulation of transcription 
by RNA polymerase 
II(GO:0006357) 
Pdxp -1.448 0.001 No ———— ———— ———— ———— 





leaflet of membrane 
bilayer(GO:0097478). 
plasma membrane protein 
complex(GO:0098797). 
extrinsic component of 












HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Pcp4 -1.442 0.000 Yes ———— ———— ———— ———— 
RGD1309036 -1.440 0.019 No ———— ———— ———— ———— 
Tmem38a -1.433 0.007 No ———— ———— ———— ———— 
Cldn11 -1.431 0.043 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 








mediated transport, Golgi 
to endoplasmic 
reticulum(GO:0006890). 










Fbxo4 -1.427 0.041 Yes 
transfer/carrier 
protein(PC00219) 
———— ———— ———— 
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Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 





















HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 








































HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
cellular response to growth 
factor 
stimulus(GO:0071363). 










positive regulation of 
epithelial cell 
proliferation(GO:0050679) 
Scg5 -1.409 0.000 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




Prune1 -1.398 0.042 Yes ———— nucleus(GO:0005634) ———— RNA splicing(GO:0008380) 
Ogn -1.398 0.030 Yes ———— ———— ———— ———— 










C1d -1.383 0.011 Yes 
transcription 
cofactor(PC00217) 
———— ———— ———— 
Bbs9 -1.377 0.022 Yes ———— ———— ———— ———— 




Lrrc4b -1.370 0.035 Yes ———— 






positive regulation of 
signaling(GO:0023056). 










regulation of system 
process(GO:0044057). 




HFD+PB vs HFD – DOWNREGULATED GENES 















repair via homologous 
recombination(GO:0000724
). 
DNA unwinding involved in 
DNA 
replication(GO:0006268) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Nsg1 -1.362 0.047 Yes ———— 
endosome(GO:0005768). 











Tyw3 -1.362 0.035 Yes ———— ———— ———— ———— 
Trafd1 -1.362 0.029 Yes 
non—motor actin binding 
protein(PC00165) 
———— ———— ———— 






mitotic sister chromatid 
cohesion(GO:0007064) 
Ly6h -1.351 0.018 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Scnm1 -1.339 0.004 Yes ———— 









Ndrg4 -1.333 0.026 No ———— ———— ———— ———— 










HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Dbndd2 -1.329 0.002 Yes 
G—protein coupled 
receptor(PC00021) 












coupled receptor signaling 
pathway(GO:0007189). 
activation of adenylate 
cyclase 
activity(GO:0007190) 
Faim -1.329 0.022 No ———— ———— ———— ———— 
Ahnak -1.322 0.044 Yes ———— ———— ———— ———— 
Camkv -1.319 0.004 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Kif16b -1.313 0.027 Yes 
















Susd1 -1.305 0.029 Yes 
voltage—gated ion 
channel(PC00241) 
integral component of 
plasma 
membrane(GO:0005887). 





response to calcium 
ion(GO:0051592). 
detection of chemical 
stimulus(GO:0009593) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 






























HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Rufy3 -1.290 0.006 Yes ———— cytoplasm(GO:0005737) ———— ———— 
Cxcl14 -1.290 0.005 Yes growth factor(PC00112) ———— ———— ———— 
Syt11 -1.280 0.003 Yes cytokine(PC00083) 
leaflet of membrane 
bilayer(GO:0097478). 





Syn2 -1.276 0.005 No ———— ———— ———— ———— 
Ncald -1.270 0.031 Yes ———— ———— ———— ———— 
Slc44a1 -1.270 0.046 No ———— ———— ———— ———— 
Snapc5 -1.268 0.009 Yes ———— ———— ———— ———— 
Zbtb22 -1.259 0.012 Yes 
non—motor actin binding 
protein(PC00165) 
———— ———— ———— 
Golga7 -1.258 0.016 Yes 
protease 
inhibitor(PC00191) 
———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Zc3h14 -1.250 0.048 No ———— ———— ———— ———— 
Stmn1 -1.234 0.000 Yes ———— ———— ———— ———— 






Cd24 -1.218 0.037 Yes ———— ———— ———— ———— 
Stmn4 -1.218 0.041 Yes ———— ———— ———— ———— 







Ckmt1 -1.218 0.003 No ———— ———— ———— ———— 
Inpp1 -1.218 0.048 Yes 
RNA binding 
protein(PC00031) 
perinuclear region of 
cytoplasm(GO:0048471) 
———— 
cellular calcium ion 
homeostasis(GO:0006874) 
Myadm -1.218 0.014 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Ivns1abp -1.218 0.022 Yes 
scaffold/adaptor 
protein(PC00226) 
———— ———— ———— 
Crym -1.218 0.044 No ———— ———— ———— ———— 
Cyp46a1 -1.218 0.019 Yes oxygenase(PC00177) ———— ———— 
organic cyclic compound 
catabolic 
process(GO:1901361). 










HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 










protein targeting to 
membrane(GO:0006612) 
Apoe -1.211 0.010 Yes apolipoprotein(PC00052) ———— ———— ———— 







Ccnh -1.196 0.025 Yes ———— ———— ———— ———— 
Tmem212 -1.195 0.006 Yes serine protease(PC00203) ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 












Nfx1 -1.192 0.038 Yes 





regulation of transcription, 
DNA—
templated(GO:0006355) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 












Ndn -1.181 0.000 Yes 
scaffold/adaptor 
protein(PC00226) 
———— ———— ———— 
Ptk2b -1.169 0.045 Yes 
calmodulin—
related(PC00061) 
———— ———— ———— 
Fam19a5 -1.169 0.032 Yes 
RNA splicing 
factor(PC00148) 
nucleus(GO:0005634) ———— ———— 
Mau2 -1.165 0.035 Yes transporter(PC00227) ———— ———— ———— 
Tmem126a -1.164 0.014 Yes ———— 









HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Marcks -1.162 0.040 Yes ———— ———— ———— ———— 
Mllt11 -1.153 0.026 Yes ———— ———— ———— ———— 















activation of protein kinase 
activity(GO:0032147). 




regulation of mitotic cell 
cycle(GO:0007346) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Nob1 -1.138 0.010 Yes ———— 


















protein import into 
nucleus(GO:0006606) 
LOC691995 -1.135 0.025 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Ate1 -1.132 0.043 Yes ———— 




Adgrg1 -1.128 0.016 No ———— ———— ———— ———— 
Nup98 -1.121 0.045 Yes 
membrane traffic 
protein(PC00150) 
———— ———— ———— 
Mrps30 -1.120 0.016 Yes ———— ———— ———— ———— 





regulation of JNK 
cascade(GO:0046328) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




cellular zinc ion 
homeostasis(GO:0006882). 
response to cadmium 
ion(GO:0046686). 
response to toxic 
substance(GO:0009636). 









Tagln2 -1.102 0.016 Yes 
non—motor actin binding 
protein(PC00165) 
———— ———— ———— 
Fkbp3 -1.093 0.000 Yes ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
38596.000 -1.086 0.004 No ———— ———— ———— ———— 






















cellular protein metabolic 
process(GO:0044267). 
negative regulation of 
endopeptidase 
activity(GO:0010951) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




















HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
















protein localization to 
plasma 
membrane(GO:0072659) 















HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 




Rgs9 -1.063 0.018 Yes ———— ———— ———— ———— 










regulation of cell 
shape(GO:0008360). 
regulation of plasma 
membrane bounded cell 
projection 
organization(GO:0120035). 
















HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
Rho protein signal 
transduction(GO:0007266). 
plasma membrane 
bounded cell projection 
assembly(GO:0120031). 
positive regulation of cell 
projection 
organization(GO:0031346) 
Dnaja3 -1.057 0.037 Yes ———— ———— ———— ———— 
Sv2a -1.057 0.031 Yes ———— ———— ———— ———— 
Nsmf -1.055 0.013 No ———— ———— ———— ———— 




———— ———— ———— 
Trim2 -1.045 0.014 No ———— ———— ———— ———— 
Eno2 -1.039 0.012 No ———— ———— ———— ———— 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
LOC10091162
5 
-1.038 0.004 No ———— ———— ———— ———— 










involved in cilium 
assembly(GO:0035735). 
vesicle targeting, trans—






ciliary transition zone 
assembly(GO:1905349). 
protein localization to 
cilium(GO:0061512) 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 





leaflet of membrane 
bilayer(GO:0097478). 
plasma membrane protein 
complex(GO:0098797). 
extrinsic component of 








Coq8a -1.035 0.047 Yes ———— ———— ———— ———— 
Tnrc6b -1.025 0.005 Yes ———— ———— ———— ———— 
LOC10834817
5 
-1.022 0.040 Yes 
non—motor actin binding 
protein(PC00165) 
———— ———— ———— 
Mcrs1 -1.016 0.011 Yes RNA helicase(PC00032) ———— ———— ———— 

















regulation of mitotic cell 
cycle phase 
transition(GO:1901990). 




transition of mitotic cell 
cycle(GO:0007091). 
mitotic sister chromatid 
separation(GO:0051306). 




HFD+PB vs HFD – DOWNREGULATED GENES 
Gene Symbol log2FC P value Hit? Molecular Function Biological Function Cellular Component Protein Class 
positive regulation of 
mitotic cell 
cycle(GO:0045931) 
Gpr162 -1.009 0.039 Yes ———— ———— ———— ———— 
Map3k10 -1.005 0.019 Yes gap junction(PC00105) ———— ———— ———— 
Map1b -1.000 0.039 Yes serine protease(PC00203) 
extracellular 
space(GO:0005615) 
———— ———— 
 
 
 
 
 
 
 
